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Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a debilitating disease affecting about 1% of the world 
population. It is an autoimmune disease that leads to inflammation and eventually 
destruction of joints (Fig. 1).The exact etiology is still not clear and seems to be multi-
factorial with risk factors including a genetic predisposition, smoking, obesity and a 
female gender (Symmons et al. 1997, van der Helm-van Mil et al. 2006). At diagnosis, 
50-70% of the patients are positive for antibodies directed against citrullinated 
proteins (ACPA, anti-CCP) or IgG (rheumatoid factor, RF) in the serum (Smolen et al. 
2016). Several proteins that occur in the joint can be citrullinated, which is thought 
to provoke the inflammatory response if encountered by autoantibodies. Many 
different cell types are involved that orchestrate the inflammation by producing 
many different pro-inflammatory cytokines, including tumor necrosis factor alpha 
(TNFα), interleukin-1β (IL-1β) and interleukin-6 (IL-6). The production of cytokines 
triggers the production of matrix-degrading enzymes and attracts even more 
immune cells, ultimately leading to joint malformations and irreversible damage. 
As of yet, RA cannot be cured, but the inflammation is efficiently suppressed by 
disease-modifying anti-rheumatic drugs (DMARDs). These include methotrexate 
(MTX) and biological drugs (biologics), which are recombinant proteins that are 
injected at regular intervals, usually weekly. Although the biologics slow down the 
progression of RA, the continuous systemic exposure can lead to opportunistic 
infections and anti-drug antibodies (Aubin et al. 2013)
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Figure 1: Comparison of a knee joint with osteoarthritis and rheumatoid arthritis, depicting the 
pathology and the performed gene therapy trials. The femur and tibia are shown covered by a 
protective layer of cartilage. In between is the synovial cavity which is filled with synovial fluid 
containing nutrients and lubricating proteins. The composition of the synovial fluid is maintained by 
the cells in the synovial lining surrounding the synovial cavity. In osteoarthritis, synovial inflammation 
is observed in a subset of patients. In addition, cartilage pathology is observed and bone spurs 
(osteophytes) develop along the edges of the bone. Rheumatoid arthritis is associated with more 
severe inflammation, which is also associated with neutrophil influx. Pannus tissue forms from the 
synovium which causes bone erosion. For osteoarthritis, several gene therapy approaches are under 
develompent including an adeno-associated virus for expression of IL-1RA which has been successfully 
tested in equine osteoarthritis. Regenerative stem cells are considered cell therapy, but they may be 
transduced with disease-modifying viral vectors prior to administration (eg. MSC-Atsttrin). The TGF-β 
transduced allogeneic chondrocytes are currently in a Phase II clinical trial. In contrast, gene therapy 
trials in rheumatoid arthritis have focused exclusively on inhibiting the inflammation by targeting 
IL-1 signaling, TNFα signaling or by depleting immune cells in the joint. IL-1RA: interleukin-1 receptor 
antagonist, SF: synovial fibroblast, TGF-β: transforming growth factor beta, TNFR:Fc: fusion protein of 
the tumor necrosis factor receptor and immunoglobulin Fc. 
Osteoarthritis  
A second rheumatic disease that is a major focus of research is osteoarthritis (OA), 
which is the most common joint disease. OA is not an autoimmune disease, but similar 
to RA, OA affects the joints and the exact cause is unknown. Risk factors for OA include 
age, obesity and previous joint trauma (Blagojevic et al. 2010). However, unlike for 
RA, no disease-modifying drugs are available for OA and affected joints are often 
ultimately surgically replaced. For many years, people have viewed OA as mechanical 
wear-and-tear of the cartilage, but in recent views OA is considered an active disease 
affecting the whole joint (Malemud 2015) (Fig. 1). Inflammation is observed in up 
to half of the OA patients and is hypothesized to be involved in the pathogenesis 
(Blom et al. 2007, Wojdasiewicz et al. 2014, de Munter et al. 2016).  
 Because no disease-modifying treatment is available yet, there is a high 
demand for an effective therapy to treat OA. Despite the association of inflammation 
with OA, the biological therapies used to treat RA have insufficient effect in OA 
(Chevalier et al. 2013). An explanation for the lack of effects from these systemic 
treatments is that OA is considered a local process and delivery of protein-based 
molecules to the joint is challenging (Chevalier 2010). The penetration of systemically 
administered protein-based drugs into the joint is low and repetitive intra-articular 
injections cause high discomfort for the patient (Wallis et al. 1987). Local gene 
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therapy with viral vectors might provide long-term expression of a protein drug in 
the joint, while preventing continuous exposure of the body to immunosuppressive 
agents.
On the origin of gene therapy  
Ever since the identification of DNA as the carrier of inheritable information and 
the capacity of viruses to transfer genetic material into cells in the 1960s, there 
have been speculations to make use of ‘gene therapy’ to correct molecular 
defects (Tatum 1966). After the development of additional molecular biological 
techniques, the first approved and successful clinical trial was started in 1990 
when 2 patients suffering from adenosine deaminase deficiency – severe combined 
immunodeficiency (ADA-SCID) were treated with a retrovirus encoding adenosine 
deaminase (Blaese et al. 1995). In patients suffering from ADA-SCID, dATP builds up 
in all cells, which results in loss of T- and B-cells leading to opportunistic infections. 
In the trial, one of the two patients showed structural improvement in adenosine 
deaminase activity and an increase in T-cell numbers over a course of 4 years. The 
first publication on successful gene therapy however, described the ex vivo retroviral 
transfer of the LDL-receptor to autologous hepatocytes for the treatment of familial 
hypercholesterolemia (FH) (Grossman et al. 1994). One patient was included in this 
study, with positive effects on the LDL/HDL ratio for at least 18 months. Importantly, 
no genotoxicity was observed in these studies, which had been a major concern 
for the integrating retroviral vectors. Recently, several additional successful gene 
therapy clinical trials have been performed, described in Text Box 1.
Text Box 1: recent successes of  gene therapy  
In recent years, the field of  gene therapy had several successful developments. The first gene 
therapy approved for the European market was alipogene tiparvovec (trade name Glybera) 
in 2012, which was developed by a Dutch company for the treatment of  LPL (lipoprotein 
lipase) deficiency (Yla-Herttuala 2012). Recently, two other gene therapies have been ap-
proved: The oncolytic T-VEC virus (Fong 2015) and the gene therapy for ADA-SCID de-
scribed above (Yla-Herttuala 2016). Additional successful clinical trials have recently been 
performed with gene therapy for Wiskott-Aldrich syndrome (Hacein-Bey Abina et al. 2015), 
the progressive retinal degenerative disease Leber’s congenital amaurosis (Bainbridge et al. 
2015), neovascular age-related macular degeneration (Rakoczy et al. 2015) and a gene editing 
approach for the treatment of  HIV (Tebas et al. 2014). Interestingly, these studies made use 
of  adeno-associated viruses (AAVs), lentiviruses and retroviruses, thus providing extensive 
safety and expression kinetics data for different viral vectors for over 3 years. No severe 
pathogenic mutagenesis has been observed in any of  these trials and individual integration 
sites were not associated with increased cell proliferation. Positive safety aspects of  these 
vectors and extensive knowledge of  their behavior are essential for the application of  gene 
therapy for non-lethal diseases, like RA and OA.
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Gene therapy vectors  
A description of the term ‘gene therapy’ is provided in Text Box 2. Roughly, gene 
therapy agents can be divided into several categories, based on vector properties. 
The most common distinction made is between viral and non-viral vectors. The non-
viral vectors are a diffuse group of recombinant gene (transgene) delivery strategies 
that includes all vectors with the exception of the viral vectors. In general, non-
viral vectors are considered less immunogenic compared to viral vectors and can 
be produced in high quantities to obtain high vector to target cell ratios (Chevalier 
et al. 2009). High relative vector quantities are required for non-viral transfections, 
because they lack the evolved sophisticated virus strategies for transfection 
efficiency, stability and transcriptional activity. Several chemical, physiological and 
biological strategies can improve the efficiency and stimulate uptake of plasmids by 
specific cells (Nayerossadat et al. 2012). For example, plasmids can be incorporated 
in liposomes, which are lipid vesicles that can be coated with specific homing 
antibodies (Xing et al. 2016).
Viral vectors make use of the efficient and sophisticated properties evolved in 
naturally occurring viruses to obtain expression of the desired transgene. Naturally 
occurring viruses contain DNA or RNA that encodes the blueprint of the virus. After 
Text Box 2: The definition of  gene therapy  
The exact definition of  gene therapy has changed over time due to new ideas for addition-
al applications (from only correcting single monoallelic defects in the initial definitions to 
the restoration of  the cytokine balance as suggested for RA gene therapy) and the develop-
ment of  new techniques (eg. gene editing). The American Society for Gene and Cell Therapy 
(ASGCT) currently defines gene therapy as follows: ‘Gene Therapy can be defined as the use 
of  genetic material (usually deoxyribonucleic acid - DNA) to manipulate a patient’s cells for 
the treatment of  an inherited or acquired disease’. The U.S. Food and Drug Administration 
(FDA) currently maintains a long definition including the core sentence: ‘Gene therapy is 
a medical intervention based on modification of  the genetic material of  living cells’. Gene 
therapy is often confused with cell therapy. Somatic cell therapy is defined by the FDA as ‘the 
administration to humans of  autologous, allogeneic, or xenogeneic living non-germline cells, 
other than transfusable blood products, for therapeutic, diagnostic, or preventive purposes.’ 
Gene therapy and somatic cell therapy can be combined if  cells are first transduced with a 
vector and subsequently administered to a patient. The careful correct terminology for all 
currently approved gene therapy trials is ‘somatic gene therapy’ to distinguish from germline 
gene therapy. If  a viral vector integrates in germline cells, all future generations will carry the 
modification of  which the consequences cannot be predicted. The risk of  germline mutations 
in somatic gene therapy is therefore a constant concern. In several countries, including the 
Netherlands, germline gene therapy is forbidden due to technical and ethical considerations. 
The US currently has no federal legislation, but the FDA does not currently approve clinical 
trials based on germline gene therapy (Ishii 2015).
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a target cell is transduced, the cell will replicate the viral genome and express the 
required proteins to assemble new virus particles. The newly produced virus 
particles can infect new cells to propagate the viral infection. In viral vectors used 
for gene therapy, the virus genome is partly replaced by a therapeutic gene. The 
viral vector particle can transduce a target cell once and start production of the 
therapeutic gene. Because the viral vector does not encode the complete viral 
genome, no viral proteins are expressed to form new virus particles and the vector 
can therefore not replicate. The most commonly used viral vectors can be divided 
into integrating vectors (eg. retrovirus, lentivirus) and mostly episomal vectors (eg. 
adenovirus, AAV). Integrating viruses integrate in the host genome and provide 
long-term expression of a transgene. When a transduced cell proliferates, it will also 
carry over the integrated vector. The major down-side of the integrating vectors is 
the risk of disrupting tumor-suppressor genes or activating proto-oncogenes (see 
Text Box 3). This risk is reduced when using episomal vectors. However, episomal 
vectors are degraded in time by the transduced cells and the vectors are divided 
over the daughter cells during replication. In general, different viral vectors can 
transduce different sets of cell types (tropism) and have a different transgene 
capacity (Bouard et al. 2009). Certain viruses, including retroviruses can only 
transduce dividing cells and viral vectors are to a different extend hampered by pre-
existing and vector-induced neutralizing antibodies (Calcedo et al. 2009). Several 
reviews have been written on the specific characteristics and limitations of the 
different viral vectors (Gardlik et al. 2005). 
In this thesis, we use lentiviral (LV) and adenoviral (AdV) vectors. LVs are derived 
from the human immunodeficiency virus (HIV) and can be integrated in the genome 
of non-dividing cells, which is an advantage compared to the integrating retroviral 
vectors. (Matrai et al. 2010). LVs have a high transgene capacity of ~10 kb, although 
even larger transgenes can be incorporated with a decreased yield (Kumar et al. 
2001). We use the self-inactiving (SIN) LV vector system in which the genes required 
to create a replication-deficient virus are dispersed over 4 expression vectors that 
are co-transfected in 293T cells. The resulting LV does not contain RNA coding for 
viral genes and contains a partly defective long terminal repeat (LTR) that cannot 
induce the expression of nearby (proto-onco)genes. The expression of transgenes 
in the SIN vector is instead regulated by a newly inserted promoter. The tropism of 
the original HIV lentivirus is restricted to CD4+ cells. By replacing the original gp120 
envelope protein with vesicular stomatitis virus G (VSV-G) protein, the virus tropism 
is greatly increased to many different cell types (Cronin et al. 2005). The low-density 
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lipoprotein (LDL) receptor has recently been identified as the main receptor for the 
VSV-G, explaining the broad tropism of VSV-G pseudotyped LVs (Finkelshtein et al. 
2013). In general, we apply LVs in the experiments where long-term expression was 
desired. Similar to the LV, AdV has a broad tropism, can transduce non-dividing 
cells and has a high transgene capacity (5.1 kb, which can be increased to up to 
37 kb if additional viral genes can be replaced) (Danthinne and Imperiale 2000, 
McConnell and Imperiale 2004). In contrast to the LV however, the AdV does not 
incorporate into the host genome, providing a more transient expression and we 
apply the AdV if particularly high and rapid transgene expression is desired.  
 The AdV we use is deficient for the Early-1 (E1) gene, which is expressed by 
the N52E6 amniotic cell line that is used for AdV production (Schiedner et al. 2000). 
The promoter sequence and the poly-A sequence surrounding the adenoviral E1 
gene in the N52E6 cells have been replaced by non-adenoviral substitutes. This 
prevents homologous recombination of the E1 gene into the produced AdVs, thus 
preventing the creation of replication-competent AdVs (RCAs) and improving the 
recombinant AdV safety.
Gene therapy in Rheumatoid arthritis   
Intra-articular gene therapy can be a useful apporach to provide long-term 
expression of potentially therapeutic proteins in the joint without administering 
weekly i.a. injections. The first gene therapy for rheumatic diseases was proposed 
in 1992 (Bandara et al. 1992). At the time, the first protein-based treatments were 
tested in arthritis models. The first treatments mainly targeted IL-1 and systemic 
Text Box 3: gene therapy setbacks 
After the hopeful results of  the first gene therapy clinical trials, several patients suffered 
severe adverse side effects in subsequent trials. A major setback occurred in 1999, when 
a patient died in a trial with gene therapy for patients suffering from Ornithine transcar-
bamylase deficiency (OTCD) 96h after receiving the highest AdV dose of  the study 
(Raper et al. 2002). The death was attributed to the administered AdV, which resulted in 
a very strong immune response and multiple organ failure. Although the subjects re-
ceiving a lower dose AdV also showed an inflammatory reaction to the vector, it remains 
unclear what caused the exaggerated immune response in the deceased patient (Rap-
er et al. 2003). A milder immune response was observed in the second patient receiving 
the highest vector dose, but the clinical trial was aborted.    
In another trial for X-linked SCID (SCID-X1) with ex vivo retroviral transduction of  bone-mar-
row-derived CD34+ cells with the IL-2 receptor γ gene, 4/10 patients developed leukemia of  
which one patient eventually died (Hacein-Bey-Abina et al. 2008). The leukemia might have 
been caused by an unfortunate combination of  the use of  a retrovirus with an LTR enhancer, 
integration near the LMO2 proto-oncogene and expression of  a pro-survival transgene in 
patients with a severe immune deficiency. These severe side effects overshadowed the fact that 
most treated children are still alive today, owing to the gene therapy.
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injections with recombinant IL-1 receptor antagonist (IL-1RA) could reduce IL-1-
induced synovitis and proteoglycan depletion (Henderson et al. 1991). Bandara 
and colleagues proposed that local gene therapy could overcome the challenges of 
physiological instability of therapeutic proteins and poor penetration of the joint after 
systemic injection. The local treatment could be ideal to treat oligoarthritis or specific 
joints refractory to mediation. The route of administration could be either by direct 
injection of the virus or by injecting ex vivo transduced autologous joint cells.  
 The promising results with IL-1RA in animal models resulted in the approval 
of the first of few clinical trials for RA in 1995. Of 9 patients scheduled for joint 
replacement surgery of multiple metacarpophalangeal (MCP) joints, one joint 
was replaced earlier and the cells retrieved from the joint were transduced with 
a retrovirus encoding IL-1RA (Fig. 1). The transduced cells were injected in the 
second joint and after 1 week, the joints were removed and analyzed. No adverse 
events occurred and IL-1RA was successfully expressed. The production of both 
IL-6 and prostaglandin E2 were reduced by the treatment. A second clinical trial 
with a similar approach and a 4-week follow-up was initiated. Two patients were 
treated and no adverse events were reported (Wehling et al. 2009). The injection 
of transduced cells reduced the pain score in the joints compared to injection of 
non-transduced cells. However, after the inclusion of these 2 patients the leukemia 
in the SCID-X1 trial occurred (Text Box 3), which used a similar retroviral vector and 
the clinical trial was aborted. Despite these promising results no additional trials 
have been initiated with this therapy, possibly in part because of the developing 
insights that the efficacy of IL-1Ra biologicals is inferior to anti-TNFα biologicals 
(Kalliolias and Liossis 2008). It has been estimated that a 100-fold molar excess of 
IL-1RA is required for successful in vivo suppression of IL-1 activity (Arend 1993).  
 After the development of biological drugs for the treatment of RA, a second 
approach involving gene therapy was tested in a clinical trial. A recombinant adeno-
associated virus serotype 2 (rAAV2) was used to express the cDNA of the extracellular 
portion of the TNFα receptor fused to the Fc portion of IgG (TNFR:Fc, tgAAC94), a 
transgene similar to the etanercept biological. After the successful treatment of 
experimental arthritis and positive safety data in non-human primates, 15 patients 
received a single intra-articular injection and no severe side effects relating to the 
viral vector were observed (Mease et al. 2009). Subsequently, the efficacy was tested 
in a phase 1/2 study on 127 patients (Fig. 1). Two virus injections were planned, 
but several patients did not receive the second injection after one of the patients 
died (Mease et al. 2010). Only marginal improvements were observed compared 
to the placebo-injected group. The death was attributed to an opportunistic 
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histoplasmosis. It could not be determined to what extent the immune suppression 
by the viral vector contributed compared to other immunosuppressive medication 
the patient received simultaneously (Frank et al. 2009). To our knowledge, the IL-
1RA retrovirus and the TNFR:Fc AAV are the only RA gene therapy clinical trials for 
which the results have been published. One last notable gene therapy approach for 
RA gene therapy is by depleting the inflammatory cells in the joint using ‘genetic 
synovectomy’ (Fig. 1). Using an intra-articularly injected adenovirus, the synovial 
cells can express the herpes simplex thymidine kinase (tk) gene. Cells expressing this 
gene can metabolize the drug Ganciclovir into a deoxyguanosine triphosphate (dGTP) 
analogue. The analogue is incorporated in the genome, but cannot be replicated by 
DNA polymerase causing apoptosis. This system has been successfully used to treat 
collagen-induced arthritis in monkeys by killing >90% of the synoviocytes (Goossens 
et al. 1999), although long-term effects on joint damage were not assessed in this 
study. A gene therapy clinical trial based on this approach has been started, but was 
stopped after inclusion of 1 patient, because of problems with patient recruitment 
(Evans 2005). 
Gene therapy in osteoarthritis  
In addition to an application in RA described above, IL-1RA therapy has been 
explored for efficacy in OA. In mouse models of OA, most successful treatments 
have been directed at inhibiting matrix-degrading enzymes, or by stimulating 
anabolic processes using various growth factors or regenerative (stem) cells (Fig. 
1). These approaches have been extensively reviewed by Goldring and Berenbaum 
(Goldring and Berenbaum 2015). One important target for OA gene therapy is IL-1β, 
which has been implicated to have a role in the pathogenesis of OA by maintaining 
a low-grade inflammation (Wojdasiewicz et al. 2014). IL-1β is upregulated in the 
synovial fluid, synovial membrane and in articular cartilage of OA patients and 
injections of recombinant IL-1β in mouse joints leads to cartilage proteoglycan 
depletion and increased expression of matrix-degrading enzymes. Repeated intra-
articular injections of IL-1RA in a dog model of osteoarthritis resulted in reduced 
osteophyte formation and reduced cartilage damage (Caron et al. 1996). However, 
a single intra-articular injection of recombinant human IL-1RA (Anakinra) showed 
no therapeutic effects in a multi-center clinical trial (Chevalier et al. 2009). The half-
life of Anakinra was determined to be only 4h, hence the potential benefit of a gene 
therapy approach to extend the exposure time to IL-1RA. Intra-articular gene therapy 
with an adenovirus coding for IL-1RA could reduce pain and cartilage damage in a 
horse model for osteoarthritis (Frisbie et al. 2002) (Fig. 1). More recently, it has 
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been shown that horse joints transduced with a self-complementary AAV2 (scAAV2) 
vector can provide intra-articular expression of IL-1RA for up to 8 months (Goodrich 
et al. 2015). Several other studies have shown promising results with IL-1RA gene 
therapy for OA and in a recent study, the safety profile of an IL-1RA-expressing 
rAAV2.5 vector has been determined in a the rat mono-iodoacetate (MIA) OA model 
(Wang et al. 2016). No adverse effects were noted and the treatment could reduce 
OA features until 180 days after induction of the model, but beneficial effects were 
gone after 1 year. Although AAV vectors are considered relatively safe vectors, also 
in this study a dose-dependent formation of neutralizing antibodies against the AAV 
capsid was measured. This can potentially reduce the effects of subsequent vector 
injections and might require switching to a different AAV serotype. Of note is the 
importance to use the correct animal model for studying the effects of IL-1-related 
therapies, as it has recently been shown that the common collagenase-induced OA 
mouse model has comparable damage in IL-1α/IL1-1β knockout mice compared to 
wild-type mice, despite the clear presence of inflammation (van Dalen et al. 2016).
TGF-β as transgene for OA  
Several other transgenes have been evaluated in single animal studies that could 
reduce experimental OA. However, the most progress toward human application 
of OA gene therapy has been made with an approach based on the application of 
chondrocytes stably transduced with a transforming growth factor beta 1 (TGF-β1) 
expressing vector (Fig. 1). Interestingly, a disease-responsive metallothionein 
promoter was used to prevent excess exposure to TGF-β. A phase I clinical trial 
in 12 OA patients was initiated with a cell mixture designated TissueGene-C, 
consisting of a 3:1 ratio of non-transduced allogeneic chondrocytes and TGF-β 
transgenic chondrocytes irradiated with 15 Gy irradiation for safety (Ha et al. 2012). 
Some fluctuating clinical benefit could be observed for up to 12 months and some 
cartilage regeneration was observed on MRI. A phase IIa clinical trial was initiated 
in 27 patients with similar improvements after 12 and 24 weeks compared to 
baseline (Ha et al. 2015). Unfortunately, no control group was included in this study. 
Therefore, it is not certain which components of the TissueGene-C are required for 
the therapeutic benefit or if other treatment factors are of therapeutic influence 
(eg. the aspiration of all joint fluid before administration of the chondrocytes, or 
the reduced loading of the joints for 7 weeks). In a separate Phase II clinical trial, 
57 patients were included and the high-dose TissueGene-C was compared to saline 
placebo (Lee et al. 2015). At 24 weeks, the clinical benefit of the TissueGene-C 
treated group was significantly higher compared to the placebo control group. 
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Although cartilage regeneration still remains to be determined in these phase II 
clinical trials, the clinical benefit was significant using different tests. Based on 
experiments from our department, caution should be exercised when applying 
TGF-β as a transgene, because adenoviral overexpression of TGF-β in mice resulted 
in osteophyte formation (Blaney Davidson et al. 2007). Moreover, a shift in TGF-β 
receptor analysis is observed during aging leading to a relative decrease in anabolic 
Smad2/3 signaling compared to detrimental Smad1/5 signaling (Blaney Davidson et 
al. 2009). This might negatively influence the therapeutic effects of TGF-β and was 
not investigated in the trials. The clinical trials using TissueGene-C are so far the 
only published gene therapy trials for OA. 
Despite the several clinical trials with optimistic results for arthritic diseases 
described above, there is no gene therapy available yet for RA or OA patients in 
clinical practice. For RA, most gene therapeutic approaches are based on existing 
biologics that show limited health risks when delivered systemically as protein drugs. 
For OA, no biologics are available and less is known about the pathophysiology 
than for RA making a targeted strategy more challenging. In this thesis we aim to 
develop and test sophisticated viral vectors that can add to the current spectrum 
of anti-arthritic viral vectors by improving natural feedback mechanisms based 
on interleukin-10 (IL-10) and by providing transcriptional targeting using disease-
inducible promoters. This approach can aid in the drug dose fine-tuning, which is 
currently an important topic for arthritis healthcare and will be further discussed in 
the ‘inducible arthritis gene therapy’ section of this introduction.
IL-10 therapy for RA  
A major emphasis in this thesis is on gene therapy with IL-10. IL-10 is a powerful 
broad-spectrum anti-inflammatory cytokine, which can inhibit the production 
and signaling of pro-inflammatory cytokines, like IL-1 and TNFα (de Waal Malefyt 
et al. 1991, Fiorentino et al. 1991) and reduce antigen presentation (Frei et al. 
1994). In contrast to the currently available biologics, IL-10 also occurs naturally 
in cells and is involved in the negative feedback of the inflammatory response. IL-
10 can induce the expression of IL-1RA, soluble TNFα receptors and suppressor of 
cytokine signaling-3 (SOCS3) (Cassatella et al. 1994, Hart et al. 1996, Cassatella et 
al. 1999). In the first in vivo experiments with arthritis models, daily i.a. injections of 
recombinant IL-10 were found to inhibit collagen-induced arthritis (CIA) (Walmsley 
et al. 1996). The first application of IL-10 for the treatment of inflammatory diseases 
in humans was by daily injections of IL-10 for 7 days to treat Crohn’s disease. 50% 
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of the patients showed clinical improvement after 3 weeks, compared to 23% of the 
placebo-treated group (van Deventer et al. 1997). A major challenge for therapy 
with recombinant IL-10 that became clear from these studies, is its short half-life 
of 1.1-2.6 hours. Patients with inflammatory diseases are prone to develop anemic 
conditions, which was observed after 4 weeks of daily IL-10 injections in patients 
with inflammatory bowel disease (Tilg et al. 2002). Several other side effects that 
can potentially be induced by continuous exposure to high levels of IL-10 are the 
increased expression of interferon gamma (IFN-γ) (Tilg et al. 2002) and increased Fc 
gamma-receptor expression in monocytes (Tilg et al. 2002). Disease-inducible gene 
therapy could be a suitable approach to provide long-lasting IL-10 expression, while 
minimizing the systemic off-target exposure to reduce these side effects.
IL-10 therapy for OA  
IL-10 has also been a successful transgene in the treatment of animal models for 
OA. Rabbit synoviocytes transduced ex vivo with a retrovirus coding for IL-10 were 
injected in the knee joint and could reduce cartilage damage in a surgical model of 
OA (Zhang et al. 2004). IL-10 could also reduce blood-induced cartilage damage in 
human cartilage explants (van Meegeren et al. 2012). In addition to suppression 
of inflammation, IL-10 can inhibit the production of matrix-degrading enzymes 
(Behrendt et al. 2016). Several other studies have provided indirect evidence for an 
association of IL-10 with OA. For example, low innate production of IL-10 by blood 
cells after stimulation ex vivo is associated with an increased risk of OA (Riyazi et al. 
2005). In another study, it has been concluded by systematic review that physical 
exercise has positive effects on pain and disability in knee OA (Roddy et al. 2005). 
These effects might be mediated by IL-10, which was found to be upregulated in 
the synovial fluid after exercise (Helmark et al. 2010). In addition to the inhibition 
of inflammation and matrix-degrading enzymes, IL-10 has chondroprotective and 
anabolic effects on cartilage by stimulating chondrocyte proliferation, stimulating 
the production of extracellular matrix components and reducing chondrocyte 
apoptosis (Jung et al. 2013, Wojdasiewicz et al. 2014). Despite the clear association 
of IL-10 with osteoarthritis, only a small amount of studies have tested IL-10 as a 
therapeutic option for OA and additional research is required to determine if IL-10 
can be successful as transgene in OA.
Inducible arthritis gene therapy 
For the use of biologics in RA, the earliest strategy was a dose escalation and 
nowadays a ‘hit hard’ approach is advocated followed by dose de-escalation. 
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Both approaches aim to find the optimal drug dose for each individual patient 
(den Broeder et al. 2010). The earliest gene therapy experiments focused on long-
term high expression of transgenes in the joint. Dose escalations were tested in 
these patients, but only for safety assessment. We recognize that in addition to 
providing local expression, gene therapy vectors can also be designed to provide 
more specific targeting compared to systemic drug injections to further minimize 
off-target exposure. One approach is by isolating specific cell types for ex vivo 
transduction or by using viral vectors with a specific tropism. This has been 
extensively reviewed (van de Loo et al. 2006). A second strategy is by using specific 
promoters to regulate the expression of transgenes. These can include cell-specific 
promoters for cell-specific targeting, drug-inducible promoters, or promoters 
that are activated under specific disease circumstances, like inflammation. The 
focus of regulated gene therapy in this thesis is on disease-inducible promoters. 
These promoters are of particular interest for RA gene therapy, because many 
patients show an intermittent disease course (van der Helm-van Mil 2014).  
 Two major approaches have been explored to obtain disease-responsive 
promoters: 1 copying the promoter region of genes activated during disease and 2 
generating artificial inducible promoters by combining a transcription start sequence 
with transcription factor binding sites. The first promoters from endogenous genes 
tested in vivo for inducible gene therapy were acute phase response (APR) promoters 
(Varley et al. 1995). The promoters of Serum Amyloid A3 (SAA3) and complement 
factor 3 (C3) were coupled to the luciferase reporter gene in an adenoviral vector 
and injected in the mouse tail vein. After injection of the bacterial lipopolysaccharide 
(LPS), luciferase activity increased in liver homogenates transduced with SAA3-luc and 
C3-luc. The increase was not observed with the constitutive active cytomegalovirus 
(CMV) promoter. The C3 promoter has been used to express the anti-inflammatory 
IL-10 in the streptococcal cell wall (SCW) model of arthritis (Miagkov et al. 2002). 
IL-10 was expressed after inflammatory stimulation and could reduce the influx of 
immune cells. The same promoter was used by our group to successfully express 
IL-1Ra to diminish collagen-induced arthritis (CIA) (Bakker et al. 2002). Although 
these two studies are promising for the gene therapy in RA, both studies used 
the C3 promoter in combination with the HIV transactivator of transcription (Tat) 
to amplify the transgene expression and the Tat protein can elicit an immune 
response and provide unwanted transactivation (Fulcher and Jans 2003).  
 Our group has also further investigated the SAA3 promoter. Murine 
joints received intra-articular injections with lentiviral SAA3-luc and the 
promoter activity was strongly increased after SCW-induced arthritis 
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(Geurts et al. 2011). In vitro, the promoter response was stronger in primary 
synovial fibroblasts with a high inflammatory phenotype compared to a 
low inflammatory phenotype. Moreover, a stable SAA3-luc cell line could 
distinguish between serum from RA patients and healthy control serum.  
 An additional inducible promoter has highlighted the importance of 
inducible gene therapy compared to constitutive transgene expression. The 
human IL-1 enhancer element was coupled to the human IL-6 promoter to provide 
inducible expression of the chondroprotective IL-4 in CIA (Geurts et al. 2007). 
Constitutive expression of IL-4 also could protect the cartilage, but the excess of 
IL-4 also increased inflammation. In a more recent study, this engineered promoter 
was cloned in front of the IL-10 gene and used to transduce Hematopoietic 
Stem Cells (HSC’s). Systemic injection of the transduced HSC’s ameliorated CIA 
(Henningsson et al. 2012). Several other promoters derived from genes have 
proven to be suitable for inducible gene therapy in animal models of arthritis. 
Garaulet and colleagues have shown that a lentivirus with the E-selectin (ESEL) 
promoter in combination with the IL-10 transgene could provide increased levels 
of IL-10 after inflammatory stimulation when injected intraplantar in the murine 
hind paw (Garaulet et al. 2013). Intraplantar treatment with the ESEL-IL10 
lentiviral vector could reduce paw swelling in zymosan-induced arthritis (ZIA).  
 Inducible promoters have also been tested in the context of genetic 
synovectomy based on principles developed for oncolytic viruses. The telomerase 
reverse transcriptase gene (TERT) shows increased expression in RA synovial fibroblasts 
compared to dermal fibroblasts (Chen et al. 2009). The TERT promoter has been 
used to create a conditionally replicating adenovirus (ad.GS1), which is dependent 
on TERT promoter activation for replication. The Ad.GS1 could specifically deplete 
RA synovial fibrobasts in the rat ankle and ameliorate collagen-induced arthritis.  
 Which inducible promoter performs best in human cells still remains 
to be determined. Not only the fold induction compared to the healthy 
situation is important, but the transcriptional activity after activation needs 
to be sufficient to produce adequate levels of the desired transgene. Which 
promoter works best is thus also dependent on the therapeutic efficacy of 
the transgene. In addition, for transgenes with a high risk of side effects, a 
low basal promoter activity during disease remission is essential.  
 The most well-studied artificial inflammation-responsive promoter for RA is 
the minimal CMV-promoter combined with 6 tandem repeats of the nuclear factor 
kappa-B (NFκB) transcription factor. The first therapeutic benefit was observed 
using an rAAV5 coding for soluble TNFα receptors (Khoury et al. 2007). Both the 
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incidence and severity of CIA were reduced after injections in the murine knee and 
ankle joints. In contrast to a constitutive promoter, the 6xNFκB promoter activity 
peaked at day 7 after an LPS injection, after which the activity decreased and could 
be re-activated by a second LPS-injection after 9 weeks. In the same month, a 
second paper was published describing the application of the rAAV5 vector with 
the 6xNFκB-promoter. In this study, beneficial effects were found in the rat adjuvant 
arthritis (AA) model after inducible expression of the immunomodulatory Beta 
interferon (IFN-β) (Adriaansen et al. 2007, Adriaansen et al. 2007). Interestingly, paw 
swelling was only reduced in the group treated with inducible IFN-β therapy and 
not after high constitutive expression of IFN-β, possibly because of lower absolute 
expression. The rAAV5-NFκB-IFNβ (ART-I02) vector has been further tested and 
found to be effective in fibroblast-like synoviocytes (FLS) of several species (Aalbers 
et al. 2015). In addition, the vector was found to be safe in rhesus monkeys with 
CIA (Bevaart et al. 2015). A non-significant reduction in inflammation was observed 
after treatment of hand joints, although the vector induced rAAV5-neutralizing 
antibodies. Currently, a Phase I clinical trial is planned with this vector by the Dutch 
company Arthrogen, the first gene therapy trial for RA to use an inducible promoter.
Compared to RA, far less effort has been put in finding inducible promoters for OA. 
The current focus of gene therapy for OA is on finding the best transgene, rather 
than fine-tuning the expression of successful transgenes with inducible promoters. 
Several inducible promoters for OA have already been investigated, but these 
were mainly based on sensitivity to inflammatory triggers, rather than OA-specific 
processes. Examples of these promoters are the COX-2 promoter (Rachakonda 
et al. 2008) and the MMP-9 promoter combined with several NF-κB binding sites 
(Campbell et al. 2005).
Personalized gene therapy  
Analysis of gene expression profiles of synovial membranes of RA, OA and healthy 
controls have yielded (in addition to pathways that were differentially affected 
between diseases) pathways that showed a large patient-to-patient variation 
(Huber et al. 2008). For example, genes in the B-cell receptor signaling pathway and 
the VEGF signaling pathway showed significant differences between RA patients. 
OA patients had variable expression of genes of genes involved in, for instance, 
oxidative phosphorylation and MAPK signaling. An earlier study on synovial gene 
expression already found that a group of RA patients showed increased expression of 
inflammatory genes, whereas a second group of RA patients had increased expression 
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of genes associated with tissue remodeling (van der Pouw Kraan et al. 2003).  
 The large inter-individual differences warrant a patient-specific treatment. 
Ideally, this can be achieved using inducible promoters and in vitro cultures can 
be the model for this challenge. A previous study from our group focused on the 
inflammatory phenotype of primary RA and OA synovial fibroblasts in culture. The RA 
and OA samples seemed to be intermingled when the samples were clustered based 
on the expression of inflammation-associated genes (Geurts et al. 2011). Interestingly, 
primary fibroblasts with a high inflammatory phenotype transduced with the Saa3-
promoter luciferase reporter showed an increased response to cytokine stimulation 
compared to primary fibroblasts with a low inflammatory phenotype.   
 Monolayer cultures of synovial fibroblast are a relatively easy in vitro model 
to test a personalized gene therapy approach. However, in monolayer the cells have 
no interaction with the surrounding matrix which greatly changes their behavior. 
One solution to preserve the cell interactions is by using tissue explants derived 
from arthroscopic biopsies or tissue samples remaining after joint replacement 
surgery. Disadvantages of this method are a high variability between samples 
and the fact that many disease processes (eg. hyperplasia, fibrosis) have already 
occurred irreversibly in this material. The response of targeted gene therapy and 
the effect of the transgene on synovial pathology can therefore better be tested 
on an human synovial membrane model. The first artificial synovium was created 
by mixing a synovial cell suspension obtained by collagenase digestion with a fibrin 
matrix (Franz et al. 2001). Under correct culture conditions, the synovial fibroblasts 
remained viable. The first attempt to create an in vitro synovial lining was by mixing 
synovial fibroblasts with Matrigel, a substance that contains extracellular matrix 
proteins from Englebreth-Holm-Swarm (EHS) tumors in mice, containing many 
basement membrane proteins (Hughes et al. 2010). The Matrigel is liquid at low 
temperatures and becomes solid at room temperature. Interestingly, when Matrigel 
droplets mixed with synovial fibroblasts are cultured, the synovial fibroblasts 
migrated toward the surface of the Matrigel droplet and form a structure that 
resembles a synovial lining (Kiener et al. 2010). The cells on the surface expressed 
Proteoglycan-4 (PRG-4), which is a marker for synovial fibroblasts. In addition, 
prolonged exposure to TNFα could induce hyperplasia, which strongly mimics the 
situation of the human synovial lining. Good 3D models of joint structures can be 
used to study the changes that occur during joint diseases and can provide a higher 
predictable value for the effects of a therapy in clinical trials. Because advanced 
models are pivotal to test the potential of gene therapy in complex human tissue 
before proceeding to a clinical trial, we aim in this thesis to improve the Matrigel-
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based 3D culture of human synovium. 
Outline of this thesis  
Rheumatoid arthritis (RA) and osteoarthritis (OA) are rheumatic diseases for which 
no cure is available yet. The aim of this thesis is to develop a gene therapy for 
the treatment of RA and OA. Gene therapy can allow the cells of a transduced 
joint to produce anti-rheumatic proteins. For RA, several successful protein-based 
therapies are already available and gene therapy can improve the treatment by 
targeting joints refractory to medication and potentially reduce side effects, while 
requiring fewer injections. In addition, the expression of the therapeutic transgene 
can be regulated by disease-inducible promoters to provide protein production only 
during flares of active disease. This can further reduce the off-target exposure to 
the therapy and potentially limit side effects. The experimental approach followed 
in this thesis is shown in Figure 2. 
 
Figure 2: General experimental approach described in this thesis. The focus of this thesis is on 
applying inducible gene therapy for arthritic diseases. The gene therapy is based on a viral vector 
that includes an inducible promoter with transcription factor binding sites for both pro-inflammatory 
(red) and anti-inflammatory (green) transcription factors to fine-tune the expression of a therapeutic 
transgene. The viral vector is be applied in experimental arthritis models and in in vitro cultures of 
primary cells derived from patient tissue. The therapies are tested in both synovial cell suspensions 
and the 3-dimensional model of the synovial lining.
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In Chapter 2 we start our quest by testing inducible promoters for the treatment 
of experimental RA. Saa3 and Mmp13 were upregulated during experimental 
RA and the promoters of these genes showed high activity in the murine 
joint during the early and the late phase of inflammation respectively. When 
these promoters were used to drive the expression of the anti-inflammatory 
Interleukin-10 (IL-10), the inflammation and cartilage damage were significantly 
reduced, showing the potential of IL-10 and the inducible promoters.  
 For OA, there is still a quest to find a functional compound that can interfere 
with the disease process. Based on current insights, the reduction of inflammation 
and cartilage damage might reduce the progression of OA. A protein with several 
functions that we speculate might reduce OA pathology is TNFα-stimulated 
gene 6 (TSG-6, TNFAIP6). In Chapter 3, we therefore switch to the treatment of 
experimental osteoarthritis and test the effects of TSG-6 overexpression. In an in 
vitro validation test, lentiviral TSG-6 overexpression could inhibit bone resorption 
by osteoclasts. However, when tested in vivo, the TSG-6 gene therapy was not 
able to reduce inflammation or cartilage damage. Instead, increased ectopic bone 
formation was observed in the medial collateral ligament. This was unexpected and 
hints at the involvement of TSG-6 in OA disease pathology. Based on these results, 
we do not recommend TSG-6 as a therapeutic agent for OA gene therapy.  
 After having established the efficacy of disease-regulated IL-10 therapy in 
experimental RA, we desired to explore the gene therapy effects in human in vitro 
systems. We first set out to tackle two important challenges faced when applying in 
vitro models based on primary human (patient) material. Firstly, primary material 
is available at irregular intervals. Patients are not operated simultaneously and 
experiments that require multiple donors cannot be concurrently executed. In 
Chapter 4, we seek to improve the possibilities for in vitro studies with primary OA 
synovial tissue by validating a protocol for cryopreservation. By applying the correct 
protocol based on CS10 cryopreservation medium, the viability of a synovial tissue 
biopsy after cryopreservation can be maintained. In addition, there is no significant 
induction of stress-related gene expression and the expression of OA-related gene 
expression, which represents the OA phenotype, is maintained. Moreover, the ability 
to produce cytokines after pro-inflammatory stimulation is not significantly affected. 
This paves the way to establish a biobank of OA in which synovial tissue can be 
stored. To even further improve the in vitro possibilities to study gene therapy in the 
complex tissue of the synovium in vitro, we add to the development of the 3D synovial 
micromass model, based on human primary synovial cells that can form a lining similar 
to the synovial membrane. Chapter 5 focuses on the characterization of the synovial 
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micromass model. In this model, a synovial cell suspension is mixed with Matrigel 
fluid, which becomes solid at 37°C and contains different basement membrane and 
extracellular matrix proteins. We observe the migration of synovial fibroblast-like 
cells and macrophage-like cells to the surface to form a lining layer reminiscent of 
the synovial membrane. Several other cell types also appear in the micromass, but 
do not migrate. After stimulation with TNFα for 3 weeks, synovial hyperplasia occurs, 
which is similar to the situation in vivo. Interestingly, the synovial micromasses 
can be cryopreserved without a loss of viability or inflammatory response.  
 After studying inducible gene therapy in experimental RA and improving 
the in vitro research options for experiments based on primary human material, 
the inducible expression of anti-inflammatory IL-10 is extended to the human 
RA situation in Chapter 6. Based on microarray data of RA and control synovium, 
the promoter of the CXCL10 gene was selected for IL-10 expression. The CXCL10 
promoter was responsive to inflammatory stimuli and serum from RA patients. 
When a cell suspension of RA synovial cells was transduced with the CXCL10-IL10P 
lentiviral vector, the production of IL-10 was increased after stimulation with pro-
inflammatory factors. The increased IL-10 levels could reduce the production of pro-
inflammatory cytokines by the cells. We ultimately apply the CXCL10p-IL10 vector 
in the micromass model in Chapter 7. OA micromasses are transduced with the 
lentiviral CXCL10P-luciferase vector. Using confocal imaging, we show that the lining 
can be transduced, which is similar to findings in viral vector-transduced murine 
joints. The CXCL10 promoter was responsive to pro-inflammatory triggers and could 
provide a disease-responsive production of IL-10. When treated with the CXCL10P-
IL10 vector, the production of pro-inflammatory factors was reduced. This shows 
that the CXCL10P-IL10 vector can suppress the inflammation in an OA synovial lining 
model, indicating that CXCL10P-IL10 might be an interesting candidate to modify 
the disease course in OA.
A discussion and future perspectives for the micromass model, cryopreservation, 
gene therapy and inducible promoters for RA and OA are provided in Chapter 8.
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Objectives:   
Rheumatoid arthritis (RA) is a chronic destructive autoimmune disease, but the course 
is unpredictable in individual patients. An attractive treatment would provide a disease-
regulated therapy that offers personalized drug delivery. Therefore, we expressed the anti-
inflammatory interleukin-10 (IL-10) gene under the control of inflammation-dependent 
promoters in a mouse model of arthritis.
Methods:   
Proximal promoters of S100a8, Cxcl1, Mmp13, Saa3, IL-1b, and Tsg6 were selected by 
whole genome expression analysis of inflamed synovial tissues from arthritic mice. Mice 
were injected intra-articularly in knee joints with lentiviral vectors expressing a luciferase 
reporter or the therapeutic protein IL-10 under control of the Saa3 or Mmp13 promoter. 
After 4 days, arthritis was induced by intra-articular injection of streptococcal cell walls 
(SCW). At different time points after arthritis induction, in vivo bioluminescent imaging 
was performed and knee joints were dissected for histological and RNA analysis.
Results:   
The disease-regulated promoter-luciferase reporter constructs showed different 
activation profiles during the course of the disease. The Saa3 and Mmp13 promoters were 
significantly induced at day 1 or day 4 after arthritis induction respectively and selected 
for further research. Overexpression of IL-10 using these two disease-inducible promoters 
resulted in less synovitis and markedly diminished cartilage proteoglycan depletion and in 
upregulation of IL-1Ra and SOCS3 gene expression.
Conclusions:   
Our study shows that promoters of genes that are expressed locally during 
arthritis can be candidates for disease-regulated overexpression of biologics 
into arthritic joints, as shown for IL-10 in SCW arthritis. The disease-inducible 
approach might be promising for future tailor made local gene therapy in arthritis. 
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Introduction
Arthritis is a debilitating disease which affects about 1% of the world population. 
The course of the disease can be intermittent, with episodes of inflammation 
and remission. Conventional treatments nowadays consist of repeated 
systemic administration of biological drugs, such as tumor necrosis factor 
alpha (TNF-α) blockers, which continuously suppress the immune system. 
This kind of treatment gives rise to different side effects, like infections and the 
formation of anti-drug antibodies.1 Local gene therapy for arthritis, with the use 
of disease-regulated promoters, represents a promising alternative for coping 
with side effects of the conventional treatments. Using gene therapy via viral 
expression systems, the patient can be treated for a prolonged time, by only 
a single intra-articular injection. Nathwani and co-workers2 already showed 
this by treating hemophilia B patients using viral overexpression of factor IX.  
 Previously, we constructed different disease-regulated promoters from 
genes differentially regulated during collagen-induced arthritis in mice, selected 
via a computational approach3. These disease-regulated promoters respond to 
transcription factors activated during inflammation, restricting the production 
of the transgene to episodes of inflammation. Several promoters showed an 
inducible profile in lentivirally transduced macrophage and fibroblast cell lines 
after in vitro stimulation with LPS. In addition, the Saa3 promoter was able 
to detect differences between high and low inflammatory profiles in synovial 
fibroblasts from rheumatoid arthritis (RA) and osteoarthritis patients.4 This 
proved the inducibility and sensitivity of this promoter to disease activity.   
 Interleukin-10 (IL-10) is a good candidate transgene to suppress arthritis 
using disease-regulated promoters. IL-10 is a broad spectrum anti-inflammatory 
cytokine and is produced by different immune cells, like Th1 and Th2 cells, B cells, 
monocytes and macrophages. Inhibition of several pro-inflammatory cytokines has 
been reported; effects were seen on interleukin-1 (IL-1) and TNF-α.5,6 IL-10 is also 
known to induce the production of interleukin-1 receptor antagonist (IL-1Ra) and 
suppressor of cytokine signaling-3 (SOCS3).7,8 Nonetheless, several clinical studies 
showed lack of efficacy using IL-10 supplementation and even increased disease 
activity as compared to placebo treated RA patients has been reported9. Because the 
half-life of IL-10 is short, around 1.1 to 2.6 hours,8 patients had to be injected either 
intravenously or subcutaneously 3 times a week. Furthermore, in different cohorts, 
IL-10 treated patients were at risk of developing anemia. This paved the way for 
developing a more effective F8-IL-10 fusion protein, which targets the systemically 
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delivered IL-10 to the fibronectin deposits in the arthritic joints.10    
 Unnecessary off-target effects can also be avoided by using disease-regulated 
gene therapy to limit the height and time of exposure to IL-10 as we previously have 
shown for IL-4, a cartilage protective cytokine that has proinflammatory properties 
in vivo.11 We previously showed feasibility of the disease-regulated IL-10 therapy 
by transplantation of lentiviral transduced haematopoeitic stem cells.12 This led to 
production of IL-10 in B and non-B APC cells in lymph nodes and clear-cut reduction 
of collagen-induced arthritis (CIA). An effect also shown by Tanaka et al.13 where 
they found effects of IL-10 protein treatment on CIA. A reduction in the incidence 
and score of the arthritis was found, together with a significant reduction of IL-6 
by macrophages. The effect of local IL-10 treatment using this disease-regulated 
gene therapy concept has not been explored and could be very promising.   
 The streptococcal cell wall (SCW) model was chosen, because repeated 
intraperitoneal IL-10 injections showed a significant reduction in joint pathology.14 
Also, different processes of influx of inflammatory cells in the joint cavity, synovitis 
and proteoglycan depletion occur sequentially at different time points, resulting in a 
predictable disease course. Because we expected the disease-regulated promoters 
to respond differently to the these events, this model was chosen to elucidate the 
different kinetics of the disease-regulated promoters.
Hence, in this study, we set out to select the suitable disease-regulated promoter 
according to the profiles of the different promoters during the SCW-induced 
arthritis model. We showed that local disease-dependent overexpression of IL-10 
diminished proteoglycan depletion and synovitis and is therefore proven to be a 
suitable strategy to suppress disease activity.
Material and Methods
Animals  
Male 12 week old C57Bl/6N mice were obtained from Janvier (Le Genest 
Saint Isle, France). During virus experiments, mice were housed in HEPA 
filtered individually ventilated cages and were fed a standard diet with food 
and water ad libitum. All in vivo studies complied with national legislation 
and were approved by the local authorities of the Care and Use of Animals.  
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Plasmids  
Recombinant lentiviral vectors were generated using the third-generation self-
inactivating transfer vector pRLL-cPPT-PGK-mcs-PRE-SIN (PGK-empty) containing 
the human phosphoglycerate kinase (PGK) promoter (kind gift from J. Seppen, AMC 
Liver Center, Amsterdam, The Netherlands). Construction of promoter-luciferase 
constructs was done as described elsewhere.3 For construction of pRLL-cPPT-PGK-
IL10-PRE-SIN, pRLL-cPPT-Saa3-IL10-PRE-SIN and pRLL-cPPT-MMP13 -IL10-PRE-SIN, 
mIL-10 was amplified from pIG1-IL1e-IL6p-IL10, a construct used by Henningsson 
and collegues,12 using primers FW 5’- tttgctagctccaccatgcctggctc-3’ and RV 
5’-aaacatatgttagcttttcattttg-3’ introducing an NheI and NdeI site, and ligated into 
the promoter constructs.
Lentiviral vector production  
Lentiviral vector production was performed as described previously3 with co-
transfection of packaging and expression plasmids at half concentration. For the in 
vivo studies, knee joints were injected with 300 ng p24gag equivalents lentivirus in a 
total volume of 6 µl.
Cell culture  
Mouse embryonic fibroblasts (NIH-3T3) and macrophages (RAW 264.7) were 
cultivated in DMEM with 1 mM pyruvate, 40 µg/ml gentamycin, and 5% or 10% 
fetal calf serum (FCS) respectively. Cells were kept at 37˚C in a humid atmosphere 
containing 5% CO
2
.
In vitro luciferase measurements  
Cells were seeded at 3 x 104 cells per well in a white clear bottom Costar 96 wells plate 
(Corning, NY). After one day, cells were transduced with 50 ng p24gag equivalents 
lentivirus in 50 µl medium supplemented with 8 µg/ml polybrene (Sigma) for 4 
hours at 37˚C. Two days after transduction, cells were serum starved (1% FCS) for 
one day and subsequently stimulated with 10 ng/ml recombinant mIL-10 (R&D 
systems) or a combination of 10 ng/ml Pam3Cys (EMC Microcollection) and 100 
ng/ml E.Coli LPS (Sigma) for indicated hours. Thereafter, cells were lysed in water 
and luciferase activity was quantified using the Bright-Glo luciferase assay system 
(Promega, Madison, WI, USA) by adding an equal volume of Bright-Glo to the cell 
lysate. Luminescence was quantified in a luminometer (Lumistar, BMG, Offenburg, 
Germany).
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Preparation of streptococcal cell walls and induction of arthritis  
Strepococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt 
broth. Cell walls were prepared as described previously.15 Uni- or bilateral arthritis 
was induced four days after transduction with the lentivirus by injection of 25µg 
SCW in 6µl of phosphate buffered saline (PBS) into the joint cavity of the knee. 
In vivo bioluminescence imaging  
At indicated time points after SCW injection, in vivo bioluminescent imaging 
was performed (n=6 mice per inducible promoter) on an IVIS Lumina system 
(Caliper Life Sciences, Hopkinton, MA, USA), 10 minutes after intraperitoneal 
injection of 150 mg/kg D-Luciferine (Caliper Life Sciences) dissolved in PBS. Mice 
were anesthetized with 2,5% isoflurane/oxygen, shaved, placed on their back in 
the light tight chamber and imaged for 4 minutes with a sensitive CCD camera. 
Images were analyzed using the Living Image 3.0 software (Caliper Life Sciences). 
Two-dimensional regions of interest (ROIs) were drawn around the knee joints. 
Luciferase activity is presented in photons emitted per second per square cm.
Histology  
In total, 9 knee joints per inducible promoter per time point were used. Histological 
sections of knee joints were analyzed for synovitis, and proteoglycan depletion as 
described earlier.16
RNA isolation and quantitative PCR analysis
One synovial tissue sample from the lateral side and one from the medial side of 
the knee joint were isolated using a 3 mm biopsy punch (Stiefel, Wachtersbach, 
Germany) and pooled. In total, 9 knee joints per promoter per time point were 
analyzed. Total RNA was extracted from the tissue homogenates and from cells 
using TRI reagent (Sigma) according to manufacturer’s protocol. Isolated RNA was 
treated with DNAse followed by reverse transcription of 1µg RNA into cDNA using 
Moloney murine leukemia virus reverse transcriptase 0.5µg/µl oligo(dT) primers, 
and 12.5mM dNTPs (Invitrogen). Quantitative real-time PCR was performed 
using the StepOnePlus sequence detection system (Applied biosystems). PCR was 
performed in a total reaction volume of 12.5 µl consisting of appropriate cDNA, 5 µM 
forward and reverse primer and SYBR green PCR master mix (Applied biosystems). 
The PCR protocol consisted of 2 min at 50°C and 10 min of 95°C, followed by 40 
cycles of 15 sec at 95°C and 1 min at 60°C. The cycle threshold value (Ct) of genes 
of interest were compared to the Ct of reference gene glyceraldehyde-3-phophate 
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dehydrogenase (GAPDH) (delta Ct). Primer sequences are listed in Table S1.
 
Blood serum cytokine measurement  
KC (the murine homologue of IL-8) levels in the blood serum, were determined on 
a Luminex-100 system (Luminex Corp) using a bead-based multiplex immunoassay 
(Milliplex, Merck Millipore). Data analysis was performed with Bio-Plex Manager 
software (Bio-Rad Laboratories).
Statistics  
Statistical analysis was performed using students’ t-test, 1way ANOVA, Pearson 
correlation or Mann-Whitney U test (GraphPad Prism, V 4.0). A p-value of <0.05 
was regarded as significant.
 
Results
 
Selection of a promoter for local gene therapy.  
Luciferase reporter expression profiles of 6 different disease-regulated promoter 
reporters were made during SCW arthritis, using bioluminescence imaging (Fig. 
1A,B). All 6 promoters showed different activation kinetics during the acute model 
of arthritis. The Saa3 promoter showed the highest fold increase (127-fold) with an 
early activation at day 1 after arthritis induction. The Mmp13 promoter response 
showed a delay and was activated at day 4 and stayed high up to 7 days. All other 
promoters peaked at day 4 or 7 after SCW injection. Because of these profiles, the 
Saa3 and Mmp13 promoters seemed interesting candidates for local gene therapy 
using the anti-inflammatory IL-10 transgene. To ascertain that both promoters 
responded only to the local arthritic process we first tested the Saa3 and Mmp13 
promoter responses to IL-10, our transgene of choice. Mice were co-injected with 
PGK-IL10 and Saa3-luciferase or Mmp13-luciferase and the luciferase signal was 
measured at the same time points of SCW-arthritis (Fig. 2). The Saa3 and Mmp13 
promoters were still activated at day 1 and 4 respectively, indicating that the inducible 
promoters are not responsive to IL-10 in vivo. Therefore, no positive feedback loop 
will be created by the promoters that might uncouple their regulation by the local 
inflammatory process. This finding was supported in vitro, where likewise no effects 
of IL-10 were found on the activation of the Saa3 promoter by SCW in fibroblasts 
and macrophages, both important cell types in the synovial lining (Fig. S1). Our 
Mmp13 promoter construct is not responsive in both cell-types to the stimuli tested 
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as we have shown before,3 therefore an IL-10 effect could not be demonstrated 
(data not shown).
a
b
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Figure 1. Profiling of the different disease-regulated promoters using bioluminescent imaging.  
A) Both knee joints of 6 C57Bl/6N mice per inducible promoter were transduced with 300 ng p24gag 
lentiviral vector containing either the Saa3, S100a8, Cxcl1, IL-1b, Tsg6 or Mmp13 proximal promoter 
with luciferase reporter gene. Four days after transduction, the knee joints were injected with 25 µg 
SCW to induce arthritis. At day 0, 1, 4, 7 and 9, mice were imaged in a light tight chamber 10 minutes 
after luciferin injection. Luciferase activity was quantified and plotted as fold induction compared to 
day 0.    B) Representative images of the bioluminescent imaging of the Saa3 promoter in one mouse 
at day 0, 1, 4, 7 and 9. Depicted as mean±SEM; n=12.
 
Figure 2. Profiling of the disease-regulated Saa3 and Mmp13 promoter in SCW arthritis 
in the presence of local IL-10 expression.      
Both knee joints of 6 C57Bl/6N mice per inducible promoter were transduced with 300 ng p24gag 
lentiviral vector containing PGK-IL-10, cotransfected with either 300 ng p24gag lentiviral vector Saa3-
luciferase (A) or Mmp13-luciferase (B). Four days after transduction, the knee joints were injected 
with 25 4g SCW to induce arthritis. At day 0, 1, 4, 7 and 9, mice were imaged in a light tight chamber 
10 minutes after luciferin injection. Luciferase activity was quantified and plotted as fold induction 
compared to day 0. Depicted as mean±SEM; n=6.
IL-10 is upregulated by the Saa3 and Mmp13 promoters during arthritis.  
Next, the disease-regulated expression of the IL-10 transgene under the control 
of the inducible promoters was examined (Fig. 1A). Mice were i.a. injected in 
both knee joints with the lentiviral construct expressing IL-10 under the control 
of the constitutive PGK or the inducible Saa3 or Mmp13 promoter. One knee 
joint was injected with 25 µg SCW and the contralateral knee joint with PBS. 
Subsequently, IL-10 mRNA expression was measured in both knee joints at day 
1 after the intra-articular injections. The constitutive PGK promoter showed 
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the same extent of IL-10 expression in both the PBS injected control joint as 
well as the SCW injected arthritic knee joint, while the inducible Saa3 promoter 
showed a significant inducible expression in the arthritic knee joint compared to 
the contralateral knee joint (Fig. 3A,B). The Mmp13 promoter showed a slightly 
higher activity in the contralateral joint compared to Saa3 (Fig. 3B,C). At day 
4 and 7, IL-10 expression was upregulated by all three promoters, compared to 
the empty control treated animals (Fig. 3D,E). This confirms that the Saa3 and 
Mmp13 promoters are activated by inflammation after induction of arthritis. 
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Figure 3. IL-10 gene expression analysis of synovial tissue from knee joints after 
arthritis induction in joints with IL-10 overexpression.     
Both knee joints received intra-articular injections with lentiviral PGK-IL10, Saa3-IL10 or Mmp13-IL10. 
Arthritis was induced in one knee joint 4 days after transduction. After 1 day, gene expression analysis 
was performed for IL-10 in synovial tissue from both the arthritic and non-arthritic contralateral knee 
joint (A-C). IL-10 expression was also measured in synovial tissue from PGK-empy, PGK-IL10, Saa3-IL10 
and Mmp13-IL10 injected arthritic knee joints at day 4 (D) and day 7 (E). Gene expression is shown 
as -delta Ct, corrected for GAPDH. Depicted as mean±SEM; n=9. * = p<0.05, *** = p<0.0001 versus 
control Group empty when using a paired t-test (a-c) or a 1way ANOVA (D,E).
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Disease-dependent IL-10 expression decreases synovitis and 
proteoglycan depletion.       
To test the therapeutic effects of disease-regulated IL-10 expression, mice were 
treated locally with IL-10 under control of the Saa3 or Mmp13 promoter. After 4 days, 
SCW arthritis was induced. Mice were sacrificed for histological- and gene expression 
analysis at 1, 4 or 7 days after arthritis induction. Synovitis was significantly reduced 
in IL-10 treated joints at day 4 after arthritis induction (Table 1, Fig. 4A-D).   
 Proteoglycan depletion was significantly lower in IL-10 treated animals 
at day 4 and 7 after arthritis induction (Fig. 4E-H). Because the extent of the 
therapeutic effect on SCW arthritis of the Saa3 and Mmp13 promoters were similar, 
the subsequent in vivo experiments were performed using the Saa3 promoter.  
 
Figure 4. Histology of day 4 and 7 after arthritis induction in joints with 
IL-10 overexpression.       
Histology of knee joints using haematoxylin-eosin staining for analysis of inflammation and safranin-O 
staining for analysis of cartilage proteoglycan depletion. Knee joints were injected with PGK-empty 
(A,E), PGK-IL10 (B,F), Saa3-IL10 (C,G) or Mmp13-IL10 (D,H). Histology from day 4 (A-D) or day 7 (E-H) 
after arthritis induction is shown. Representative pictures from mice described in table 1 are depicted. 
p=patella, f=femur, s=synovium, c=cartilage.
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Table 1. Histological scoring after local inducible IL-10 gene therapy in 
SCW-induced joint pathology.      
Histological scoring of exudates (exu), synovitis (syn) and proteoglycan depletion (PG depl) at day 1, 4 
and 7 after arthritis induction showed a significant decrease in synovitis and proteoglycan depletion 
after IL-10 overexpression. Depicted as median±interquartile range. n=6 mice. * = p<0.05, ** = p<0.01, 
*** = p<0.0001 statistically significant as compared to control group PGK-Empty using a 1way ANOVA.
Day 1 Day 4 Day 7
Exu Syn PG depl Exu Syn PG depl Exu Syn PG depl
PGK 
Empty
3.0
(2.6-3.0)
1.0
(0.6-1.0)
1.0
(0.1-1.5)
1.5
(1.0-1.5)
2.0
(2.0-2.5)
3.0
(2.0-3.0)
0.5
(0.5-0.5)
1.0
(1.0-1.8)
2.0 
(1.5-3.0)
PGK
IL10
2.3
(2.0-2.9)
1.0
(1.0-1.4)
0.8 
(0.1-1.0)
1.5
(1.0-1.8)
1.5**
(1.3-2.0)
2.0*
(1.5-2.0)
0.5
(0.5-0.5)
1.0
(1.0-1.5)
0.5**
(0.0-1.3)
Saa3
IL10
3.0
(2.3-3.0)
1.0
(0.6-1.0)
0.8
 (0.5-1.4)
1.0
(0.5-1.5)
1.5**
(1.0-2.0)
1.5***
(1.0-1.8)
0.5
(0.0-0.5)
1.0
(0.8-1.3)
0.0**
(0.0-1.8)
Mmp13
IL10
2.8
(2.5-3.0)
1.0
(0.6-1.4)
1.0
(0.6-1.4)
2.0
(0.8-2.0)
1.5**
(1.0-2.0)
1.5**
(0.5-2.3)
0.5
(0.3-0.5)
1.5
(1.0-1.8)
1.0*
(0.3-2.0)
 
Disease-dependent IL-10 upregulation has an effect on protein and 
gene expression.  
Keratinocyte chemoattractant (KC) protein concentration was measured one 
day after arthritis induction in the serum of Saa3-IL-10 mice. KC is the murine 
homologue of IL-8, a cytokine involved in recruiting inflammatory cells to invade 
the joint. A significant reduction in KC concentration from 359±84 pg/ml to 161±32 
pg/ml using the PGK promoter and to 139±26 pg/ml using the Saa3 promoter was 
seen compared to the control group (Fig. 5). In addition, IL-1Ra was upregulated in 
the synovium at the gene expression level at day 7 in the Saa3 group, compared to 
the empty control virus. This effect was also seen on Socs3 gene expression at day 4 
and 7 (Fig. 6A,B). At these time points, IL-1Ra and Socs3 expression was significantly 
correlated with IL-10 expression (Fig. 6C), indicating that the upregulation is the 
result of IL-10 expression. 
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Figure 5. Expression of KC at day 1 after arthritis induction in knee joints with IL-10 
overexpression.   
KC protein concentration (pg/ml) was measured in blood serum at day 1 after arthritis induction using a 
bead array. A significant (p<0.05) lower concentration was found in the blood serum of mice treated with 
Saa3-IL10. Depicted as mean±SEM; n=9. * = p<0.05 versus control group empty using a 1way ANOVA. 
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Figure 6. IL1Ra and Socs3 mRNA expression after IL-10 overexpression.
IL1Ra (A) and Socs3 (B) gene expression in synovial tissue from knee joints was measured by qPCR. 
Significant upregulation was seen in the PGK-IL10 and Saa3-IL10 treated groups, compared to the 
PGKempty group. Gene expression is shown as -delta Ct, corrected for GAPDH. Depicted as mean±SEM; 
n=9. * = p<0.05, ** = p<0.01, *** = p<0.0001 versus control group empty when using a 1way ANOVA. 
The expression levels at day 7 were correlated with IL-10 overexpression for IL1Ra (C) and SOCS3 (D). 
Depicted as individual joints. * = p<0.05, *** = p<0.0005 using Pearson r correlation analysis.
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Discussion 
In this study, we have shown that IL-10 under the control of the 
disease regulated promoters Saa3 and Mmp13 can diminish synovitis 
and cartilage proteoglycan depletion in experimental arthritis. Effects 
were seen on histology, protein- and gene expression levels.  
 SCW-induced arthritis is an acute and transient model, which triggers the 
alternative complement activation cascade to attract neutrophils to the joint, already 
at day 1 after induction. A peak in synovitis is seen at day 4 after induction and 
proteoglycan depletion is most severe at day 7. During these stages of the disease, 
different transcription factors are activated, triggering the recombinant promoters at 
different time points, resulting in distinct profiles between the different promoters. 
The Saa3 promoter contains multiple predicted binding sites for C/EBPβ,3 which is 
associated with the acute phase of inflammation.11 Microarray analysis also revealed 
a high and quick upregulation of the Saa3 gene in the knee joints of mice with RA.3 
According to the in vivo profile of promoter activation, Saa3 is highly upregulated with 
a 127 fold increase one day after induction of arthritis, as expected for an acute phase 
protein. In contrast, the Mmp13 promoter contains at least three functional binding 
sites for ETV4, which is associated with tissue remodeling and repair mechanisms 
taking place in the remission phase of arthritis.17 This explains the observed delay 
in MMP13-luciferase expression in the short-lasting SCW-arthritis model.  
 The inducibility of the Saa3 and Mmp13 promoters was shown by upregulation 
of IL-10 in the arthritic knee, compared to the non-arthritic knee. The constitutive 
PGK promoter, on the other hand, did not show inducibility, but a continuous 
upregulation of IL-10 in both the arthritic and non-arthritic knee. No direct effects 
of IL-10 on Saa3 promoter activation were found, indicating that the Saa3-IL-10 
construct produces no positive feedback loop. Among others, the Mmp13 promoter 
was activated at from day 4. The Tsg6 promoter even showed strongest induction at 
day 7, indicating that the promoters are activated during different phases in disease. 
Therefore, promoters can be selected for temporal delivery of therapeutic transgenes 
to target a specific process during the course of disease, e.g. osteophyte formation 
or synovial fibrosis. Such stratified approacheswarrant further investigation.  
 Upregulation of IL-10 was seen at all days after disease induction. 
The therapeutic effect of IL-10 overexpression was seen on histology: both 
proteoglycan depletion and synovitis were significantly decreased. This is in 
line with the results of Lubberts et al.14 where likewise an effect of IL-10 on 
inflammatory cell influx and proteoglycan depletion was found after repeated 
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injections of IL-10 during SCW arthritis in mice. In addition, both IL1Ra and SOCS3 
were upregulated. These genes are known to be induced by IL-10.6,7 IL1Ra is 
known to counteract the detrimental IL-1-dependent production and activation 
of different MMPs and aggrecanases.18 By blocking IL-1 with IL-10 induced IL-1Ra, 
these effects might be inhibited. SOCS3 can inhibit the JAK/STAT pathway and 
therefore diminish synovitis by, for instance, downregulating IL-6.7,19   
 The neutrophil attracting chemokine KC protein levels were also 
significantly lower at day 1 after disease induction, which can influence 
synovitis as well.20 Arthritis activates the complement cascade, with subsequent 
release of C5a21 C5a can activate the p38 MAP kinase pathway22 and as a 
consequence KC is upregulated.23 The p38 pathway can be inhibited by IL-1024 
and therefore influence the expression of KC. Alternatively, IL-10 can induce 
instability of KC mRNA by repressing the mRNA stabilizing protein HuR.24,25  
 We showed that treatment of an acute joint inflammation with local IL-10 
overexpression under the control of disease-regulated promoters, is a promising 
concept to modulate arthritis progression. By precise timing and prolonged, 
restricted production at the site of inflammation we might limit adverse IL-10 side 
effects in RA patients, such as the risk of developing anemia. It has been shown that 
IL-10 can enhance the FcγRI and IIa expression on monocytes/macrophages resulting 
in enhanced TNF-α production in response to immune complexes.9 Although we did 
not use an antibody-mediated arthritis model, IL-10 in our study did not enhance the 
expression of both receptors (data not shown). Disease-inducible promoters might 
be applied for expression of a transgene as a quick response to inflammation, or for 
supplementing the endogenous production of anti-inflammatory mediators at later 
time points, as we showed for the Saa3 and Mmp13 promoters respectively. This 
study showed that our previously described computational approach for selecting 
disease-response promoters combined with thorough in vivo validation using 
bioluminescent imaging of transgene expression results in promising candidates for 
tailor made/personalized therapy using local delivery of biological genes in arthritis. 
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Supplementary information
Supplementary Table S1. Sequences of primers used for quantitative PCR measurements.
Primer FW RV
IL-10 ATTTGAATTCCCTGGGTGAGAA ACACCTTGGTCTTGGAGCTTATTAA
IL-1Ra CAAGATGCAAGCCTTCAGAATCT CACCATGTCTATCTTTTCTTCTAGTTTGA
SOCS3 TAGACTTCACGGCTGCCAAC CGGGGAGCTAGTCCCGAA
 
Supplementary Figure S1: Luciferase signal in stimulated fibroblasts and macrophages in vitro 
after transduction with Saa3-luciferase.      
NIH-3T3 fibroblasts (A) or RAW264.7 macrophages (B) were transduced with 50 ng p24gag lentiviral 
vector containing the Saa3 proximal promoter and luciferase reporter gene. Subsequently, cells were 
stimulated with either IL-10, SCW or a combination IL-10 and SCW. 6 hours after stimulation, luciferase 
activity was quantified and plotted as relative light units.
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Objective: 
Tumor necrosis factor-inducible gene 6 (TSG-6) has anti-inflammatory and 
chondroprotective effects in mouse models of inflammatory arthritis. Because cartilage 
damage and inflammation are also observed in OA, we determined the effect of viral 
overexpression of TSG-6 in experimental osteoarthritis.
Methods: 
Bone marrow-derived cells (BMDCs) were differentiated to multinucleated osteoclasts in 
the presence of recombinant TSG-6 or after transduction with a lentiviral TSG-6 expression 
vector. Multi-nucleated osteoclasts were analyzed after tartrate resistant acid phosphatase 
(TRAP) staining and resorption activity was determined on dentin slices. Collagenase-
induced osteoarthritis (CIOA) was induced in C57BL/6 mice after intra-articular injection 
of an adenoviral TSG-6 or control luciferase expression vector. Inflammation-related 
protease activity was measured using bioluminescent Prosense probes. After a second 
adenovirus injection, cartilage damage was assessed in histological sections stained with 
Safranin-O. Ectopic bone formation was scored in X-ray images of the affected knees.
Results: 
TSG-6 did not inhibit the formation of multi-nucleated osteoclasts, but caused a significant 
reduction in the resorption activity on dentin slices. Adenoviral TSG-6 gene therapy in 
CIOA could not reduce the cartilage damage compared to the luciferase control virus and 
no significant difference in inflammation-related protease activity was noted between the 
TSG-6 and control treated group. Instead, X-ray analysis and histological analysis revealed 
the presence of ectopic bone formation in the TSG-6 treated group.
Conclusion: 
Gene therapy based on the expression of TSG-6 could not provide cartilage protection 
in experimental osteoarthritis, but instead resulted in increased ectopic bone formation.
Introduction
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No disease-modifying treatments are currently available for the treatment of OA 
and affected end-stage joints are often surgically replaced. OA was once viewed as 
mechanical wear-and-tear of the cartilage, but in recent years there is increasing 
evidence that OA is a complex disease affecting the whole joint. Multiple proteins 
might interfere with OA pathology, including tumor necrosis factor-alpha (TNFα)-
stimulated protein 6 (TSG-6).
TSG-6, encoded by the TNFα-induced protein 6 (TNFAIP6) gene, is expressed 
by different cell types after inflammatory stimulation.1 The protein consists of a 
Link and a CUB domain that can bind multiple proteins and extracellular matrix 
molecules2 and has shown protective effects in experimental arthritis models. 
Transgenic mice with cartilage-specific constitutive overexpression of TSG-6 show 
chondroprotective effects of TSG-6 in the antigen-induced arthritis model.3 In 
addition, recombinant TSG-6 also showed anti-inflammatory effects in collagen-
induced arthritis.1
Several mechanisms have been proposed for the chondroprotective and 
anti-inflammatory effects of TSG-6.2 Firstly, TSG-6 can activate the inter-α-inhibitor 
(IαI) by transferring its heavy chains to hyaluronan (HA). The activated IαI can 
subsequently inhibit the activation of plasmin and thus prevent the cleavage and 
activation of pro-matrix metalloproteinases (pro-MMPs). Secondly, TSG-6 can 
modulate the interaction between HA and CD44 to influence CD44-dependent 
migration of leukocytes into the joint.4 In addition, TSG-6 has been shown to interact 
with CXCL8, BMP-2 and RANKL influencing inflammation and bone remodeling.5,6
Because cartilage damage, inflammation and bone remodeling have also 
been implicated in the pathogenesis of OA, we hypothesized that TSG-6 gene 
therapy might also have protective effects in experimental OA. In this study we first 
showed functionality of the TSG-6 gene therapy in vitro by inhibiting osteoclast 
activity. Subsequently, we tested the TSG-6 gene therapy in the collagenase-induced 
OA (CIOA). We did not observe therapeutic effects of TSG-6 overexpression on 
inflammation or cartilage damage. In contrast, we observed ectopic bone formation 
at the medial femur/tibia region of the joint.
 
Materials and methods
Virus production  
Vector cloning is described in the supplementary methods. Lentiviral and adenoviral 
vector production were performed as described previously.7,8
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Bone marrow-derived cell culture  
Bone marrow-derived cells (BMDCs) of C57BL/6 mice were obtained from the femur 
and the tibia. Bone marrow cells were flushed from the bones using RPMI medium 
supplemented with 10% fetal bovine serum (FBS), 1 mM pyruvate and 1% penicillin/
streptomycin (P/S) using a Microlance 3 needle (Becton Dickinson (BD), Breda, The 
Netherlands). Cells were passed trough a 70 µm cell strainer (Corning, NY, USA) 
and centrifuged for 5 min at 1500 rpm/423 g in a Heraeus Megafuge 16R (Thermo 
Scientific). In a 96-well plate (Greiner Bio-one, Alphen a/d Rijn, The Netherlands), 
105 cells were seeded on the surface of the plate for differentiation analysis or on 
an elephant dentin slice for the bone resoption assay. Osteoclast differentiation 
was induced in alpha-MEM medium, supplemented with 5% FBS, 1% P/S, 30 ng/ml 
M-CSF (R&D systems, Oxford, UK) and 20 ng/ml RANKL (R&D systems). For tartrate 
resistant acid phosphatase (TRAP) staining, after 72h the the osteoclast medium was 
replaced to induce osteoclast fusion with or without 1 µg/ml recombinant murine 
TSG-6 (rmTSG-6) (R&D) for 24h. Subsequently, cells were fixed and stained with the 
TRAP staining kit (Sigma-Aldrich, Zwijndrecht, The Netherlands) according to the 
manufacturer’s protocol. For the bone resorption assay, after 72h the differentiation 
medium was replaced and cells were transduced with 166 ng lentivirus per 105 cells 
in each well or left untreated until day 4, at which 1 μg/ml rmTSG-6 was added to 
the rmTSG-6 group to align with protein production in the TSG6-transduced cells. 
At day 7, medium was removed from all dentin slices and cells were lysed with H
2
O.
Resorption assay  
After incubation with the osteoclasts, dentin slices were incubated with 10% 
NH
3
 and sonicated for 20 cycles 30 seconds on/off. After washing, the slices were 
incubated for 10 minutes with 10% Kal(SO
4
)
2
 and stained with PhastGel Blue R-350 
coomassie tablets (GE Healthcare, Eindhoven, The Netherlands) according to the 
manufacturer’s protocol. For the quantification, 5 pictures at 200x magnification 
were taken from every dentin slice using the Labovert FS (Leitz, Leica, Rijswijk, The 
Netherlands). The Leica application Suite (LAS) was used to analyse the average 
bone resorption percentage per dentin slice.
Synovial biopsy culture  
Synovial biopsies were obtained from surplus C.B-17 mice after sacrifice. Using 
a 3 mm biopsy punch (Stiefel, Wachtersbach, Germany), synovial explants were 
obtained and combined from the lateral and medial synovium. The biopsies were 
kept in 200 µl RPMI medium supplemented with 1 mM pyruvate and 1% P/S and 107 
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infectious units adenovirus CMV-luc or CMV-TSG6 was added. After 2h, 20 µl FBS 
was added and after 24h, total RNA was isolated using 500 µl Tri reagent (Sigma) 
according to the manufacturer’s protocol and processed and analyzed as decribed 
in the supplementary materials. 
Collagenase-induced OA  
Detailed animal experimental procedures are described in the supplementary 
methods in accordance with the ARRIVE guidelines. In short, 30 female C57Bl/6J 
mice (Janvier) received intra-articular (i.a.) injections of 107 infectious units 
adenovirus CMV-luc or CMV-TSG6 4 days prior to the start of the induction of the 
model in the right knee. Collagenase-induced OA (CIOA) was induced by two i.a. 
injections of 1 unit collagenase type VII (Sigma) at day 1 and day 3. A second virus 
injection was given at day 21 of CIOA and mice were sacrificed at day 42.All animal 
experiments were approved by the local authority Animal Care and Use Committee 
and local ethics committee (RU-DEC 2014-080).
Prosense measurement 
6 days after the first collagenase injection, 5 mice per group received i.v. injections 
of 1,33 nmol Prosense 680 probes (PerkinElmer, Groningen, The Netherlands) in 
100 µl in the orbita plexus. At day 7, hair was removed from the knees and the 
mice were imaged with the IVIS Lumina (PerkinElmer) using the Cy5.5 filter. The 
data was analyzed using Living Image 3.0 (PerkinElmer). Regions of interest (ROIs) 
of the same size were drawn around the knees and the florescence intensity were 
determined for the experimental and contralateral knees.
X-ray imaging  
After sacrifice, the mouse knees were removed and imaged using the Faxitron FX-
20 (Faxitron, Tucson, AZ, USA) at 26 KV for 10 seconds. The images were blinded 
and randomized and the ectopic bone formation was given an arbitrary score of 
0-5. 0=no ectopic bone formation visible, 1=ectopic bone formation just detectable, 
2=clear ectopic bone formation, 3=bone formation stretching along femur and 
tibia, 4=large ectopic bone formation, 5=severe ectopic bone formation, similar to 
the most severe sample.
Histological analysis  
After X-ray imaging, knee joints were fixed in formalin, embedded in paraffin 
and cut in 7 µm sections. The sections were stained with Safranin-O/Fast Green, 
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blinded and randomized. Cartilage damage was assessed using an arbitrary score 
of 0-30 based on the modified OARSI cartilage OA histopathology grading system as 
described by Glasson et al. OAC 2010. Several mice showed dislocation of the knee 
joint, but these were distributed equally between the groups and are incorporated 
in the analysis.
Statistical analysis  
Statistical comparisons were performed by One-way analysis of variance (ANOVA) 
and Mann-Whitney U test as indicated in the text using GraphPad Prism 5.03. 
Results are depicted as mean +/- 95% confidence interval (CI) and p-values below 
0.05 were regarded as significant.
 
Results  
 
We first tested the functionality of viral expression of TSG-6 in vitro. BMDCs 
were differentiated to multinucleated osteoclasts using M-CSF and RANKL in 
the absence or presence of recombinant murine TSG-6. We did not observe any 
effect of TSG-6 on the ability of the BMDCs to form multi-nucleated osteoclasts 
(Fig. 1A). We subsequently assessed the effects of TSG-6 on osteoclast resorption 
activity on dentin slices. Under positive control conditions with lentiviral control 
virus, resorption pits covered ~20% of the dentin surface (Fig. 1B). The resorption 
by the multinucleated osteoclasts was significantly reduced by both recombinant 
TSG-6 (~72%) and the lentiviral expression of TSG-6 (~49%). This shows that 
viral overexpression of TSG-6 can result in functional levels of TSG-6.   
 Overexpression of TSG-6 in synovium was first investigated in synovial 
explants. After transduction with adenoviral CMV-TSG6, the expression of TSG-6 
was significantly increased compared to CMV-luciferase (Fig. 2A). The protective 
effects of TSG-6 on inflammation and cartilage damage were tested in the CIOA 
model. Mice received an injection with adenovirus to provide high expression levels 
of TSG-6 or control luciferase in the right knee 4 days prior to the first collagenase 
injection8. The effects of TSG-6 on inflammation-associated protease activity was 
determined in a subset of the mice after injection of Prosense 680 probes at day 6 
after the first collagense injection. At day 7, the fluorescence intensity was measured. 
No strong protease activity was measured compared to the naïve contralateral knee 
and no significant
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Figure 1: Osteoclastogenesis and bone resorption by bone marrow-derived cells (BMDCs) after TSG-
6 treatment. (A) TRAP staining of BMDCs differentiated to osteoclasts using M-CSF and RANKL. Multi-
nucleated osteoclasts are indicated by black arrows. (B) BMDCs were seeded on dentin slices and 
differentiated to osteoclasts. After 3 days of differentiation, cells were transduced with control of TSG-
6 virus or not transduced. After 24 hours, 1 μg/ml recombinant murine TSG-6 (rmTSG6) was added 
to the rmTSG-6 group The cells were incubated for 3 additional days and thereafter the resorption 
pits were evaluated. RANKL was present during the whole experiment, but was omitted in the ‘no 
RANKL’ group. Every sample represents an average of 5 pictures and the bone resorption is depicted 
as percentage resorption of the complete surface. Statistical comparisons were performed by one-way 
ANOVA.
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differences were found between the TSG-6 adenovirus and the luciferase control 
virus (Fig. 2B). A second adenovirus injection was given at day 20 to provide TSG-6 
expression for the second half of the model and mice were sacrificed at day 42. The 
cartilage damage was assessed in histological sections using the OARSI cartilage OA 
histopathology grading system. No significant differences were observed in cartilage 
damage between the control group and the TSG-6 treated group (Fig. 2C,D).   
 Before the joints were processed for histological analysis, the bone structure 
was analysed using X-ray imaging and scored using an arbitrary scoring method 
from 0 to 5. Surprisingly, mice treated with adenoviral TSG-6 showed significantly 
more ectopic bone formation (77%) compared to the control group (20%) located at 
the medial collateral ligament (Fig. 2E,F). Safranin-O staining of histological sections 
of the joints shown in Figure 2G show the presence of cartilage around the ectopic 
bone, indicating that the ectopic bone formation might be the result of cartilage 
ossification (Fig. 2G).
 
 
Figure 2: Effects of adenoviral luciferase or TSG6 on collagenase-induced osteoarthritis (CIOA). 
(A) Expression of TSG-6 in synovial explants, 24h after transduction with adenoviral CMV-luciferase 
(CMV-luc) or CMV-TSG6. (B) Prosense measurement at day 7 to assess the inflammation-associated 
protease activity. The fluorescence intensity ratio compared to the contralateral knee was calculated. 
(C) Magnification of examples of cartilage damage. Representative pictures of the medial femur and 
tibia are shown after Saphranin-O staining. (D) Cartilage damage at day 42. For every knee joint, the 
cartilage damage was determined in the medal tibia, medial femur, lateral tibia and lateral femur in 
three sections. The average cartilage damage is depicted. (E) Typical X-ray images of knee joints at 42. 
Ectopic bone formation is indicated by the red arrow. (F) Arbitrary scoring of ectopic bone formation 
(0-5) in the X-ray images. (G) Histological sections of the knee joints shown in Figure 3E. Sections were 
stained with Safranin-O and counterstained with Fast Green. Ectopic bone formation is indicated with 
black arrows. Statistical comparisons were performed by Mann-Whitney U test.
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Discussion
In this study, we show that in vitro viral overexpression of TSG-6 in BMDCs has no 
effect on multinuclear osteoclast formation, but can reduce resorption activity of 
the osteoclasts. This has been observed in earlier studies6 and shows that functional 
TSG-6 can be expressed after viral gene transfer. However, when tested in the CIOA 
model, TSG-6 could not reduce cartilage damage. In contrast, we observed increased 
ectopic bone formation in mice with TSG-6 overexpression.    
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 Although TSG-6 is associated with different functions that might be 
protective for OA, the expression and activity of TSG-6 correlate with progression 
of OA.9 The exact mechanisms by which TSG-6 might be involved OA progression 
is not completely understood and is difficult to study because of the ability of 
TSG-6 to bind many different proteins and matrix components. One potential 
mechanism could be related to a disturbance of damage repair mechanisms. TSG-
6 has been shown to bind to fibronectin (FN), stimulating FN matrix assembly 
involved in damage repair.10 However, TSG-6 can also serve as a bridging 
molecule between FN and thrombospondin-1 (TSP-1). TSP-1 is increased in OA 
chondrocytes and osteophytes and has multiple functions, including the activation 
of latent Transforming Growth Factor-β (TGF-β).11,12 Increased TGF-β activity has 
previously been correlated with chondrocyte differentiaton and enthesophyte 
formation similar to this study in the medial collateral ligament in CIOA.8,13  
 An alternative mechanism for increased TGF-β activity could be related to 
HA. In the context of fibrosis, studies have shown that the heavy chain transfer 
to HA by TSG-6 can stabilize the HA coat, which is essential for TGF-β-mediated 
myofibroblast differentiation.14 Possibly, TSG-6 can increase TGF-β-mediated 
chondrogenesis in a similar way. HA could also increase chondrogenesis in adipose-
derived stem cells.15 This was dependent on the interaction between HA and 
CD44, which is influenced by TSG-6.4 The formation of bone is dependent on the 
ratio between bone matrix deposition and bone resorption. The inhibiting effects 
on osteoclast activity observed in Figure 1B might favor the anabolic activity and 
stimulate the ectopic bone formation. Although the exact mechanism by which 
TSG-6 can increase ectopic bone formation in vivo remains to be elucidated, no 
improvement in cartilage damage in CIOA was observed, indicating that intra-
articular gene therapy with TSG-6 might not be a promising treatment for OA and 
our study places TSG6 as a potential target in OA that warrants future studies.  
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Ethical approval of animal studies  
  
All animal experiments were approved by the local authority Animal 
Care and Use Committee and local ethics committee (RU-DEC 2014-
080). Animal care was in accordance with the institution guidelines.  
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Supplementary methods
Vector cloning  
For cloning of the third generation self-inactivating lentiviral vector (sin), the TSG-
6 coding sequence was obtained from a cDNA sample of inflamed synovium of a 
C57BL/6 mouse by nested PCR. The first round of PCR was done by amplification 
using forward primer 5’-CGGCTCTGCAACCGAAGA-3’ and reverse primer 
5’-ATCCAAAAGTATTTATTACAGCAAT-3’. For the second round of amplification, 
forward primer 5’-GTCGACGCCACCATGGTCGTCCTCC-3’ and reverse primer 
5’-CATATGATCCAAAAGTATTTATTAC-3’ were used, introducing restriction sites for 
SalI and NdeI respectively. The TSG-6 gene was cloned in the pRRL-cPPT-PGK-luc-
PRE-SIN vector using the strategy previously described1. As a control vector, the 
Trifusion reporter gene was digested from the pcDNA3.1 vector (kind gift from 
Robert E. Reeves, Stanford University) using NheI and XbaI (New England Biolabs). 
For adenovirus cloning, TSG-6 was digested from the PCR-script CAM vector using 
SalI and ligated in the SalI pre-digested pShuttle-CMV (Stratagene, La Jolla, CA, 
USA). The CMV-luciferase adenovirus was used as control vector.
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RNA isolation and qPCR 
Synovial biopsies in Trizol were first homogenated using Magnalyzer Green Beads 
(Roche Life Sciences, Almere, The Netherlands) and processed according to the 
provided protocol. DNA was removed by DNAse and cDNA was generated using 
Moloney murine leukemia virus reverse transcriptase, 0.5µg/µl oligo(dT) primers 
and 12.5mM dNTPs (Thermo Scientific). Quantative real-time PCR was perfomed 
as previously described7 using forward primer 5’-CAACCCACATGCAAAGGAG-3’ and 
reverse primer 5’-TACTCATTTGGGAAGCCCG-3’.
Collagenase-induced OA  
30 Female C57BL/6J mice (Janvier) of 10-12 weeks old were randomized and housed 
in groups of 5 in filtertop cages at DM-II level with 12-h light-dark cycles and water 
and standard diet (AB Diets, Woerden, The Netherlands) were provided ad libitum. 
The mice received an intra-articular (i.a.) injection of 107 infectious units adenovirus 
CMV-luc or CMV-TSG6 dissolved in 6 µl 0.9% NaCl 4 days prior to the start of the 
induction of the model. All i.a. injections were performed during the day in the right 
knee using a BD microlance needle 30G 1/2’ (BD) under general anaesthesia using 
2,5% isoflurane. The injections were performed by a technician without knowledge 
of the viral vector content in a laminar flow cabinet. Collagenase-induced OA (CiOA) 
was induced by two i.a. injection of 1 unit collagenase type VII (Sigma) in 6 µl 0.9% 
NaCl at day 1 and day 3. At day 21, a second injection with the same viral vector was 
given and mice were sacrificed by cervical dislocation at day 42.
TSG-6 gene therapy in experimental osteoarthritis results in ectopic bone formation
70
     
Chapter 4
Functional Tissue Analysis Reveals Successful 
Cryopreservation of Human Osteoarthritic 
Synovium
Mathijs G.A. Broeren, Marieke de Vries, Miranda B. Bennink, Peter L.E.M. van Lent, 
Peter M. van der Kraan, Marije I. Koenders, Rogier M. Thurlings, Fons A.J. van de Loo
PLoS One. 2016 Nov 21;11(11)
Functional Tissue Analysis Reveals Successful Cryopreservation of Human Osteoarthritic Synovium
72
Osteoarthritis (OA) is a degenerative joint disease affecting cartilage and is the most 
common form of arthritis worldwide. One third of OA patients have severe synovitis and 
less than 10% have no evidence of synovitis. Moreover, synovitis is predictive for more 
severe disease progression. This offers a target for therapy but more research on the 
pathophysiological processes in the synovial tissue of these patients is needed. Functional 
studies performed with synovial tissue will be more approachable when this material, that 
becomes available by joint replacement surgery, can be stored for later use. We set out 
to determine the consequences of slow-freezing of human OA synovial tissue. Therefore, 
we validated a method that can be applied in every routine laboratory and performed 
a comparative study of five cryoprotective agent (CPA) solutions. To determine possible 
deleterious cryopreservation-thaw effects on viability, the synovial tissue architecture, 
metabolic activity, RNA quality, expression of cryopreservation associated stress genes, 
and expression of OA characteristic disease genes was studied. Furthermore, the biological 
activity of the cryopreserved tissue was determined by measuring cytokine secretion 
induced by the TLR ligands lipopolysaccharides and Pam3Cys. Compared to non frozen 
synovium, no difference in cell and tissue morphology could be identified in the conditions 
using the CS10, standard and CryoSFM CPA solution for cryopreservation. However, we 
observed significantly lower preservation of tissue morphology with the Biofreeze and 
CS2 media. The other viability assays showed trends in the same direction but were not 
sensitive enough to detect significant differences between conditions. In all assays tested 
a clearly lower viability was detected in the condition in which synovium was frozen 
without CPA solution. This detailed analysis showed that OA synovial tissue explants can 
be cryopreserved while maintaining the morphology, viability and phenotypical response 
after thawing, offering enhanced opportunities for human in vitro studies.
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Introduction
Osteoarthritis is a common joint disease characterized by degenerative alterations 
in the articular cartilage. However, it is becoming more evident that OA is not 
just a wear and tear disease of the cartilage but involves multiple joint tissues 
including the synovium.1,2 The synovium is the tissue lining the joint capsule and 
in OA often shows signs of inflammation, for example by macrophages infiltrating 
the synovium. These macrophages produce pro-inflammatory cytokines like 
IL1β and TNFα, activating the fibroblast-like synoviocytes to release additional 
cytokines (IL6 , IL8) and matrix-degrading enzymes.3 These cytokines and 
enzymes damage the articular cartilage, resulting in the release of damage-
associated molecular patterns (DAMPS) that have pro-inflammatory properties 
as well, creating a perpetuating loop causing low grade chronic inflammation.3,4 
This inflammation is suggested to contribute to the disease phenotype and 
disease progression.1,2,5 Studying the fundamental pathological processes in 
the OA synovium would help in finding a treatment for this disease.   
 Of importance for such studies is the availability of synovial tissue. 
Patient material becomes available as remnant material after joint replacement 
surgery, or via synovial biopsy. Functional studies on synovial tissue are often 
limited to a small number of patients as material needs to be used immediately 
when becoming available. Thus, timing is an important issue, hampering 
optimal planning and synchronization of an experiment. A solution would be to 
cryopreserve the valuable synovial tissue in such a way that the thawed synovial 
tissue performs identical to freshly obtained material. To our knowledge there 
are no studies describing cryopreservation of human OA synovial tissue in 
which the disease characteristic cell functions and interactions are maintained.  
 Although cryopreservation of cell lines is widely and successfully 
applied in almost every cell culture lab, the cryopreservation of primary cells 
and especially complex tissues is still challenging,6-11 as no regeneration takes 
place. Furthermore, a tissue is composed of a mixture of cell types, all with their 
specific optimal cryopreservation requirements.8,10 Size is another obstacle, as 
this influences CPA solution penetration and leads to differences in exposure 
to CPAs.12 Globally, two cryopreservation methods exist, slow freezing and 
vitrification. Vitrification has theoretical advantages over slow freezing once the 
optimal conditions are determined. However, the high CPA concentration needed 
to vitrify the material is a major drawback, due to their toxicity.10 Slow freezing 
uses low concentrations of CPA, reducing CPA toxicity. Another advantage of slow 
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freezing is that the procedure to get the tissue ‘freezer-ready’ is fast and easy 
to apply in every routine laboratory without needing advanced equipment.   
 We have compared four commercially available and one homemade CPA 
solution for their suitability to cryopreserve human OA synovial tissue. These CPA 
solutions are developed for application in a slow freezing protocol. To validate 
our method we studied the viability of the cells and the conservation of tissue-
specific responses to inflammatory stimuli. Therefore, we studied the ability of the 
tissue to respond to the pathogen associated molecular pattern (PAMP) TLR ligands 
lipopolysaccharides (LPS) and Pam3Cys (P3C) by measuring cytokine secretion. 
Both DAMPs and PAMPs can activate macrophages and fibroblasts via the TLR-4 
and TLR-2 pathway. TLR4 can be activated in similar fashion by the PAMP LPS and 
the OA related DAMP S100A8/9. TLR2 can be activated by the PAMP P3C and the 
OA related DAMP hyaluronic acid.13 In previous studies PAMPs have been shown to 
upregulate several plasma proteins in the OA synovial fluid, similar to the DAMPs.13 
In this study we therefore included LPS and P3C to study the TLR-2/4 response.   
 This detailed analysis showed that OA synovial tissue 
explants can be cryopreserved while maintaining the morphology, 
viability and phenotypical response after thawing.    
Materials & Methods
Synovial tissue   
Synovial tissue was obtained as remnant material, after written informed consent, 
from OA patients undergoing joint replacement surgery at the Orthopedics 
department of the Radboud University Medical Center. Protocols were approved by 
the local committee on research involving human subjects (CMO region Arnhem-
Nijmegen, the Netherlands) under NL-number 54055.091.15. Dissected synovial 
samples were immediately placed in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco), supplemented with 1% penicillin–streptomycin at 4°C. To confirm synovial 
origin, characterized by the presence of a synovial lining, representative tissue 
samples were embedded in OCT and 6 µM cryosections were cut and subsequently 
stained by Hematoxilin and Eosin (H&E). Histology and general viability assays were 
performed with synovial tissue from three donors, gene expression analysis and 
cytokine secretion assays were performed with synovial tissue from four different 
donors. For microarray analysis synovial samples were obtained by surgery or via 
fine-needle arthroscopy from 10 OA patients and 7 controls.
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Cryopreservation procedure  
Biopsies were punched out of the synovium using a disposable 3 mm biopsy punch 
(KAI medical) and collected in RPMI medium (Gibco) containing 10% FCS, pyruvate 
and pen/strep. Biopsies were transferred into a cryovial and 1 ml of CPA solution 
(4°) was added. Five CPA solutions were compared in this study: 1. CS2 (BioLife 
Solutions), 2. CS10 (BioLife Solutions), 3. Standard: 10 % DMSO, 10% FCS in RPMI, 
4. Cryo-SFM (PromoCell), 5.Biofreeze (Biochrom, Merck Millipore). The cryovial was 
incubated for 10 minutes on ice before being transferred to an isopropanol container 
(Nalgene, Mr. Frosty). The next day, the cryovials were relocated to liquid nitrogen 
where they were stored for one week. Thawing was performed by transferring the 
cryovial as quickly as possible from the liquid nitrogen into a 37°C water bath until 
all ice has disappeared. Subsequently, the tissue was washed 3 times 10 minutes 
in pre-warmed RPMI (37°C) before being cultured in RPMI (10% FCS, pyruvate and 
pen/strep) at 5% CO
2
, 37°. 
Histology and histological analysis  
Non-frozen or thawed synovial biopsies from three patients were cultured for 24 
hours before fixation in 4% formalin for 1 hour. For every condition, a minimum of 
3 separate 3 mm biopsies was included. Fixation was followed by dehydration and 
embedding in paraffin. Sections were cut at 7 µm and stained by H&E. Histology of 
every biopsy was scored in duplo using an arbitrary scale (0-1) for global morphology, 
appearance of the intimal lining layer, cellular and nuclear morphology, morphology 
of infiltrating cells, blood vessel morphology and fat cell morphology. All parameters 
were given a score of 1, 0.5 or 0. A score of 1 indicated no observed change, a score 
of 0,5 was given when the morphology was clearly distinct from non-frozen and a 
score of 0 was given to complete structural loss and cell death of the tissue. The 
mean score of these parameters is displayed in Figure 1. Pictures were taken at 400x 
magnification.
General viability assays  
Non-frozen or thawed synovial biopsies were cultured overnight in a 96-wells plate 
in 100 µl RPMI (10% FCS, pyruvate and pen/strep) as described above. For the 
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) 
assay, 50 µl XTT reagent (Cell Proliferation Kit II, Roche) was added per well and the 
absorbance was measured at 450 and 655 nm after 2, 4 and 6 hours using a BioRad 
iMark microplate reader. Values were corrected for the reference wavelength 
and background signal. For the adenosine triphosphate (ATP) assay, 100 µl lysis 
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buffer (Promega, Cell-Titer Glo) was added to each well and vigorously shaken for 
5 minutes before incubation for 25 minutes at room temperature. Luminescence 
was determined using the BMG Labtech CLARIOstar microplate reader. Values were 
corrected for the background signal and depicted as relative light units (RLU).
RNA isolation  
Non-frozen and thawed synovial biopsies were cultured for 24 hours and 
subsequently snap-frozen in liquid nitrogen. Total RNA was isolated using the RNeasy 
fibrous tissue kit (Qiagen, Venlo, The Netherlands). Frozen synovial samples were 
transferred to MagNA Lyser Green Beads tubes (Roche) containing RLT lysis buffer. 
The tissue was disrupted in the MagNA lyser for 3 x 20 sec at 6000 rpm with one 
minute cooling between cycles. The remainder of the procedure was performed 
according to manufacturer instructions with on column DNA digestion.
RNA integrity assessments  
The RNA integrity number (RIN) was determined directly after RNA isolation with 
the Agilent RNA 6000 Nano kit using the protocol provided by the manufacturer. The 
Nano chip was run on the Agilent 2100 Bioanalyzer using the 2100 Expert Software.
Microarray analysis  
Microarray analysis was performed as described earlier.14 Briefly, total RNA was 
isolated from the synovial samples, using the RNeasy kit for fibrous tissues (Qiagen, 
Venlo, The Netherlands). Total RNA (100 ng) was hybridized to a U133Plus 2.0 
oligonucleotide array (Affymetrix, Santa Clara, CA). The arrays were scanned with 
a GeneChip scanner (Affymetrix) and analyzed with GeneChip operating software 
version 1.4 (Affymetrix). Array normalization and expression value calculations were 
performed with DNA-Chip Analyzer version 1.3 (www.dchip.org), using the invariant 
set normalization and the model-based method.15 The OA synovial samples and 
control samples were deposited in the GEO database under accession number 
GSE82107. 
qPCR analysis  
An unpublished systematic review of the literature was performed to find genes 
upregulated during cryopreservative stress. All Pubmed and Embase articles 
depicting cryopreservation and gene expression analysis of living human and animal 
cells and tissue were assessed and revealed six genes of which the expression is 
known to respond to cryopreservation conditions: two heat shock protein genes 
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(HSPA1A,16 HSP2717) and four apoptosis-related genes (CASP3,16 BAX,18 CD95 16 
and MCL116). The expression of above mentioned genes was either increased 
or decreased (HSPA1A, MCL1) in comparison to non frozen cells or tissue. We 
determined their expression level after 24 hour culture.cDNA synthesis and qPCR 
analysis were performed as described previously.14 Primer sequences are listed in 
Table S1.
Multiplex ELISA  
Non-frozen and thawed synovial tissue was cultured for 24 hours in the presence or 
absence of LPS (100 ng/ml) and Pam3CSK4 (P3C) (1 µg/ml). Cytokine concentrations 
(IL1β, TNFα, IL-6 and IL-8) were determined in culture supernatants by Luminex 
multianalyte technology using the Bio-Plex 200 (Bio-Rad, Hercules, CA) and the Bio-
Plex pro human cytokine kits (Bio-Rad) according to manufacturer instructions. To 
measure IL-6 and IL-8 levels, culture supernatants were diluted 200-fold. 
Statistics  
For statistical analysis GraphPad Prism version 5.03 was used. To determine 
significant differences between groups ANOVA was performed in combination 
with the Tukey test (Fig 1-5). To determine significant differences between non-
stimulated and stimulated tissue for cytokine expression, the Student t-test was 
applied (Fig 6). Results are depicted as means +/- SD, and p values below 0.05 were 
regarded as significant.
 
Results
Effect of cryopreservation on tissue morphology and cell composition  
We first determined the effects of cryopreservation on tissue morphology and 
histological integrity by comparing freezing with five different cryopreservation 
media and freezing without cryoprotectant to non-frozen biopsies. The histological 
tissue integrity was assessed for structural integrity of the different structures 
within the tissue and cell death using an arbitrary scoring system.A significantly 
lower histological score was found for the CS2, Biofreeze and without CPA condition 
compared to the non-frozen condition (Fig. 1A-F). When studying the individual 
patients highest differences were observed in patient 1. A relatively high cellularity 
and influx of inflammatory cells were present in the tissue of patient 1 (Fig. 1B), 
which were not observed in the tissue of the second patient (Fig. 1C), indicating that 
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infiltrating cells might be more vulnerable to cryopreservation-induced damage. This 
was in line with the observation that the lowest histological scores were obtained 
for the parameter ‘morphology of infiltrating cells’ using the CS2 (patient 1: 0.4, p2: 
no infiltrating cells present, p3: 0.5) and Biofreeze medium (patient 1: 0.56, p2: no 
infiltrating cells present, p3: 0).
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Figure 1. Histological analysis of cryopreserved synovial explants.  
(A) Histological preservation was determined by assessing global histological parameters 
using an arbitrary score. Mean score is displayed. A significantly lower score was 
determined for the CS2, Biofreeze and without CPA condition. Blue dots: patient 1, black 
dots: patient 2, grey dots: patient 3. For statistical analysis, one-way ANOVA was performed, 
comparing the non frozen control to the cryopreserved conditions. *** p<0.001. Displayed 
is the mean. (B) Non frozen highly cellular synovium from patient 1. (C) Synovium of low 
cellularity cryopreserved with CryoSFM of patient 2 displaying an intact and smooth 
intimal lining layer (arrow), intact cells and blood vessels (*). (D) Synovium from patient 
3 cryopreserved with CryoSFM, displaying mainly intimal lining hyperplasia (arrow), the 
Chapter 4
79
4
lining is smooth and intact, cells and blood vessels (*) are intact. (E) Synovium of patient 2 
cryopreserved using the Biofreeze medium, showing a disrupted intimal lining layer (arrow), 
a high number of disrupted cells and disrupted blood vessels (*). (F) Synovium of patient 1 
frozen without protecting CPA solution showing almost complete disruption of cells.  
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Figure 2. No change in metabolic activity in synovial explants after thawing. 
ATP and XTT levels were determined in triplo in OA synovial tissue of 3 patients. Patient 
4: blue dots, patient 5: black dots, patient 1: grey dots. (A) Shown are the relative light 
units (RLU) (B) Shown is the percentage increase in absorbance over a 4 hour period, 
depicted as the mean +/- the SD. Statistical analysis was performed by one-way ANOVA, 
comparing the non-frozen control to the cryopreserved conditions. *** p<0.001.  
Effect of cryopreservation on tissue viability   
The metabolic activity reflects the global cellular viability of the tissue. The effect 
of cryopreservation on the metabolic activity of human OA synovial tissue from 
three patients was measured using the ATP and XTT metabolic assays (Fig. 2). 
Both assays showed similar results: all conditions displayed a lower, though not 
significant decrease in metabolic activity compared to the non-frozen control and 
the condition cryopreserved without CPA solution showed a significant decrease in 
both assays.
Effect of cryopreservation on RNA integrity  
Cell death leads to rapid RNA degradation, so the RNA quality (RIN values) is a 
direct measure of cryodamage and low RIN values impair reliable gene expression 
Functional Tissue Analysis Reveals Successful Cryopreservation of Human Osteoarthritic Synovium
80
analysis by microarray analysis. This analysis was performed to check whether the 
cryopreserved synovium is suitable for gene expression analysis by microarray 
studies, requiring minimal RIN values of 7. As depicted in figure 3, high RIN values, 
well above 7, could be obtained for the non-frozen and cryopreserved tissues. No 
significant differences could be detected between the non-frozen condition and the 
cryopreserved conditions. However, not every tissue biopsy yielded enough RNA 
(> 5 ng/ul) to successfully determine the RIN. This was the case in the biopsies 
that were cryopreserved without protecting CPA solution. This might indicate that 
the amount of isolated RNA gives an indication of the number of intact cells in 
the tissue at the time of isolation. As depicted in figure 3 the non-frozen, CS10 
and CryoSFM conditions have a higher number of biopsies with an appropriate 
yield than the CS2, Standard and Biofreeze conditions. Furthermore, the average 
RIN value of the CryoSFM condition was the highest, although not significant and 
displayed the smallest standard deviation of all conditions tested (Fig. 3). These 
results indicate that cryopreserved tissue can be used for gene expression analysis 
by qPCR. However, for microarray analysis several 3 mm biopsies might need to be 
pooled to obtain a sufficient amount of RNA.
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Figure 3. No effect of cryopreservation on RNA integrity in synovial explants. 
The RIN was determined in triplo of OA synovial tissue from four patients, 24 hours after 
thawing. Numbers indicate the number of biopsies of which the RIN could be successfully 
determined. Displayed is the mean +/- the SD. Statistical analysis was performed by 
one-way ANOVA, comparing the non-frozen control to the cryopreserved conditions. 
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Figure 4. No increase in stress gene expression after cryopreservation. 
Gene expression of (A) HSPA1a, (B) HSP27, (C) CASP3, (D) BAX, (E) CD95 and (F) MCL1 was determined 
by qPCR analysis in four patients, 24 hours after thawing. Patient 6: green dots, patient 7: black dots, 
patient 8: dark blue dots, patient 4: light blue dots. Displayed is the mean. Statistical analysis was 
performed by one-way ANOVA, comparing the non-frozen control to the cryopreserved conditions. 
** p<0.01; *** p<0.001.
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Effect of cryopreservation on stress gene expression  
We compared the expression of 2 heat-shock proteins and 4 apoptosis-related 
genes in response to cryopreservation and CPA solutions. Compared to the non 
frozen control no differences could be detected in the cryopreserved conditions (Fig. 
4A-F). Higher levels of stress gene expression were found in the negative control 
condition where the tissue was cryopreserved without protecting CPA solution). 
When studying the individual patients no other significant differences could be 
observed than already described above, except for the MCL1 gene in patient 6. 
Here, a significant upregulation was identified for the CS2 and Biofreeze condition 
(Fig. 4F). These results show that cryopreservation of OA synovial tissue does not 
induce upregulation of the selected stress genes indicating the absence of a stress 
response in the OA synovial tissue 24 hours after thawing.
Effect of cryopreservation on disease characteristic gene expression   
Analyzing tissue morphology, metabolic assays and stress gene expression 
does not reflect the interaction between cell types, typical for proper tissue 
functioning. Therefore, we have functionally analyzed the tissue by determining the 
expression of disease-characteristic genes.     
 Disease-characteristic genes were selected via microarray analysis 
performed on synovial samples from 10 OA patients and 7 control probands. TIMP3, 
CCL18 and MMP9 were highly expressed in all patients and showed a fold increase 
of 14.1, 9.11 and 7.56 respectively compared to the control samples, indicating that 
these genes are characteristic for the OA disease phenotype (data not shown). We 
analyzed in four patients whether the expression of these three genes would be 
influenced by cryopreservation. Cryopreservation did not influence the expression 
of these three genes as no significant changes could be observed compared to the 
non frozen control (Fig 5A-C). When patients were analyzed separately significant 
differences could be observed (Table 1). The Biofreeze CPA solution showed the most 
changes in gene expression. Furthermore, most changes in gene expression were 
observed in biopsies from patient 7 while none were identified in patient 8, indicating 
differences in tissue sensitivity to cryopreservation between patients (Table 1). 
           
Table 1. Analysis of cryopreservation-induced changes in disease- characteristic gene 
expression compared to non-frozen tissue in individual OA patients.  
Expression of TIMP3, CCL18 and MMP9 was determined in four patients (P6-P8, P4, Figure 5). 
Unchanged refers to no changes in gene expression compared to the non frozen condition. Where a 
CPA solution is mentioned an arrow indicates whether the expression of the gene was upregulated or 
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down regulated compared to non frozen tissue. Statistical analysis was performed by one-way ANOVA, 
comparing the non frozen control to the cryopreserved conditions. *p<0.05; **p<0.01.
Symbol Gene P6 P7 P8 P4
TIMP3 TIMP metallo-pepti-
dase inhibitor 3 
unchanged CS2 ↑ **
Standard ↑ *
Biofreeze ↑ **
unchanged unchanged
CCL18 chemokine (C-C mo-
tif) ligand 18 
unchanged Biofreeze↓ ** unchanged Biofreeze ↓ **
MMP9 matrix metallo-pepti-
dase 9 
CS2 ↑ **
CS10 ↑ *
unchanged unchanged unchanged
 
Figure 5. No effect of cryopreservation on disease characteristic gene expression.  
Gene expression of TIMP3 (A), CCL18 (B) and MMP9 (C) was determined after thawing and 24 hours 
culture of synovial biopsies of four patients. Per patient 3 biopsies were included in the analysis. Patient 
6: green dots, patient 7: black dots, patient 8: dark blue dots, patient 4: light blue dots. Displayed is the 
mean +/- SD. Statistical analysis was performed by one-way ANOVA, comparing the non-frozen control 
to the cryopreserved conditions.
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Effect of cryopreservation on cytokine secretion  
To analyze whether the inflammatory pathways, involved in the pathology of part 
of the OA patients, were affected by cryopreservation, we studied the spontaneous 
release of TNFα, IL1β, IL6 and IL8 into the culture medium (Fig. 6A-D). For IL6, a 
significantly lower cytokine secretion was only observed compared to the non-
frozen control in the condition without CPA (Fig. 6C). Although, compared to 
the non frozen control, clear decreases were observed for the other cytokines 
in the condition without CPA, these were not significant. However, no changes 
were observed in all conditions cryopreserved with a CPA solution compared to 
the non frozen control condition. When studying the individual patients (not 
shown) significant differences were detected for patient 7 for IL6 secretion 
which showed lower levels in the CS2 (228 ± 115 ng/ml), CS10 (378 ± 53 ng/ml) 
and CryoSFM (312 ± 83 ng/ml) condition compared to the non frozen control 
(1182 ± 626 ng/ml). For patient 4 TNF secretion was higher in the Biofreeze 
condition compared to the non frozen control (38 ± 6 pg/ml vs 18 ± 8 pg/ml). 
 The intrinsic capacity of synovial tissue to respond to TLR-ligands P3C and 
LPS by cytokine release was also tested after cryopreservation. Again, only for 
IL6 a significantly lower cytokine secretion was observed compared to the non 
frozen control in the condition without CPA while not for the other conditions 
cryopreserved with a CPA solution, nor for IL1β, TNFα and IL8 in the condition 
cryopreserved without CPA (Fig 6). Although a clear decrease compared to the 
non-frozen control was observed in the secretion of these cytokines as well. 
At the individual patient level the IL8 secretion was significantly decreased in 
patient 7 (70 ± 67 ng/ml vs 1619 ± 49 ng/ml) and 8 (8 ± 2 ng/ml vs 1358 ± 639 
ng/ml) in the condition without CPA compared to the non frozen control. 
Furthermore, compared to the non frozen control, the IL6 secretion was decreased 
in the Biofreeze condition in patient 4 (536 ± 396 ng/ml vs 2430 ± 1062 ng/ml). 
 For every condition a clear increase in cytokine secretion was observed 
after stimulation, indicating the tissue is able to respond to inflammatory stimuli. 
However, the increase in IL1β secretion was not significant for the condition 
in which the synovium was cryopreserved in the standard medium and without 
CPA (p-values for all conditions are shown in Table S2). For IL6 the increase was 
not significant for the Biofreeze and without protection condition and for IL8 the 
increase was not significantly different for the CS2 medium and without protection 
condition. These results indicated that except for TNF secretion, the tissue was not 
capable of responding to inflammatory stimuli after being cryopreserved without 
any protecting CPA solution. After cryopreservation with the CS10 and CryoSFM 
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medium the tissue showed upregulation of all four cytokines studied.
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Figure 6. Cryopreserved synovial tissue is responsive to inflammatory stimuli. 
The secretion of proinflammatory cytokines IL1β (A), TNFα (B), IL6 (C) and IL8 (D) was determined 
before and after 24 hour stimulation with P3C/LPS. Displayed is the mean +/- SD. Statistical analysis 
was performed by Students t-test, comparing the unstimulated control to the stimulated conditions. 
** p<0.01; *** p<0.001.
 
Discussion  
 
In this study we validated our slow freezing protocol for human OA synovial tissue 
by using 4 commercially available and one homemade CPA solution. We determined 
the viability of the tissue after 24 hours culture at the histological, metabolic, gene 
expression and protein secretion level. Significantly lower histological scores were 
detected for the CS2 and Biofreeze medium, indicating these media are suboptimal 
for maintaining tissue morphology. The other assays performed could not reveal 
significant differences between conditions. However, in the stress- and disease 
characteristic gene expression analyses, trends were observed pointing at negative 
changes in gene expression compared to the non frozen control for the Biofreeze 
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and CS2 medium as well. With the CS10, Standard and CryoSFM CPA solution only 
minor differences were observed compared to the non-frozen condition, indicating 
we have successfully cryopreserved human OA synovial tissue using these CPA 
solutions. Taking into account that the CS10 and CryoSFM media are produced 
under GMP conditions, which guarantees standardized and validated quality of CPA 
solutions, less batch-to-batch variation is expected compared to home-made CPA 
solutions containing FCS and DMSO.   
 As described above, the CS2 and Biofreeze medium most often showed a 
divergence from the non frozen condition. Although the exact composition of the 
commercially obtained media was unknown to us, the DMSO content of the media 
was described. The CS10 and standard medium contain 10% DMSO, the CryoSFM 
medium 7.5%, the Biofreeze medium does not contain DMSO and the CS2 medium 
only 2%. Without knowing about other differences in composition our results 
suggest that a low DMSO concentration is not beneficial for the cryopreservation of 
human OA synovium. The fact that the only difference between the CS2 and CS10 
medium is the DMSO concentration strengthens this suggestion.  
 Our results show a lack of response to LPS/P3C in the conditions 
cryopreserved without protecting CPA solution. The secretion of IL1β, IL6 and IL8 
were not significantly elevated in this condition. However, TNFα was. It might be 
that freeze-thawing stress in the unprotected tissue causes release of membrane-
bound TNFα, which leads to a higher protein concentration, while no new protein is 
secreted. There are links described between increased cellular stress and higher 
levels of activated TACE/ADAM17 leading to higher protein concentrations of 
TNFR1, released together with TNFα.19   
 When comparing the results of the XTT and ATP assay, which both reflect 
the metabolic activity of the tissue, there was one major difference. The ATP levels 
in patient 4 are the lowest in all conditions compared to the other patients while in 
the XTT assay the metabolic activity of patient 4 is comparable or higher compared 
to the other two patients. It might be that the difference in outcome can be 
explained by a difference in assay mechanism: the XTT assay is based on the cleavage 
of the tetrazolium salt XTT, probably at the plasma membrane, to an orange 
formazan dye by the reducing properties of NADH produced by mitochondria.20 The 
ATP assay is based on the conversion of Luciferin to the light emitting Oxyluciferin 
by Ultra-Glo Luciferase. In this reaction ATP is the missing factor and becomes 
available after cell lysis. Furthermore, it has been described that cellular stress due 
to inflammation21 or hypotonic swelling in lung epithelial cells,22 leads to active ATP 
release. Hypotonic swelling might also occur during thawing, upon removal of the 
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CPA solution. Active release of ATP might be involved in the lowered ATP levels in 
patient 4.   
 We evaluated the expression of several known stress genes: The heat shock 
protein family, of which HSPA1A and HSP27 are members, is known to be induced 
in response to stress. Although HSPA1A is also described to be downregulated by 
cryopreservation in bovine blastocysts.23 Heat shock proteins bind to denatured 
proteins as chaperones assisting in refolding and prevention of aggregation.24 In our 
analysis we could not detect significant differences between conditions analyzing 
these genes, except for the upregulation of HSPA1A and HSP27 upon cryopreservation 
in the condition in which the synovial tissue was cryopreserved without CPA. CASP3, 
BAX, CD95 and MCL1 are apoptosis associated proteins. CASP3, BAX and CD95 are 
pro-apoptotic proteins while MCL1 is anti-apoptotic. Programmed cell death is a 
mechanism known to be upregulated when experiencing stressful conditions, 
including cryopreservation.10 CASP3, BAX and CD95 were described to be 
upregulated upon cryopreservation while MCL1 was described to be down-
regulated.25 Similar to the heat shock proteins, no significant differences were 
identified between the cryopreservation conditions except for the non-protected 
condition in which an upregulation of all four apoptosis related genes was found, 
including for the anti-apoptotic gene MCL1. An explanation for this could be that 
there are differences between cell types in expression of pro- and anti-apoptotic 
genes resulting in upregulation of pro-apoptotic genes in one cell type and anti-
apoptotic genes in different cells, resulting in the observation of upregulation of 
both genes. All together, analyzing stress gene expression after cryopreservation 
could only be used to detect major stress responses and was not applicable to 
identify minor qualitative differences between cryopreservation solutions. In 
contrast to the stress-related genes, the expression of disease-specific genes TIMP3, 
CCL18 and MMP9 was not significantly affected by cryopreservation and the only 
differences were observed between samples of individual patients. TIMP3 is a 
metallopeptidase inhibitor, suggested to have a protective effect against degradation 
of articular cartilage in vivo.26 CCL18 is a chemokine belonging to the CC chemokine 
family. CCL18 is mainly produced by antigen presenting cells, to attract among 
others T-and B-cells.27,28 MMP9 is a metallopeptidase involved in OA cartilage 
degeneration.29 Our results indicate that these genes can be suitable to detect 
subtle cryoprotectant or cryopreservation effects other than cryotoxicity at an 
individual.   
 In our approach we cultured the tissue for 24 hours after thawing and 
subsequently performed analysis to determine the viability. This time point was 
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chosen as it has been suggested by the manufacturer of the BioLife CPA solutions. 
Furthermore, measuring cellular viability within the first hours after thawing likely 
results in an overestimation of the viability.30 Additionally, the 24 hour time point is 
a common culture time point in functional studies, although some parameters 
might be best studied at a different time point. For instance, a peak in Caspase 3 
expression was described 18 hours post thawing in normal human dermal 
fibroblasts. However, also at 24 hours post thawing, levels were still elevated 
compared to the control.31 We have not included more time points in our analysis 
due to scarcity of material.  
 A validated cryopreservation protocol is of high importance in research. In 
the first place to obtain reproducible results and in the second place cryopreservation 
offers the possibility to pre-select tissue at certain characteristics to be used in a 
study. Furthermore, if the same cryopreservation protocol is used it offers the 
possibility to combine synovial material obtained at multiple locations. An important 
effect we foresee by improving the availability of human synovial tissue for research 
is that this could lead to a decrease in the number of experimental animals. The 
possibility to perform more complex and larger experiments (for example drug 
compound testing) with human material instead of mice will prevent generation of 
results that cannot be translated to the human situation. Related to this is the 
increasing interest in precision medicine,32-34 followed by an increasing demand for 
human tissue. Precision medicine includes the adjustment and development of 
therapies and drugs for specific patient subsets with a similar genetic background, 
leading to for instance a similar response to treatment. This will improve healthcare 
by applying the best therapy to each patient, additionally this approach will be 
more cost effective and prevent possible side effects in patients not benefitting 
from a therapy. The development of precision medicine and the existing research 
lines using human synovial tissue of both pharmaceutical companies and universities 
are dependent on the availability of high quality patient material. By performing 
mechanistic and intervention studies, the development of new treatment options 
for OA would likely benefit from the use of cryopreserved synovial tissue.   
We showed that a slow freezing cryopreservation protocol using commercially 
available CPA solutions and a homemade CPA solution can protect human OA 
synovial tissue from cryodamage. We have validated a protocol to determine the 
viability of the tissue after cryopreservation, including an extensive analysis of the 
tissue functionality after thawing. Three CPA solutions were identified that 
performed equally well. A next step is to perform a reproducibility study, in which 
other labs will use our cryopreservation protocol to test if our results are 
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reproducible. Furthermore, this study can be used as a template to investigate the 
possibility to cryopreserve the even more complex synovial tissue of rheumatoid 
arthritis patients and isolated primary cells acquired by synovial tissue digestion. 
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Supplementary information
Table S1. List of qPCR primers 
Gene sym-
bol
Forward sequence Reverse sequence
GAPDH ATCTTCTTTTGCGTCGCCAG TTCCCCATGGTGTCTGAGC
HSPA1A CAAGGCCAACAAGATCACC CTCGATCTCCCCTGCTC
HSP27 CTGGATGTCAACCACTTCG AGATGTAGCCATGCTCGTC
CASP3 AGCACCTGGTTATTATTCTTGG TACTGTTTCAGCATGGCAC
BAX CTTCAGGGTTTCATCCAGGA TTACTGTCCAGTTCGTCCC
CD95 CTCTTTAAGACTGTTCTTACGTCTG CTTGGAGTTGATGTCAGTCAC
MCL1 GCTAGTTAAACAAAGAGGCTGG CTTCTAGGTCCTCTACATGGA
TIMP3 TCTCCTTGTCCCTGCTTCATG AGGCCCTTGACTACACTCTCATCT
CCL18 GGTGTCATCCTCCTAACCA GTCGCTGATGTATTTCTGGAC
MMP9 CTTCCAGTACCGAGAGAAAGCCTAT CAGGACGGGAGCCCTAGTC
 
Table S2. p-values of increase in cytokine secretion after stimulation 
Statistical analysis was performed by Students t-test, comparing the cytokine secretion of control 
(unstimulated) synovium to P3C/LPS stimulated synovium. Non significant p values are displayed in 
italics.  
Control vs P3C/LPS 
stimulation
Cytokines
IL1β TNFα IL6 IL8
Non frozen 0,0431 < 0.0001 0,0041 0,0011
CS2 0,0292 0,0026 0,0021 0,2380
CS10  0,0053 0,0001 <0,0001 0,0002
Standard 0,0506 0,0120 0,0003 0,0010
CryoSFM  0,0035 0,0256 0,0003 0,0021
Biofreeze  0,0249  < 0,0001 0,0502 0,0391
Without CPA  0,1103  0,0155 0,3212 0,4334
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In this study, we characterized the synovial membrane model made from micromasses of 
primary synovial cell suspensions by analyzing the cell composition at several stages of 
development using immunohistochemical staining and flow cytometry. We observed a 
gradual decrease in T cells, B cells and endothelial cells, whereas the synovial fibroblasts 
and synovial macrophages were maintained. Around week 2 of culture the micromasses 
developed a synovial lining of both macrophages and fibroblasts and showed an acute 
gene expression response to inflammatory stimuli. Long-term exposure of micromasses to 
tumor necrosis factor alpha (TNFα) resulted in synovial lining hyperplasia involving both 
synovial fibroblasts and macrophages. Interestingly, the macrophages in the micromass 
showed phenotypic plasticity as prolonged TNFα stimulation strongly reduced the 
occurrence of CD68/CD163-positive M2 macrophages. Micromasses with an established 
synovial lining can be cryopreserved and after thawing the integrity of the lining remains 
intact and cellular response to inflammatory stimuli was unchanged. In conclusion, we 
showed that a large number of micromasses can be made from a single synovial biopsy 
and that these micromasses spontaneously develop a synovial membrane containing 
both macrophages and fibroblasts. This synovial membrane model responded to TNFα 
by enhanced gene expression and hyperplasia. The micromasses are also suitable for 
cryopreservation and when kept on ice, the micromass dissolves allowing the analysis 
of individual cells without the requirement of an additional enzymatic digestion. The use 
of micromasses and the ability to store in biobanks for later use will aid in performing 
comparative studies using multiple donors simultaneously, and this may have a significant 
impact on translational arthritis research. 
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Introduction
Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common rheumatic 
diseases. The global incidence of RA is estimated to be 0,5%-1%1 and an estimated 
12.1% of the adult population has clinical symptoms of OA.2 RA and OA are both 
viewed as multi-factorial diseases involving multiple risk factors3,4 but their exact 
etiology is unknown. Both diseases cannot be cured at present, but disease-
modifying drugs (DMARDs) are available for RA and non-steroidal anti-inflammatory 
drugs (NSAIDs) for OA.
During disease, many processes occur in the synovium. Already in the early 
phase of RA, hyperplasia of the synovial lining occurs and immune cells infiltrate 
the sublining.5, 6 The cells in the synovium can produce several pro-inflammatory 
cytokines and matrix-degrading enzymes. At the interface of the synovium, cartilage 
and bone, pannus tissue is formed that contributes to bone destruction. Synovial 
pathology is also described for OA. Although OA has traditionally been described as 
a wear-and-tear disease of the articular cartilage, synovitis is observed in up to 50% 
of the OA patients and might contribute to the disease process.7 In addition, fibrotic 
tissue contributes to the synovial thickening in OA,8 which is also observed as a 
secondary process in RA.9 Because hyperplasia, cellular infiltration, joint damage, 
production of Matrix Metalloproteinases (MMPs), production of cytokines and 
fibrosis occur in both RA and OA with large patient-to-patient variation, RA and OA 
have many features in common on histological level.10 The similarities imply that on 
local level, the same anti-inflammatory treatment might influence both diseases. 
One of the cytokines produced by the synovium is Tumor Necrosis Factor alpha 
(TNFα) and anti-TNF biological drugs are successful in the treatment of RA patients 
but also a promising strategy in OA.11,12 However, there is a lack of relevant in vitro 
models to study therapies in these specific disease processes.
Translational arthritis research with human cells is often performed in 
monolayer culture with in vitro expanded synovial fibroblasts. Although monolayer 
culture with fibroblasts is easy to perform, the absence of extracellular matrix 
and other cell types result in alterations of cell functioning and a rapid loss of 
phenotype.13 One way to maintain the cell composition and matrix interactions of 
the cells is by using synovial explants instead of cultured monolayer cells. Although 
synovial explants better represent the original joint environment for the cells, 
important disease processes including hyperplasia and cartilage damage may have 
already taken place and can thus not be studied using explants. Moreover, there 
is considerable variability between biopsies from a single joint, resulting from a 
variation in lining thickness,14 sublining composition and an unequal distribution of 
synoviocyte types in the synovial membrane.15,16
To circumvent these challenges and provide a relevant model for the synovial 
membrane in which cells can interact with cellular matrix, Kiener and co-workers 
have developed a 3-dimensional (3D) micromass model based on a mixture of 
fibroblast-like synoviocytes (FLS) and Matrigel solution. When kept on ice, the 
Matrigel was liquid and could be mixed with cells to obtain a homogenous solution. 
Single drops were pipetted in a culture well and became solid at 37°C. Within weeks, 
the FLS formed a lining layer on the matrigel-medium surface that was reminiscent 
of a synovial membrane.17 Reticulin fibers on the surface of the micromasses were 
arranged in an orientation similar to basement membrane structures in synovial 
biopsies. The FLS in the micromass lining produced lubricin and showed hyperplasia 
after 3 weeks stimulation with tumor necrosis factor alpha (TNFα).18 The lining 
formation was not observed when using dermal fibroblasts.
We have recently applied the synovial micromass using the complete 
cell suspension after biopsy digestion for micromass formation19 without further 
isolation and purification of the synovial fibroblasts to better mimic their cellular 
composition and interactions as present in the starting material. In this study, 
we further characterized the synovial micromasses to study the fate of the 
different cell types. After lining formation, the micromass mainly consisted out 
of synovial fibroblasts and macrophages, which also appeared after induction of 
lining hyperplasia. TNF exposure of the synovial micromasses was used to mimic 
the inflammatory conditions present in RA and OA. This showed that short-term 
exposure to TNFα already leads to proinflammatory gene expression and long-
term exposure to hyperplasia. A valuable property is that the micromasses could 
be cryopreserved without loss of structural integrity and biological response. In 
conclusion, these results provide a detailed analysis of the synovial micromasses 
and show the suitability as a synovial membrane model for translational research 
in RA and OA. 
Materials and methods
Patient material
Synovial biopsies from 4 RA patients and 2 OA patients were obtained from the 
Orthopedics department (Radboud university medical center, Nijmegen, the 
Netherlands) and the Sint Maartenskliniek, Nijmegen, the Netherlands during 
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joint replacement surgery. All patients signed an informed consent and the 
research protocols were approved by the local committee on research involving 
human subjects (CMO region Arnhem-Nijmegen, the Netherlands) under NL-
number 54055.091.15. The presence of a synovial lining was determined on 7 
µm cryosections stained with hematoxylin and eosin staining (HE) to confirm the 
synovial origin of the tissue (not shown).
Micromass production
Micromasses were produced as described previously.19 In short, the biopsies were 
digested using Liberase (Roche, Basel, Switzerland) for 1h at 37°C and the cells were 
filtered through a 70 µm cell strainer (Corning, NY, USA). Red blood cells (RBCs) were 
lysed for 2 min at RT in 4 ml RBC lysis buffer (155 nM NH
4
Cl, 12 mM KHCO
3
, 0.1 mM 
EDTA, pH 7.3). The cells were mixed on ice with liquid Matrigel and 25 µl droplets 
containing ~5x105 cells were pipetted on a poly-(2-hydroxyethyl methacrylate) 
(poly-HEMA) (Sigma-Aldrich, Zwijndrecht, The Netherlands) coated 24-wells plate 
(Greiner Bio-one, Alphen a/d Rijn, the Netherlands). After 30 min gelation at 37°C, 
500 µl RPMI medium supplemented with 10% fetal calf serum (FCS), 1 mM pyruvate 
and 1% penicillin/streptomycin (P/S) was added. The micromasses were cultured 
for the time and conditions as indicated in the separate Figures. In general, medium 
was replaced twice weekly and micromasses were cultured at 37°C and 5% CO
2
.
Flow cytometry
Micromasses were kept on ice for 2h and the cells were washed to remove the 
liquid Matrigel. For 11-Fibrau staining, cells were incubated with 11-Fibrau (1:50 
for 60 minutes) (clone D7-fib, Imgen, distributed by ITK Diagnostics, Uithoorn, The 
Netherlands) and subsequently with donkey-anti-mouse conjugated to Alexa Fluor 
568 (1:100 for 30 minutes) (A-10037, Thermo Scientific). CD90 was stained using 
mouse anti-human CD90-APC (1:20 for 30 minutes) (17-0909 eBioscience, San 
Diego, CA, USA). CD68 was stained using mouse anti-human CD68-PE (1:20 for 60 
minutes) (12-0689, eBioscience); CD14 was stained using mouse anti-human CD14-
APC (1:20 for 60 minutes) (301808 Biolegend, San Diego, CA, USA). The samples 
were measured on the CyAn ADP analyser (Beckman Coulter, Woerden, The 
Netherlands) using the 488 nm laser at the FL1, FL7 and FL8 channels for GFP, Alexa 
Fluor 568/PE and APC respectively.
Immunohistochemistry
Micromasses were fixated in 2% paraformaldehyde in phosphate-buffered saline 
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(PBS)/1mM CaCl2 for 2h, dehydrated and embedded in paraffin. 7 µm sections 
were deparaffinized, rehydrated and stained with hematoxylin and eosin (HE) or 
with primary antibodies for 60 minutes: 11-Fibrau (1:100), mouse anti-human CD68 
(1:100 for 60 minutes, M0814, DAKO, Heverlee, Belgium), mouse anti-human CD20 
(1:100 for 60 minutes, 120M-84, Cellmarque, Rocklin, CA, USA), mouse anti-human 
CD3 (1:50 for 60 minutes, M0814, DAKO, Heverlee, Belgium), rabbit anti-human CD31 
(1:50 for 60 minutes, GTX48364, Genetex, Hsinchu City, Taiwan), mouse anti-human 
CD163 (1:25, BAM16072, R&D systems, Oxford, UK). Isotype control antibodies 
were Mouse IgG1κ (X0931, DAKO), mouse IgGακ (X0943, DAKO) and Rabbit IgG 
(X0936, DAKO). Endogenous Peroxidase activity was blocked with 3% H2O2 (Merck 
Millipore, Amsterdam, The Netherlands) in methanol. Subsequently, the murine 
primary antibodies were stained with HRP-conjugated rabbit-anti-mouse IgA/G/M 
(1:200 for 60 minutes, P0260, DAKO) and the rabbit primary antibodies were 
stained with HRP-labeled goat anti-rabbit-Ig(all) (1:200, P0448, DAKO). Peroxidase 
was developed with diaminobenzidine and counterstained with hematoxylin for 
60 seconds. For CD68-staining of synovial cryosections, primary antibody mouse 
anti-human CD68 (1:100, M0718, DAKO) was used and for CD3 staining of synovial 
cryosections rat anti-human (1:50, MCA1477, Bio-Rad, Puchheim, Germany).
 
Image analysis
Microscopic images were taken using the Leica DMR light microscope after 
randomization of the samples. For hyperplasia analysis, 3 sections were analyzed 
per micromass and per section 3 pictures were taken from the micromass surface 
after 11-Fibrau staining. The lining hyperplasia was scored based on an arbitrary 
scale ranging from 0 (the surface with the fewest cells) to 3 (most cellular surface). 
For the counting of the large CD68 and CD163-positive cells, 2 pictures from 3 
sections per micromass were analyzed using the Leica Application Suite (LAS) 
software. The total number of large cells was counted and divided by the surface 
area of the micromass in the analyzed image.
Micromass cryopreservation and viability assay
Cryopreservation of micromasses was performed using the protocol previously 
described for synovial biopsies.20 In short, micromasses in which the lining had 
formed were submerged in 1 ml Cryostor CS10 medium (Sigma-Aldrich) and 
incubated on ice for 10 min. Subsequently, the micromasses were transferred to 
-80°C in a Mr. Frosty isopropanol container (Thermo Scientific) pre-incubated at 
4°C. After overnight cooling, the micromasses were transferred to liquid nitrogen. 
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After 7 days, the micromasses were thawed and washed 3 times in 1 ml PBS. After 
24h acclimatization in 200 µl supplemented RPMI medium in a 96-wells plate, 
the viability was assessed using the cell titer Glo kit (Promega, Madison, WI, 
USA) according to the manufacturer’s recommendations. The non-frozen control 
micromass viability was assessed after 24h culture in a 96-wells plate.
Gene expression analysis
The micromasses were dissolved in 500 µl Tri reagent (Sigma-Aldrich) and 
total RNA was isolated according to the manufacturer’s protocol. qPCR was 
performed as previously described 21. The following primer sequences were 
used: GAPDH forward primer: ATCTTCTTTTGCGTCGCCAG, GAPDH reverse primer: 
TTCCCCATGGTGTCTGAGC. IL-1β forward primer: TGGGTAATTTTTGGGATCTACACTCT, 
IL-1β reverse primer: AATCTGTACCTGTCCTGCGTGTT, IL-6 forward primer: 
AGCCCACCGGGAACGA, IL-6 reverse primer: GGACCGAAGGCGCTTGT, TNFα forward 
primer: TCTTCTCGAACCCCGAGTGA, TNFα reverse primer: CCTCTGATGGCACCACCAG. 
Values are depicted as threshold cycle, corrected for GAPDH expression.
Statistical analysis
Statistical analysis was performed by Student’s t-test, 1-way ANOVA or 2-way 
ANOVA as indicated in the figure legends using Graphpad Prism software v5.03. 
p-values below 0.05 were regarded as significant.
Results
Analysis of cell synovial cell suspensions
The composition of the cell suspension after digestion of a synovial biopsy was 
determined using cell surface markers. After 24h culture we observed cells positive 
for synovial fibroblast marker 11-Fibrau (70.0%), fibroblast/endothelial cell marker 
CD90 (68.9%), monocyte/macrophage marker CD68 (24.0%) and monocyte marker 
CD14 (CD14low 22,6% and CD14high 6,48%) (Fig. 1A). This cell composition was 
comparable in repeat experiments. No T cells (CD3), B cells (CD20) or dendritic cells 
(CD11c) were observed in this cell suspension (data not shown). Cells that were 
stained positive with CD90 also stained positive for 11-Fibrau. Almost all CD68-
positive cells also stained positive for CD14. The CD68-positive cells were CD14low.
After 72h culture, the cell composition was re-analyzed to determine the 
culture effects on the cell suspension. We observed a minor decrease in 
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11-Fibrau and CD90-positive cells (to 65.5% and 67.8% respectively) and a 
slight increase in CD68-positive cells (to 27.3%) (Fig. 1B). The CD14high fraction 
dropped to 3,19% and the CD14low to 13.1% after 72h culture. The distinct 
CD68-positive and CD14low cells lost most CD14 expression after 72 hours 
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Figure 1: Flow cytometry analysis of cell suspension after biopsy digestion.   
An RA synovial biopsy was digested using Liberase. Cells were cultured for 24 hours (A) or 72 hours 
(B). The cell suspensions were subsequently stained with markers for synovial fibroblasts (11-Fibrau), 
endothelial cells (CD90), macrophages (CD68) and monocytes (CD14). FS: forward scatter.
Kinetics of micromass lining formation and cell type composition
The kinetics of lining formation in the synovial micromasses was assessed at 
different time points. 1 day after biopsy digestion and micromass production, 
the cells had not regained their original morphology and all cells were round-
shaped (Fig. 2). The first time point at which a distinct lining was visible, was 
after 14 days. In multiple experiments we observed lining formation between 
day 7 and day 14. In contrast, lining formation in micromasses from cultured 
FLS was typically completed between day 5 and day 7 (data not shown). The 
synovial lining remained visible until the end of the experiment at day 35. 
D1 D3 D5
D14 D21 D35
Figure 2: Kinetics of micromass formation.   
Micromasses were generated from an RA synovial biopsy. At different time points (day 1, 3, 
5, 14, 21 and 35) micromasses were fixed and embedded in paraffin. 7 µm sections were 
stained with HE. Pictures were taken at 200x magnification and black scale bars represent 
100 µm.
We analyzed the composition of the synovial micromasses at several time points 
during development both by flow cytometry and histology. For flow cytometry 
analysis of mature micromasses after lining formation, the micromasses were 
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incubated on ice for 2h. The Matrigel re-liquidized and was washed away prior to 
cell staining. The composition of the micromass was comparable to the cultured 
cell suspension described in Figure 1 (Fig. 3). We observed adequate amounts of 
cells positive for 11-Fibrau, CD68 and CD90. The CD68-positive cells showed only 
low expression of CD14, reminiscent of the culture effects observed with culture of 
the cell suspension. These results show that the mixed cell population is maintained 
during micromass culture.
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Figure 3: Flow cytometry analysis of micromass cell composition after lining formation. Micromasses 
from RA biopsies were cultured for 7 days until lining formation and subsequently incubated on ice 
until the Matrigel became liquid. The cells were stained with 11-Fibrau, CD90, CD68 and CD14. Similar 
profiles were obtained in multiple experiments. FS: forward scatter.
 
In the synovial biopsy, cells that stained positive for macrophage-marker CD68 were 
primarily localized in the lining of the synovium (Fig. 4). Immediately after formation 
of the micromasses, CD68-positive cells appeared randomly distributed over the 
complete micromass. During the first week of micromass culture, a gradual increase 
in the relative amount of CD68-positive cells was observed and after 7 days most 
CD68-positive cells appeared as large cells. The analyzed biopsy also contained foci 
of B cells (CD20-positive) and T cells (CD3-positive) (Fig. 4). 
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At lower frequency compared to CD68-positive cells, these cells were incorporated 
in the micromass. We observed a gradual decrease in the number of B cells and T 
cells and after 7 days none could be observed. Similar results were obtained with 
endothelial marker CD31, which stained the blood vessels in the biopsy cryosections 
(Fig. 4).
Short-term exposure of synovial micromasses to inflammatory stimuli leads to 
inflammatory gene expression.
We established the inflammatory response of mature micromasses (i.e. micromasses 
with a completed lining) after stimulation with recombinant human IL-1β, TNFα and 
lipopolysaccharide (LPS). We observed a significant increase in expression of IL-1β 
and IL-6 with all three stimuli (Fig. 5A, B). The upregulation of TNFα mRNA was only 
significant after LPS stimulation (Fig. 5C). These results show that the micromasses 
are sensitive to inflammatory triggers.
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Figure 5: Gene expression after short-term micromass exposure to inflammatory stimuli. 
Micromasses were generated from an RA knee biopsy and cultured until lining formation was 
complete. Subsequently, the micromasses were stimulated for 6h with regular culture medium, 10 ng/
ml IL-1β, 10 ng/ml TNFα or 100 ng/ml LPS. The gene expression of pro-inflammatory cytokines IL-1β 
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(A), IL-6 (B) and TNFα (C) were measured by qPCR. Gene expression values were corrected for GAPDH 
expression and are depicted as mean +/- SD. Symbols represent individual micromasses. Expression 
levels were compared to medium condition by 1-way ANOVA and Dunnett’s multiple comparison test. 
* =P<0.05, ** =P<0.01, *** =P<0.001.
Long-term TNFα exposure of synovial micromasses leads to hyperplasia
An important feature of arthritis is synovial hyperplasia, which is hard to study in 
biopsies. The hyperplasia and cell composition of the lining were assessed after 
3 weeks of repeated stimulation with TNFα. Without TNFα stimulation, the lining 
thickness was on average 1 cell layer (Fig. 6A). After long-term stimulation with 
TNFα, the lining thickness increased (Fig. 6B). The cells in the lining were positive 
for 11-Fibrau (Fig. 6C) and CD68 (Fig. 6D), indicating that after hyperplasia in the 
synovial micromass model, the lining contains both FLS and macrophage-like cells. 
The hyperplasia was quantified using an arbitrary scoring system (0-3) based on the 
average lining cellularity of 9 images per micromass. The cellularity was significantly 
increased after TNFα stimulation (Fig. 6E).
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Figure 6: Micromass lining hyperplasia. Micromasses were generated from OA synovial tissue. At day 
7, micromasses received 10 ng/ml TNFα for 3 weeks, which was replaced 2 times per week. Control 
micromasses received culture medium without TNFα. (A) HE-staining of micromasses stimulated 
without TNFα. (B) HE-staining of micromasses stimulated with TNFα. (C) 11-Fibrau staining of 
micromasses after hyperplasia. (D) CD68-staining of micromasses after hyperplasia. (E) Quantification 
of lining cellularity after hyperplasia. Symbols indicate separate micromasses and the average score 
of 3 images per 3 slides of every micromass (one dot represents the average of 9 images from one 
micromass). Statistical analysis was performed by Student’s t-test. * =P<0.05.
In addition to effects on lining hyperplasia, we observed striking differences in the 
cells residing in the micromass matrix. When the micromasses were not treated 
with TNFα, some cells positive for CD68 showed a hypertrophic phenotype (larger) 
(Fig. 7A). These cells were not observed after stimulation with TNFα (Fig. 7B). At 
the location of the cell membrane, we observed positive staining for CD163, a 
membrane marker associated with type 2 macrophages (Fig. 7C,D). The appearance 
of these cells could be abolished by TNFα stimulation (Fig. 7E).
Figure 7: Macrophage phenotype after TNFα stimulation. Micromasses were stimulated for 3 weeks 
with medium (A,C) or TNFα (B,D) and stained with CD68 (A,B) or CD163 (C,D). (E) Quantification of 
large CD68-positive cells. Values were corrected for the total surface area of the images analyzed. 
Values are depicted as mean +/- SD Statistical analysis was performed by Student’s t-test. n=4/group 
* =P<0.05.
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Cryopreservation of synovial micromasses
An important challenge in the application of primary patient material is the sparse 
availability of the biopsies, which greatly hampers the planning and synchronization 
of experiments with biopsies from multiple patients. We therefore determined the 
physiological response of cryopreserved and non-frozen synovial micromasses. After 
cryopreservation, the metabolic activity was measured, but, insufficient samples 
were analyzed to enable statistical analysis and draw solid conclusions (Fig. 8A). 
The synovial lining integrity on histological sections were similar in cryopreserved 
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micromasses compared to non-frozen micromasses (Fig. 8B). To assess the 
inflammatory response after cryopreservation, we compared the gene expression 
data from Figure 5 to micromasses from the same patient that received the same 
pro-inflammatory stimuli, but were cryopreserved between lining formation and 
6h stimulation. Similar to non-frozen micromasses, the cryopreserved micromasses 
were responsive to all three tested stimuli (Fig. 8C). These results show that 
micromasses can still respond to pro-inflammatory triggers after cryopreservation 
similar to non-frozen controls.
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Figure 8: cryopreservation of synovial micromasses. (A) ATP viability assay before and after 
cryopreservation with CS10. Values are the average of duplo measurement and depicted as relative 
light units (RLU). (B) HE-staining of paraffin sections of non-frozen and cryopreserved micromasses. 
(C) Gene expression of cytokines IL-1β, IL-6 and TNFα after 6h stimulation with recombinant human 
IL-1β, TNFα or LPS. Gene expression values were corrected for GAPDH expression and are depicted as 
mean +/- SD. Comparisons within groups were performed by 2-way ANOVA and comparisons between 
groups by 1-way ANOVA, n=4/group. Significanties indicate a comparison to the appropriate medium-
stimulated control. * =P<0.05, ** =P<0.01, *** =P<0.001.
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Discussion
In this study, we further characterized the 3D synovial micromass model produced 
from primary human biopsies for application in both RA and OA research. The model 
was first explored by Kiener and co-workers, based on primary synovial fibroblasts 
(FLS) culture. The experiments were focused on cell-cell and cell-matrix interactions 
during the formation of the lining and the involvement of Cadherin-11.17,22 We have 
constructed micromasses from digested biopsies containing the complete cell 
composition of the synovium. We observed that during culture of the micromass, 
11-Fibrau-positive fibroblasts and CD68-positive macrophages migrate towards 
the lining and can survive for at least 35 days. These 2 cell types correspond with 
the predominant cell types observed in the intimal layer of the synovium, the 
type B synoviocyte (FLS) and type A synoviocyte (macrophage-like synoviocyte) 
respectively.23 In addition, the CD3-positve T cells, CD20 positive B cells and CD31 
or CD90-positive endothelial cells mainly derived from the subintimal synovium 
are present in the initial Matrigel mixture, but disappear during the first 7 days of 
culture. 
The behavior of the different cell types may in part be explained by 
the composition of the Matrigel extracellular matrix. Matrigel is an extract of 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, cultured as a tumor in 
mice. The extracellular matrix produced in high quantities by these cells contains 
proteins associated with the basal membrane, including Collagen type IV, laminin 
and perlecan.24 Cells cultured on or in Matrigel showed increased differentiation 
and migration. This behavior might be caused by the presence of different growth 
factors in the Matrigel, including transforming growth factor beta (TGFβ), epidermal 
growth factor (EGF), fibroblast growth factor (FGF) and platelet-derived growth 
factor (PDGF).25 The loss of T and B cells is likely to be related to the absence of 
survival factors like IL-2,26 which should be added during culture to study the T cells 
and B cells in mature micromasses. Moreover, the presence of T cells and B cells in 
the starting biopsy should first be determined, because T cells and B cells were only 
observed in a portion of the biopsies.
The predominant survival of FLS and macrophage-like cells was observed 
both by immunohistochemistry and flow cytometry. Several results imply changes 
in the macrophage population. During culture, the amount of CD68+ cells expressing 
CD14 decreased at day 3 compared to day 1. The same decrease was observed 
in macrophages at day 7 after formation of the micromasses. This can be the 
result of macrophage differentiation, which is associated with a decrease in CD14 
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expression.27 During the 3-week micromass culture, we observed large CD68+ and 
CD163+ cells. These cells represented an M2-like anti-inflammatory macrophage 
phenotype.28,29 The appearance of these cells was abolished by stimulation with 
TNFα, which is known to polarize the macrophages to a pro-inflammatory M1-
like phenotype.30 Although additional markers are required for more accurate and 
reliable identification of specific cell types and cell subsets, the results clearly indicate 
a plasticity in the macrophage-like cell population in the synovial micromass.
Both the short-term effects of TNFα and the long-term effects on micromasses were 
evaluated. In addition to the well-known role of TNFα in RA, the TNFα produced 
by the osteoarthritic synovium is strongly associated with systemic low-grade 
inflammation and production of matrix-degrading enzymes by multiple cells in the 
joint.31,32 The observation that systemic TNFα levels are increased prior to the most 
pronounced cartilage damage supports the hypothesis that inflammation in OA is a 
cause rather than a consequence. We observed that the pro-inflammatory effects 
can be studied in the micromasses after short stimulation with pro-inflammatory 
triggers. In addition, synovial hyperplasia is observed in the synovium of both RA 
and OA patients.33 We could re-create this pathogenic process by stimulating the 
micromasses for 3 weeks with TNFα, which is a major advantage compared to 
studies using synovial biopsies, in which hyperplasia has already occurred.
Interestingly, we found that when kept on ice, the Matrigel liquidized 
and could be washed away from the cells. The resulting cell suspension could be 
analyzed by flow cytometry without the requirement of enzymatic digestion. This 
further enhances the applicability of the micromass model. When performing flow 
cytometry, we noticed a cell population with low forward and side scatter which 
was not included in the live gate in our experiments. These cells were not stained 
by any of the tested membrane markers and could be removed by Zapoglobin 
treatment, indicating that these cells were red blood cells not completely lysed 
during micromass production. However, the Zapoglobin treatment also affected the 
flow cytometry stainings and we recommend for future studies to exclude these 
cells from the live gate.
The observation that cryopreservation of the synovial micromasses does not 
influence the histological integrity or the inflammatory response is important 
for future applications. The availability of biological material for the production 
of synovial micromasses is dependent on the planning of surgery and therefore 
sporadic and highly variable. This provides particular challenges for experiments in 
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which fresh material of multiple patient donors needs to be included simultaneously. 
By cryopreservation of the micromasses, acquired biopsies can be processed 
immediately and surplus micromasses can remain in storage for future experiments. 
In addition, cryopreservation might facilitate the possibility to ship micromasses to 
different facilities and support multi-center studies.
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Objective:   
Disease-inducible promoters for the treatment of rheumatoid arthritis (RA) have the 
potential to provide regulated expression of therapeutic proteins in arthritic joints. In 
this study, we set out to identify promoters of human genes that are upregulated during 
RA and are suitable to drive the expression of relevant amounts of anti-inflammatory 
Interleukin-10 (IL-10). 
Methods:  
Microarrays on RA joint tissues was compared to healthy controls. The CXCL10 promoter 
was obtained from human cDNA and cloned into a lentiviral vector containing firefly 
luciferase. The promoter inducibility was determined in primary synovial cells and in THP1 
cells. The luciferase gene was replaced with IL-10 to determine the therapeutic properties 
of the CXCL10p-IL10 lentiviral vector.
Results:   
Microarray analysis yielded a list of 22 genes upregulated during RA. Of these genes, 
CXCL10 showed the highest induction in LPS-stimulated synovial cells. The promoter 
activation was strongest at 8-12h after stimulation with the pro-inflammatory cytokine 
TNFα and was re-inducible after 96h. The CXCL10 promoter showed a significant response 
to RA patient serum, compared to serum from healthy individuals. Primary synovial 
cells transduced with CXCL10p-IL10 showed a great increase in IL-10 production after 
stimulation, which reduced the release of pro-inflammatory cytokines TNFα and IL-1β.
Conclusion:   
The selected proximal promoter of the CXCL10 gene responds to inflammatory mediators 
present in serum of RA patients and transduction by the lentiviral CXCL10p-IL10 vector 
reduces inflammatory cytokine production by primary synovial cells from RA patients. 
CXCL10 promoter-regulated IL-10 overexpression can thus provide disease-inducible local 
gene therapy suitable for RA.
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Introduction
Gene therapy for rheumatoid arthritis (RA) enables transduced joint cells to express 
biological drugs. Because the therapy can be applied locally and requires fewer 
injections, the side effects of continuous systemic drug administration can be reduced. 
In addition, off-target effects can be even further reduced by using a disease-responsive 
promoter that is only active during disease flares and silent during remission.1  
 Derivatives of currently applied biological drugs have been tested as a 
potential gene therapy in multiple clinical studies after successful application 
in animal models of RA, including the Interleukin-1 receptor antagonist (IL1-
RA) and the soluble extracellular domain of the TNF receptor fused to an IgG 
tail.2,3 No severe adverse side effects were reported that could be contributed 
to the gene therapies.4 However, only minor clinical improvements were 
observed. These results solicit for the use of a more potent anti-inflammatory 
transgene, like Interleukin-10 (IL-10). IL-10 has pleiotropic effects and can 
inhibit the development of Th1 cells and the production of multiple pro-
inflammatory cytokines as comprehensively reviewed by Bijjiga and Martino.5   
 Clinical studies with recombinant IL-10 are impeded by the short half-life of 
IL-10 in vivo.6 In addition, Crohn’s disease patients systemically treated with high doses 
of recombinant IL-10 showed a significant reduction in hemoglobin levels.7 These 
issues might be circumvented in RA by using local gene therapy. Recent studies have 
successfully attempted to provide disease-inducible expression of IL-10 in murine 
experimental arthritis.8, 9 The promoters that were tested for therapeutic application 
with IL-10 in these studies were the IL1E-IL6P, a combination of the IL-1β enhancer 
element and the IL-6 promoter, the Saa3 promoter and the Mmp13 promoter.  
 The translation of the use of inducible promoters from experimental arthritis 
to the human situation is hampered by both differences in the disease process and 
the subsequent activation of the associated genes, as well as the differences in the 
sequences of homologous promoters. For instance, the Saa3 promoter showed the 
highest inducibility in previous studies,10 but is only present as a pseudogene in 
humans.
In this study, we show the upregulation of the human CXCL10 promoter in joint 
tissue of RA patients and the inducibility of the isolated CXCL10 promoter in THP-1 
monocytes and in primary synovial cells. When the CXCL10 promoter was used to 
drive the transcription of the IL-10 transgene in a lentiviral vector, IL-10 production 
was significantly increased in cells stimulated with pro-inflammatory cytokines. The 
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increased production of IL-10 resulted in a decreased release of pro-inflammatory 
cytokines by synovial cells, indicating the potential of the CXCL10p-IL10 construct to 
provide a disease-regulated production of anti-inflammatory IL-10.
 
Materials and methods
Patient material  
Synovial samples for microarrays were obtained during surgery or by fine-needle 
arthroscopy and stored in liquid nitrogen until further processing. In total, an additional 
8 synovial biopsies for digestion were obtained during surgery from the Department of 
Orthopedics (Radboud University Medical Center, Nijmegen, The Netherlands) or the 
Sint Maartenskliniek, Nijmegen, The Netherlands. Synovial biopsies were transported 
in DMEM culture medium, supplemented with 1% penicillin/streptomycin at 4°C. 
First, the pieces were confirmed to contain a synovial lining by histological analysis 
of cryosections. Examples of the sample cryosections are shown in Figure S1.   
 Subsequently, the pieces were digested with 50 µg/ml Liberase TM 
(Roche, Basel, Switzerland) for 1h at 37°C in plain RPMI culture medium. The 
digestion was quenched by adding 10% fetal calf serum (FCS). Subsequently, the 
synovial cells were passed through a 70 µm cell strainer (Corning, NY, USA) and 
centrifuged for 5 min at 1500 rpm. Red blood cells were lyzed using RBC lysis 
buffer (155 nM NH
4
Cl, 12 mM KHCO
3
, 0.1 mM EDTA, pH 7.3) for 2 min at RT.   
 Sera from RA patients were obtained from early RA at the Department of 
Rheumatic Diseases, Radboud University Medical Center, Nijmegen, Netherlands. 
Sera from age- and sex matched healthy controls were obtained from the Sanquin 
Bloedbank, Nijmegen, The Netherlands. Serum samples were stored at -80°C. All 
patients included in this study gave their informed consent and the study protocol 
was approved by the Medical Ethics Committee. In total, material of 28 patients was 
included in this study.
Microarray analysis  
Total RNA was isolated from the synovial samples using the RNeasy kit for fibrous 
tissues (Qiagen, Venlo, Netherlands). 100 ng of total RNA was used for the 
preparation of biotinylated cRNA as described earlier11 and hybridized to a U133Plus 
2.0 oligonucleotide array (Affymetrix, Santa Clara, CA, USA), according to the 
Affymetrix Expression Analysis Technical Manual for two-cycle amplification. The 
arrays were scanned using the GeneChip Scanner (Affymetrix) and analyzed using 
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the GeneChip Operating Software version 1.4 (Affymetrix). Array normalization and 
expression value calculations were performed by the DNA-Chip analyzer version 
1.3 (www.dchip.org) using the Invariant Set normalization and the Model-based 
method.12 The RA synovium samples were obtained from the GEO database (13, 
accession number GSE9027). The control samples were deposited under accession 
number GSE77298).
Cell culture  
THP-1 monocytes were seeded in a 24-well plate at 3x10E5 cells/well for RNA 
analysis and multiplex assay or in a µClear white 96-well plate (Greiner Bio-one, 
Alphen a/d Rijn, Netherlands) at 5x10E4 cells/well for luciferase measurements in 
RPMI culture medium, supplemented with 10% FCS, 1 mM pyruvate and 1% pen/
strep. Synovial cells were centrifuged and resuspended after red blood cell lysis 
and cultured at similar concentrations and conditions. All cell cultures were kept in 
humidified atmosphere at 37°C and 5% CO
2
. The cells were stimulated with E. Coli 
lipopolysaccharide (LPS) (Invivogen, San Diego, CA, USA), Pam3CSK4 (Invivogen), 
rhIL-1β (R&D systems, Oxford, UK), rhTNFα (Abcam, Cambridge, UK) or rhIL-10 (Life 
Technologies Europe, Bleiswijk, Netherlands) at concentrations indicated in the text.
RNA isolation and qPCR 
Total RNA from cells was isolated using TRI Reagent (Sigma, St. Louis, MO, USA) 
according to the manufacturer’s recommendations and treated with DNase I 
(Invitrogen, Carlsbad, CA, USA) for 15 min. cDNA was synthesized by reverse 
transcription PCR using MLV Reverse transcriptase (Invitrogen) and oligo(dT) 
primers. The qPCR was performed using Power SYBR Green PCR master mix (Apllied 
Biosystems, Waltham, MA, USA) and the StepOnePlus Real-Time PCR system 
(Applied Biosystems) according to the manufacturer’s instructions. The reaction 
volume contained 5 µl SYBR master mix, 1 µl 2 µM forward primer, 1 µl 2 µM reverse 
primer and 3 µl cDNA template. Primer sequences are listed in Table S1. The PCR 
protocol consisted of 10 min at 95°C, followed by 40 cycles of 15 seconds at 95°C 
and 60 seconds at 60°C.
Plasmid cloning 
For the production of lentiviral vectors, we made use of the third generation 
self-inactivating lentiviral (sin) vector. Cloning of the pRLL-cPPT-PGK-luc-PRE-
SIN vector has been described previously.14 The 535 bp proximal promoter of 
the CXCL10 gene was isolated from purified human genomic DNA (Promega, 
Madison, WI, USA) using Phusion polymerase (New England Biolabs, Ipswich, 
MA, USA), the forward primer TTTTGTCGACTCAAGGAGGACTGTCCAGGT and 
reverse primer TTTTGCTAGCGGTGCTGAGACTGGAGGTTC. The primers introduced 
restriction sites for SalI and NheI respectively. The promoter was first cloned 
into PCR-Script using the PCR-Script CAM cloning kit (Agilent, Santa Clara, CA, 
USA) according to the manufacturer’s protocol. SalI and NheI (New England 
Biolabs) were used to clone the CXCL10 promoter in the pRRL-cPPT-mcs-luc-
PRE-SIN vector. The human IL-10 transgene was isolated from cDNA obtained 
from primary human macrophages by nested PCR using forward primer 
AAAGAAGGCATGCACAGCTCA and reverse primer TGGAAGCTTCTGTTGGCTCC to 
obtain a 903 bp PCR nest. The 537 bp gene was subsequently isolated from the 
nest with forward primer GCTAGCGCCACCATGCACAGCTCAGCACTGCTC and reverse 
primer TCTAGATCAGTTTCGTATCTTCATTGTCATG, which introduced restriction sites 
for NheI and XbaI. NheI and XbaI (New England Biolabs) were used to replace the 
firefly luciferase gene in the pRLL-cPPT-CXCL10-luc-PRE-SIN by the therapeutic IL-10 
gene. 
Lentivirus production  
293T cells were seeded at density 1x10E5 cells/cm2 in a T75 culture flask in DMEM 
medium, supplemented with 10% FCS, 1 mM pyruvate, 1% pen/strep and 0.01 mM 
cholesterol (Sigma) one day prior to the plasmid transfection. The cells were co-
transfected with a calcium phosphate precipitate containing 5,3 µg sin vector, 4,0 
µg MDL packaging plasmid, 3,5 µg VSV-G expression plasmid and 1,8 µg RSV-REV 
expression plasmid in mediumwithout antibiotics. After 16h, the medium was replaced 
and new complete medium containing the produced virus was collected after 24h 
and 48h. The supernatant was passed through a 0.22 µm Stericup filter (Millipore, 
Bedford, MA, USA). Subsequently, 32 ml supernatant was layered on 4 ml 20% sucrose 
(Sigma) and centrifuged for 2h at 25k rpm in a Surespin 6x50ml swingout bucket 
rotor (Sorvall) in a Discovery 100WX ultra centrifuge (Sorvall). The viral vectors were 
resuspended in sterile PBS and stored at -80°C. Virus concentrations were determined 
using the INNOTEST HIV antigen mAb kit (Diasorin, Saluggia, Italy) and expressed 
as ng p24/µl. Viral transduction of cells was performed with 50 ng virus/5x10E4 
cells in complete medium supplemented with 8 µg/ml polybrene (Sigma).  
 
Luciferase measurements  
The luciferase measurements were performed in 96-well white clear-bottom plates 
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(Greiner Bio-one) in total volumes of 50-60 µl using the BrightGlo luciferase assay 
system (Promega). 30 µl BrightGlo substrate was added to cells and light production 
was measured on a Lumistar luminometer (BMG, Offenburg, Germany). The values 
were corrected for the background signal and depicted as relative light units (RLU).
Multiplex Elisa assay  
Cytokine and chemokine concentrations were determined by luminex multianalyte 
technology on the Bio-Plex 200 (Bio-Rad, Hercules, CA, USA) in combination 
with Bio-Plex pro human cytokine kits (Bio-Rad) according to the manufacturer’s 
protocol. For IL-10, MCP-1, IL-6 and IL-8 measurements, the culture supernatants 
were first diluted 25x. Samples below the detection limit were set at the lowest 
measureable quantity to perform statistical analysis.
Statistical analysis  
Statistical analysis was performed using the Student’s t-test, 1-way ANOVA 
and 2-way ANOVA. Results are depicted as mean +/- SD and P-values < 0.05 
were regarded as significant.        
Results
Microarray analysis of RA synovium samples  
Potential disease-regulated promoters can be obtained from endogenous promoters 
of genes upregulated during disease. Therefore, we analyzed 20 microarrays of RA 
patient synovium biopsies and compared the gene expression levels to 8 control 
synovium biopsies without arthritis. The criteria for candidate genes included at least 
10-fold upregulation in RA with P<0.01 compared to control and a minimal average 
relative probe intensity of 500 (arbitrary units) in RA to find promoters of sufficient 
capacity. The genes that do not code for a transcribed mRNA were removed from 
the list. In addition, the immunoglobulin genes were removed, as their proximal 
promoters rely on B-cell-specific factors and are dependent on intronic enhancer 
elements.15 22 genes met these criteria and are summarized in Table 1.   
 The upregulation of the genes in the RA patient synovium was confirmed by 
qPCR on a subset of the biopsies (Supp. Fig. 2, Table 1).
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We first determined if the gene upregulation in the joints was the result of pro-
inflammatory signaling and if inflammation-sensitive cells can activate the gene 
promoters after stimulation in vitro. Human synovial biopsies were digested and 
stimulated for 6h with bacterial lipopolysaccharide (LPS), which activates the pro-
inflammatory TLR4 signaling. Several genes that were selected from the microarrays 
were upregulated after stimulation, of which CXCL10 showed the highest induction 
(Fig. 1A). These results confirm that a pro-inflammatory stimulus can activate 
transcription of the genes and the promoters of these genes therefore might be 
applicable for disease-regulated gene therapy. Similar results were obtained 
in human THP-1 monocytes after stimulation with the synthetic lipopeptide 
Pam3CSK4, which triggers TLR2 signaling16 (Fig. 1B). Based on the microarray and 
the high inducibility in both synovial cells and THP1 cells, the CXCL10 promoter was 
selected for the remainder of this study.
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Figure 1: Upregulation of candidate genes in synovial cells and THP1 cells after TLR stimulation. (A) 
Gene expression levels in primary cell cultures of digested synovial biopsies from patient 21after 6h 
stimulation with 100 ng/ml LPS. Genes are sorted from left to right according to fold induction over 
unstimulated cells. (B) Gene expression levels in THP-1 cells stimulation with 100 ng/ml Pam3CSK4. 
Expression levels are depicted as threshold cycle (CT) +/- SD, corrected for GAPDH expression. 
Statistical analysis was performed by Student’s t-test. * =P<0.05, ** =P<0.01, *** =P<0.001.
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Promoter inducibility  
The proximal promoter of the CXCL10 gene was obtained from human 
cDNA and cloned into a lentiviral vector expressing the luciferase reporter 
gene. THP1 cells were transduced with the inducible reporter construct and 
stimulated with pro-inflammatory cytokines IL-1β, TNFα and TLR triggers LPS 
and Pam3CSK4 for 6h. The promoter showed a robust response to all stimuli 
(Fig. 2A). In primary RA synovial cell culture, the isolated promoter was 
inducible by IL-1β, TNFα and LPS, but not by Pam3CSK4 (Fig. 2B).  
 An important characteristic of disease-inducible therapy for RA is the 
net response of the promoter to the balance of pro- and anti-inflammatory 
proteins present in the patient. Therefore, we compared the CXCL10 promoter 
response to serum from 63 RA patients to serum from 62 age- and sex matched 
healthy donors. The RA patient sera showed a stronger induction of the 
CXCL10 promoter compared to healthy control sera (Fig. 2C). This confirms 
that the inducible CXCL10 promoter is more active in RA patients.  
 For the most accurate treatment of an RA patient, the inducible promoter 
activity should return to basal levels if the disease activity decreases and should 
be activated again if a new stimulus appears. Therefore, we compared the kinetics 
of the CXCL10 promoter to the constitutive active PGK promoter at different time 
points after stimulation with TNFα. Indeed, the PGK-luciferase activity remained 
around basal levels for 96 hours (Fig. 2D). The CXCL10 promoter showed highest 
activity at 8-12h after the stimulation (Fig. 2E), although the peak activity was still 
below PGK-level. As the TNFα was used and degraded by the cells,17 the promoter 
activity decreased. Re-stimulation of the cells with TNFα 8h prior to the 96h time 
point resulted in a significant second induction of the promoter.
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Figure 2: Inducibility of the CXCL10 promoter in synovial cells and THP1 cells. (A) Relative light signal 
of CXCL10 promoter-luciferase construct after stimulation with pro-inflammatory factors. THP1 cells 
were transduced with CXCL10 promoter-luciferase lentiviral vector and stimulated for 6h with 10 ng/
ml IL-1β, 10 ng/ml TNFα, 100 ng/ml LPS or 100 ng/ml Pam3CSK4. Light values are shown as relative 
light units (RLU) +/- SD. (B) CXCL10 promoter-luciferase construct activation in primary RA synovial 
cell culture from patient 22. (C) CXCL10 promoter-luciferase activation by RA patient serum. A stably 
transduced THP1 clone was stimulated with 10% RA patient serum or age- and sex-matched healthy 
control serum (HC). The light signal after 6h is shown as RLU, corrected for the average signal from 
the control group +/- SD. (D,E) THP-1 cells were transduced with lentiviral PGK-luciferase vector (D) 
or CXCL10-luciferase (E) and stimulated with 10 ng/ml TNFα. At multiple time points, the luciferase 
activity was determined. Light values are shown as relative light units (RLU) +/- SD. A second 10 ng/ml 
TNFα stimulation was provided at 88h, 8h prior to the last measurement. For statistical analysis, the re-
stimulated sample was compared to the 96h time point without re-stimulation. Statistical analysis was 
performed by Student’s t-test compared to the medium control. * =P<0.05, ** =P<0.01, *** =P<0.001.
Recombinant human IL-10 effects on cytokine production  
The therapeutic potential for IL-10 was assessed using recombinant human IL-10 
(rhIL-10). Primary RA synovial cell cultures of 3 patients were stimulated for 6h with 
LPS with or without the addition of rhIL-10. Despite differences in absolute quantity 
between patients, the production of TNFα was increased after LPS stimulation and 
could be significantly reduced with rhIL-10 (Fig. 3A). To determine the effects of 
the cytokines produced by the synovial cells on the CXCL10 promoter, THP1 cells 
transduced with CXCL10prom-luciferase were stimulated with the synovial cell 
culture supernatant of one of the patients from Figure 4A (Fig. 3B, closed bars). To 
test the effects of residual LPS and IL-10 that might be left in the supernatant from 
the synovial cells, LPS and rhIL-10 effects were first tested separately (open bars). No 
direct activation of the CXCL10 promoter by rhIL-10 was observed and LPS showed 
some activation of the CXCL10 promoter. However, the cell culture supernatant from 
LPS-stimulated synovial cells showed a stronger induction compared to LPS alone. 
If the synovial cells were treated with rhIL-10, the capacity of its supernatant to 
activate the CXCL10 promoter was significantly reduced. This shows that activated 
synovial cells produce the required factors to activate the CXCL10 promoter and that 
IL-10 can diminish this production. All conditions were also tested in the presence 
of the specific TNFα-inhibitor Etanercept. In the presence of Etanercept, the CXCL10 
promoter induction by synovial cell supernatant was significantly lower, indicating 
that TNFα produced by the stimulated synovial cell culture is the most important 
trigger for CXCL10 promoter activation in this setting.
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Figure 3: TNFα levels in the supernatant of stimulated synovial cells and the activation of the 
CXL10p-luciferase by the supernatant. (A) Synovial biopsies from patient 23, 24 and 25 were digested 
using Liberase and passed through a cell strainer. After red blood cell lysis, cells were seeded and 
allowed to attach and recover. Subsequently, the synovial cell suspension was stimulated for 6h 
with 5 ng/ml LPS and 20 ng/ml recombinant human IL-10. The cell culture medium was removed 
and the produced TNFα was measured using multiplex assay. (B) THP1 cells stably transduced with 
the CXCL10p-luciferase reporter lentivirus were stimulated for 6h with medium containing 20 ng/ml 
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recombinant IL-10 (+I10), 5 ng/ml LPS (+L5), 100 ng/ml LPS (+L100) or a combination (open bars). In 
addition, the cells were stimulated with the cell culture supernatant obtained from Figure 4A (closed 
bars) that might contain residual IL-10 (I10) or LPS (L(5) and L(100)). All samples were tested in the 
presence and absence of 50 ng/ml TNFα-inhibitor Etanercept. Light values are shown as relative light 
units (RLU) +/- SD. Results were similar with supernatants from all three patients (data not shown). 
Statistical analysis between subgroups of different stimulations was performed by 2-way ANOVA and 
other comparisons were performed by Student’s t-test. ** =P<0.01, *** =P<0.001.
 
Effects of CXCL10-IL10 lentivirus on cytokine production  
The potential of the CXCL10 promoter to produce therapeutic quantities of IL-10 
was tested by replacing the luciferase reporter transgene by the coding region of the 
human IL-10 gene (CXCL10p-IL10). THP-1 cells transduced with PGK-luciferase control 
lentiviral vector produced low quantities of IL-10 (Fig. 4A). After transduction with 
CXCL10p-IL10, the basal activation of the of the CXCL10 promoter already resulted 
in increased IL-10 levels. Stimulation of the transduced cells with Pam3CSK4 caused 
a significant increase in production of IL-10. Pam3CSK4-stimulated THP-1 cells with 
control virus showed a marked increase in production of inflammatory cytokines 
MCP-1, IL-6 and IL-8 (Fig. 4B-D). The release of these cytokines was inhibited by 
the CXCL10p-IL10 lentivirus, which shows the anti-inflammatory potential of the 
CXCL10p-IL10 treatment.
Subsequently, the CXCL10p-IL10 lentivirus was tested in synovial cell cultures of 
three patient donors. After transduction with control virus or CXCL10p-IL10, the 
cells were stimulated with 5 or 100 ng/ml LPS. Only minor quantities of IL-10 were 
produced by cells with the control virus (Fig. 5A). After transduction with the 
CXCL10p-IL10 lentivirus, basal production levels of IL-10 were observed, which 
significantly increased after LPS stimulation in all patients, although the magnitude 
varied between patients. LPS triggered the release of TNFα, which was reduced by 
the CXCL10p-IL10 treatment of the cells (Fig. 5B). With the exception of the third 
donor, the same effects were also observed for IL-1β. In the third donor, IL-1β levels 
remained low after stimulation with LPS (Fig. 5C). The production of MCP-1, IL-8 
and IL-6 were also decreased in cells transduced with CXL10p-IL10, although the 
decrease was not significant for most samples (Supp. Fig. 3). These results show 
that in the synovial cells of the patient, the CXCL10p-IL10 gene therapy can provide 
inducible expression of therapeutic levels of IL-10 that can suppress the production 
of pro-inflammatory cytokines.
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Figure 4: Production and effects of IL-10 in CXCL10p-IL10 transduced THP1-cells. (A) THP-
1 cells were transduced with lentiviral vectors containing PGK-luciferase or CXCL10p-IL10. 
After 48h, the cells were stimulated with medium control or with 100 ng/ml Pam3CSK4 
for 24h. IL-10 production was measured in the culture supernatant by multiplex assay. 
Statistical analysis was performed by 1-way ANOVA. (B-D) THP-1 cell culture supernatant 
concentrations of MCP-1 (B), IL-6 (C) and IL-8 (D). Statistical analysis was performed by 
Student’s t-test, compared to the stimulated control cells. * =P<0.05, *** =P<0.001.
 
Figure 5: Production and effects of IL-10 on TNFα and IL-1β in CXCL10p-IL10 transduced synovial 
cells. Synovial tissue biopsies from patient 26, 27 and 28 were digested and cells were transduced 
with lentiviral PGK-luciferase (control) or lentiviral CXCL10p-IL10. After a minimum of 48h after 
transduction, the cells were stimulated for 24h with 5ng/ml LPS or 100 ng/ml LPS. The supernatant 
was collected and the concentrations of IL-10 (A), TNFα (B) and IL-1β (C) were measured by multiplex 
assay. The cytokine concentration of samples left of the dotted line are shown on the left y-axis and 
the samples on the right of the dotted line are depicted on the right y-axis. Statistical analysis was 
performed by 1-way ANOVA. * =P<0.05, ** =P<0.01, *** =P<0.001.
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Discussion
In this study we showed that the promoter from the CXCL10 gene is inducible by pro-
inflammatory TLR triggers and cytokines. In human THP-1 monocytes, the promoter 
showed a significant induction by RA patient serum, compared to healthy control serum. 
Using the CXCL10p-IL10 lentivirus in LPS-stimulated cells from RA patient biopsies, 
therapeutic levels of anti-inflammatory IL-10 were produced that could reduce 
the release of pro-inflammatory cytokines TNFα, IL-1β, IL-6, IL-8 and MCP-1.  
 The promoters of genes that were upregulated in RA synovium microarrays 
are the possible candidates for disease-regulated therapy. We first determined if 
the gene upregulation was the result of pro-inflammatory signaling rather than an 
altered cell composition in RA synovium by using broad TLR triggers which activate 
the major inflammatory transcription factors.18 TLRs are important players in RA 
and can be triggered by damage-associated molecular patterns (DAMPs) present 
in the RA joint.19 A TLR2 trigger was used for THP1 cells, because TLR2 shows the 
highest expression in THP1 cell.20 In contrast, TLR2 is not uniformly expressed on 
synovial fibroblasts and is upregulated after stimulation.21,22 Therefore, the synovial 
cell cultures were stimulated with a TLR4 ligand. Based on the obtained data, the 
promoter of the CXCL10 gene was selected. In accordance with our results, previous 
studies have shown increased levels of CXCL10 in synovial fluid of RA patients.23  
 CXCL10 is a C-X-C motif ligand chemokine, responsible for the recruitment 
of several immune cell types into the inflamed joint.24 The isolated region of 
the CXCL10 promoter contains predicted binding sites for immunoregulatory 
transcription factors C/EBPβ, NF-κB, AP-1 and an interferon-stimulated response 
element (ISRE).25 Point mutations in the NF-κB and the ISRE sites resulted in 
reduced promoter activity after stimulation with TNFα and IFNγ or by TLR 
triggers in hepatocytes.26 Interestingly, promoter constructs with mutations in 
the AP-1 or C/EBPβ binding sites showed increased activity upon stimulation, 
indicating orchestration of the promoter activity by multiple factors.  
 The CXCL13 gene, also known as B-lymphocyte chemoattractant, showed 
the highest upregulation in the RA microarrays and in stimulated THP-1 cells. In 
mice, the promoter of CXCL13 contains a TATA-box and transcription factor binding 
sites.27 In humans this region is conserved, but located in a large intron in the 5’UTR. 
We isolated both the proximal promoter region from the human transcription 
start site and the first intron, but we could not observe an upregulation of either 
promoter activity after stimulation (data not shown). In addition, we did not find an 
upregulation of endogenous CXCL13 in Pam3CSK4-stimulated synovial cells.  
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 During RA pathogenesis, cells in the joint produce chemokines and 
cytokines to induce pannus formation and attract different immune cells to the 
joint, including neutrophils, monocytes, T-cells and B-cells.28,29 As a consequence, 
the synovial cell cultures after digestion of the synovium are of heterogeneous 
composition with patient-to-patient variation. This results in differences in cytokine 
production levels. For example, Il-1β has been suggested to be predominantly 
produced by activated monocytes and macrophages.30 The third donor in 
Figure 5 showed the highest TNFα production upon stimulation, but only a very 
low production of IL-1β, which might reflect a low abundance of monocytes.   
 In general, the cells in the synovium of RA patients have an inflammatory 
phenotype, which has also been observed in microarrays. Compared to healthy 
controls, the signaling networks associated with upregulated genes in RA include 
inflammatory response, T-cell activation and apoptosis.31 As a result, the cytokine 
concentrations are increased in the synovial fluid of RA patients.32 The inflammatory 
phenotype of the synovial cells in this study is reflected by the basal production of IL-1β 
(Figure 5C) and IL-10 after CXCL10p-IL10 transduction (Figure 6A) and by a relatively 
high basal activity of the CXCL10 promoter in RA synovial cells (Figure 2B).   
 To avoid effects of the basal activation state on the CXCL10 promoter, THP-1 
cells were used to study promoter activation. THP-1 cells are human monocytes which 
are responsive to multiple TLR ligands and cytokines and can subsequently activate 
different inflammatory pathways.33 In addition, gene expression analysis of peripheral 
blood in RA patients showed an enrichment in monocyte-specific transcripts,34 
indicating that THP-1 is a sensitive cell model relevant to RA. Indeed, the CXCL10 
promoter in THP-1 cells showed a strong induction by the cytokines produced by 
stimulated synovial cells. In addition, the responsiveness of the CXCL10 promoter in 
a monocyte cell line to RA serum factors might enable the use of the promoter to treat 
systemic components of the disease, like atherosclerosis and autoimmunity.  
 Patients with inherited deficiencies in IL-10 signaling are rare, but suffer 
from early-onset inflammatory bowel disease (IBD).35 In addition, some studies 
found that the frequency of a polymorphism associated with low serum levels of 
IL-10 was increased in RA patients.36,37 Currently, research is focusing on obtaining 
long-term active IL-10 targeted to the inflamed joint both by disease-responsive 
gene therapy and by fusing IL-10 to homing antibodies38 to provide regulated 
suppression of the inflammation.
In conclusion, we have shown the temporal and spatial activation of the 
CXCL10 promoter, which was used to provide inducible expression of the anti-
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inflammatory IL-10. The vector was capable of reducing the release of pro-
inflammatory cytokines by RA synovial cells and might therefore be suited to 
provide local and disease-responsive gene therapy in RA patients.  
Acknowledgements
This study was financially supported by the Dutch Arthritis Foundation (11-1-409) 
and The Netherlands Organisation for Health Research and Development (ZonMw, 
114021001).
 
References
1. van de Loo FA, de Hooge AS, Smeets RL, Bakker AC, Bennink MB, Arntz OJ, et al. An 
inflammation-inducible adenoviral expression system for local treatment of the arthritic 
joint. Gene Ther 2004; 11: 581-590.
2. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, et al. Gene transfer 
to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005; 
102: 8698-8703.
3. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, et al. Safety, tolerability, 
and clinical outcomes after intraarticular injection of a recombinant adeno-associated 
vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J 
Rheumatol 2010; 37: 692-703.
4. Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, et al. Local delivery 
of a recombinant adenoassociated vector containing a tumour necrosis factor alpha 
antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability 
study. Ann Rheum Dis 2009; 68: 1247-1254.
5. Bijjiga E, Martino A. Interleukin 10 (IL-10) Regulatory Cytokine and its Clinical Consequences. 
J Clin Cell Immunol S 2013; 1: 2.
6. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in 
steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997; 
113: 383-389.
7. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. 
J Immunol 2002; 169: 2204-2209.
8. Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, et al. Disease-
dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS One 
Chapter 6
137
6
2012; 7: e49731.
9. Vermeij EA, Broeren MG, Bennink MB, Arntz OJ, Gjertsson I, P LEMvL, et al. Disease-
regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion 
in experimental arthritis. Ann Rheum Dis 2014.
10. Geurts J, Vermeij EA, Pohlers D, Arntz OJ, Kinne RW, van den Berg WB, et al. A novel Saa3-
promoter reporter distinguishes inflammatory subtypes in experimental arthritis and human 
synovial fibroblasts. Ann Rheum Dis 2011; 70: 1311-1319.
11. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring 
by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14: 1675-1680.
12. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index 
computation and outlier detection. Proc Natl Acad Sci U S A 2001; 98: 31-36.
13. Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL, et al. Inflammation and 
ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics 
technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid 
neogenesis. Arthritis Rheum 2007; 56: 2492-2502.
14. Geurts J, Joosten LA, Takahashi N, Arntz OJ, Gluck A, Bennink MB, et al. Computational 
design and application of endogenous promoters for transcriptionally targeted gene therapy 
for rheumatoid arthritis. Mol Ther 2009; 17: 1877-1887.
15. Ren X, Siegel R, Kim U, Roeder RG. Direct interactions of OCA-B and TFII-I regulate 
immunoglobulin heavy-chain gene transcription by facilitating enhancer-promoter 
communication. Mol Cell 2011; 42: 342-355.
16. Vasselon T, Detmers PA, Charron D, Haziot A. TLR2 recognizes a bacterial lipopeptide through 
direct binding. J Immunol 2004; 173: 7401-7405.
17. Yoshie O, Tada K, Ishida N. Binding and crosslinking of 125I-labeled recombinant human 
tumor necrosis factor to cell surface receptors. J Biochem 1986; 100: 531-541.
18. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb 
Perspect Biol 2012; 4.
19. Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid 
arthritis. Rheumatology (Oxford) 2012; 51: 7-23.
20. Parker LC, Whyte MK, Vogel SN, Dower SK, Sabroe I. Toll-like receptor (TLR)2 and TLR4 
agonists regulate CCR expression in human monocytic cells. J Immunol 2004; 172: 4977-
4986.
21. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation 
of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 1221-1227.
Disease-regulated gene therapy with anti-inflammatory interleukin-10 under control of the CXCL10 
promoter for the treatment of Rheumatoid Arthritis
138
22. Philippe L, Alsaleh G, Suffert G, Meyer A, Georgel P, Sibilia J, et al. TLR2 expression is regulated 
by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J Immunol 2012; 188: 454-
461.
23. Ueno A, Yamamura M, Iwahashi M, Okamoto A, Aita T, Ogawa N, et al. The production of 
CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. 
Rheumatol Int 2005; 25: 361-367.
24. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. 
Ann N Y Acad Sci 2009; 1173: 310-317.
25. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D. Human airway epithelial cells produce 
IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol 
Physiol 2005; 289: L85-95.
26. Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, Gale M, Jr., et al. Direct, interferon-
independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory 
factor 3 during hepatitis C virus infection. J Virol 2014; 88: 1582-1590.
27. Britanova LV, Kuprash DV. [New putative control elements in the promoter OF CXCL13 
chemokine gene, a target of alternative NF-kappaB pathway]. Mol Biol (Mosk) 2009; 43: 
657-665.
28. Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin 
Rheumatol 2008; 22: 239-252.
29. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial 
cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis 
Rheum 1997; 40: 217-225.
30. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor 
necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
31. Ungethuem U, Haeupl T, Witt H, Koczan D, Krenn V, Huber H, et al. Molecular signatures and 
new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics 2010; 
42a: 267-282.
32. Lettesjo H, Nordstrom E, Strom H, Nilsson B, Glinghammar B, Dahlstedt L, et al. Synovial fluid 
cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol 
1998; 48: 286-292.
33. Xue X, Lai KT, Huang JF, Gu Y, Karlsson L, Fourie A. Anti-inflammatory activity in vitro and in 
vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther 2006; 317: 
53-60.
34. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood 
gene expression profiling in rheumatoid arthritis. Genes Immun 2005; 6: 388-397.
Chapter 6
139
6
35. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, et al. Clinical 
outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem 
cell transplantation. J Allergy Clin Immunol 2013; 131: 825-830.
36. Paradowska-Gorycka A, Trefler J, Maciejewska-Stelmach J, Lacki JK. Interleukin-10 gene 
promoter polymorphism in Polish rheumatoid arthritis patients. Int J Immunogenet 2010; 
37: 225-231.
37. Ying B, Shi Y, Pan X, Song X, Huang Z, Niu Q, et al. Association of polymorphisms in the 
human IL-10 and IL-18 genes with rheumatoid arthritis. Mol Biol Rep 2011; 38: 379-385.
38. Hughes C, Sette A, Seed M, D’Acquisto F, Manzo A, Vincent TL, et al. Targeting of viral   
 interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves  
 its therapeutic potency. Arthritis Res Ther 2014; 16: R151.
Disease-regulated gene therapy with anti-inflammatory interleukin-10 under control of the CXCL10 
promoter for the treatment of Rheumatoid Arthritis
140
Supplementary information
Table S1: List of primer sequences for qPCR analysis 
Gene symbol Forward primer (5’→3’) Reverse primer (5’→3’)
GAPDH ATCTTCTTTTGCGTCGCCAG TTCCCCATGGTGTCTGAGC
CXCL13 CTCTGCTTCTCATGCTGCTG CAGCTTGAGGGTCCACACAC
VSNL1 CCAATGGGGAGGCTAAATC GAAGTCAATGGTGCCGTC
POU2AF1 CAATGTCACGACAAGAAGCT CACGGGAAATAGGTGAGGG
SPP1 CTCCTAGGCATCACCTGTG GGGTATTTGTTGTAAAGCTGCT
MMP13 ATTAAGGAGCATGGCGACTTCT CCCAGGAGGAAAAGCATGAG
IBSP GCAGTAGTGACTCATCCGA CTCCTTCATTTGAAGTCTCCTC
NMES1 AGGAAGGAACTCATTCCCT CCAAAGAGAATACACAGCGA
TNFRSF17 CGACTCTGACCATTGCTTTCC AAGCAGCTGGCAGGCTCTT
ADAMDEC1 TCAAACTCAAGCAATAGCCA TGTCTGGTTGTTCTTGATCTC
CSN1S1 AGGCTCTGATAACCATGAGG GTTTCTCTGCCTGTTCATACC
CXCL6 AGAGCTGCGTTGCACTTGTT GCAGTTTACCAATCGTTTTGGGG
SLAMF7 TCCACTGTGGAAATACCGA GGCAAATAGCCTTGGTGTG
COL1A1 AGATCGAGAACATCCGGAG AGTACTCTCCACTCTTCCAG
IL4I1 CTCAAAGACCTCAAGGCAC CCCGAGAAGATATTCCAAGAG
SLAMF8 CTCAAGGTGTACGATGCAG GTTATTTCGCTGATGTTGGG
CXCL8 AGAAGTTTTTGAAGAGGGCTGAGA AGTTTCACTGGCATCTTCACTGATT
RGS1 ACTCATTCACTTCTAGACGAC GGTATGCTTTCATATCCATTCC
CCL18 GGTGTCATCCTCCTAACCA GTCGCTGATGTATTTCTGGAC
FKBP11 GATTCCAGGTCTGGAGCAG CATAGGCCAAGTGAGAAGGA
CXCL10 ATTTGCTGCCTTATCTTTCTG GACATCTCTTCTCACCCTTCT
TREM1 TTGTCTCAGAACTCCGAGC CATTTCACATCCAGGGTCTG
CXCL9 GGAGTGCAAGGAACCCCAGTA GAGAAACAGGTCAGCCAAAAG
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Supplemental Figure 1: Examples of histological sections of the synovium samples used in this 
study from patients 23, 24, 26 and 27. 7 µm cryosections were stained with haematoxylin and eosin. 
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Supplemental Figure 2: Gene expression levels of genes upregulated in RA in synovium biopsies. n=4 
and n=5 samples per group were measured and the expression levels are depicted as threshold cycle 
(CT) +/-SD, corrected for GAPDH expression. Statistical analysis was performed by Student’s t-test. * 
=P<0.05, ** =P<0.01.
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Supplemental Figure 3: Production and effects of IL-10 on MCP-1, IL-8 and IL-6 in CXCL10p-IL10 
transduced synovial cells. Synovial tissue biopsies from patient 26, 27 and 28 were digested and cells 
were transduced with lentiviral PGK-luciferase (control) or lentiviral CXCL10p-IL10. After a minimum 
of 48h after transduction, the cells were stimulated for 24h with 5ng/ml LPS or 100 ng/ml LPS. The 
supernatant was collected and the concentrations of MCP-1 (A), IL-8 (B) and IL-6 (C) were measured 
by multiplex assay. Statistical analysis was performed by 1-way ANOVA. * =P<0.05, ** =P<0.01, *** 
=P<0.001.
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Background:  
Gene therapy has the potential to provide long-term production of therapeutic proteins 
in the joints of osteoarthritis (OA) patients. The objective of this study was to analyse the 
therapeutic potential of disease-inducible expression of anti-inflammatory interleukin-10 
(IL-10) in the 3-dimensional micromass model of the human synovial membrane.
Methods:   
Synovial tissue samples from OA patients were digested and the cells were mixed with 
Matrigel to obtain 3D micromasses. The CXCL10 promoter combined with the firefly 
luciferase reporter in a lentiviral vector was used to determine the response of the CXCL10 
promoter to tumor necrosis factor α (TNFα), interleukin-1β (IL-1β) and lipopolysaccharide 
(LPS). The effects of recombinant IL-10 on gene expression were determined by quantative 
PCR. The production of IL-10 from the CXCL10p-IL10 vector and the effects on pro-
inflammatory cytokine production were assessed by multiplex ELISA.
Results:  
Micromasses made from whole synovial membrane cell suspensions form a distinct surface 
composition containing macrophage and fibroblast-like synoviocytes thus mimicking the 
synovial lining. This lining can be transduced by lentiviruses and allow CXCL-10 promoter-
regulated transgene expression. Adequate amounts of IL-10 transgene were produced 
after stimulation with pro-inflammatory factors able to reduce the production of synovial 
IL-1β and IL-6. 
Conclusions:  
Synovial micromasses are a suitable model to test disease-regulated gene therapy 
approaches and the CXCL10p-IL10 vector might be a good candidate to decrease the 
inflammatory response implicated in the pathogenesis of OA.
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Background
Osteoarthritis (OA) is the most common joint disease and no adequate disease-
modifying treatments are available yet.1 Although the exact etiology of OA is still unclear 
and may be dependent on multiple risk factors, there is increasing evidence that in 
many OA patients inflammation is involved in the pathogenesis.2 IL-1β and TNFα are 
key pro-inflammatory cytokines, primarily produced by macrophages that infiltrate 
the synovium during inflammatory OA.3 These cytokines trigger the release of other 
cytokines and matrix-degrading enzymes from resident articular cells, including the 
fibroblast-like synoviocytes (FLS) that damage the articular cartilage. This results in the 
release of damage-associated molecular patterns (DAMPs) with pro-inflammatory 
properties, potentially creating a positive vicious circle of inflammation and damage.4 
 Several strategies have been explored to treat inflammation in the OA joint, 
including biological therapies that were developed for the treatment of rheumatoid 
arthritis (RA). However, the therapeutic effects are disappointing.5 A possible 
explanation might be the relative strong contribution of systemic factors in RA. In 
contrast, OA is considered primarily to be a local process and systemically injected 
therapeutics may not reach the target joints in sufficient amounts. Intra-articular 
injections are feasible but proteins injected in the joint are rapidly cleared and 
consequently the invasive injections have to be repeated increasing the discomfort 
for patients.6 These considerations ask for the development of a different strategy 
to obtain long-term drug effects in the OA joint. Local gene therapy can be a suitable 
approach and might even be used to express proteins with a short half-life like 
interleukin-10 (IL-10), which is a potent anti-inflammatory cytokine.7
Previous studies with IL-10 gene therapy in experimental models of rheumatoid 
arthritis have explored the use of inducible promoters to drive the expression of 
IL-10.8-10 These promoters contain binding sites for transcription factors that are 
activated during active disease, which might reduce side effects of continuous IL-10 
exposure as observed in patients suffering from chronic active Crohn’s disease. These 
patients received daily injections of high dose IL-10 and showed a drop in hemoglobin 
levels.11 We recently adapted the inducible IL-10 gene therapy to human synovial 
cells.12 For this purpose, the promoter from the CXCL10 gene was selected based on 
microarray analysis of RA synovium. The inflammatory chemokine CXCL10 protein 
concentration has also been found to be significantly upregulated in the synovial fluid 
and in the serum of OA patients compared to healthy controls.13,14 Because CXCL10 
can be expressed from multiple cell types, no selective expression is expected from 
the vector.15 CXCL10 expression is associated with OA-related disease processes, 
including inflammation and osteoclastogenesis,15 which indicates that CXCL10 
promoter-driven expression of IL-10 might be a viable option for the treatment of 
OA. In addition, the OA synovium could be more sensitive to IL-10 therapy, because 
of relatively high expression of the IL-10 receptor α chain as compared to RA.16   
 The CXCL10p-IL10 gene therapy approach showed promising results in 
synovial cell suspensions. Based on the known IL-10 effects we postulate that local 
IL-10 gene therapy would be efficacious at the early stage of OA when synovitis 
is developing and before irreversible fibrotic changes occur. In this study, we 
determined the inflammatory response and anti-inflammatory potential of the 
CXCL10p-IL10 lentiviral vector in the three-dimensional (3D) micromass synovial 
membrane model. In a 3D culture model, the cell-matrix and cell-cell interactions 
are more biologically relevant, providing a more predictive system for the in vivo 
situation, compared to classic 2D culture.17 Synovial micromasses were generated 
from primary synovial cells isolated from OA patients by digestion, containing both 
FLS and macrophage-like synoviocytes (MLS). The micromasses were transduced 
after establishment of a synovial lining layer and the CXCL10 promoter was responsive 
to lipopolysaccharide (LPS), TNFα and IL-1β. The activated promoter could provide 
therapeutic quantities of IL-10, which reduced the release of IL-1β and IL-6. These 
results show that the CXCL10p-IL10 vector can provide self-regulated inhibition of 
the inflammatory response in a synovial membrane model.
 
Materials and methods
Patient material  
Synovial osteoarthritis (OA) tissue samples were obtained during joint replacement 
surgery from the department of Orthopedics (Radboud university medical center, 
Nijmegen, The Netherlands). Patients gave their informed consent and protocols 
were approved by the medical ethics committee. In total, synovium of 12 OA patients 
was included in this study. The micromasses shown in Figure 1A-D were derived 
from a patient diagnosed with RA. Before processing, representative samples were 
embedded in Tissue-Tek O.C.T. (Sakura, Alphen a/d Rijn, The Netherlands). 7 µm 
cryosections were cut using the Cryostar NX70 (Thermo Scientific, Waltham, MA, 
USA) and stained for hematoxylin and eosin (HE) to confirm that the tissue samples 
contained a synovial lining. Fig. S1 contains HE images of 12 patients.
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The synovial samples were digested using 50 µg/ml Liberase TM (Roche, Basel, 
Switzerland) for 1h at 37°C in RPMI culture medium without supplementations. 
The digestion was stopped by adding 10% fetal calf serum (FCS). Subsequently, the 
synovial cells were passed through a 70 µm cell strainer (Corning, NY, USA) and 
centrifuged. All cell centrifugations were performed for 5 min at 1500 rpm/423 g 
in a Heraeus Megafuge 16R (Thermo Scientific). Red blood cells were lysed for 2 
min at RT using 4 ml RBC lysis buffer (155 nM NH
4
Cl, 12 mM KHCO
3
, 0.1 mM EDTA, 
pH 7.3). The lysis reaction was quenched by adding 6 ml RPMI culture medium, 
supplemented with 10% FCS and 1 mM pyruvate and 1% P/S.
Micromass production and culture  
For micromass construction, the synovial cell suspensions were centrifuged and cell 
pellets were dissolved in ice-cold Matrigel (Corning) at an average density of 2x10E7 
cells/ml. Using cooled pipette tips, 25 µl droplets were placed in 24-well culture 
plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) or conical 12 ml tubes 
(Greiner Bio-one), which were coated with poly-(2-hydroxyethyl methacrylate) (poly-
HEMA) (Sigma-Aldrich, Zwijndrecht, The Netherlands). After 30 minutes gelation at 
37°C, 500 µl RPMI culture medium, supplemented with 10% heat-inactivated FCS, 
1 mM pyruvate and 1% P/S was added. Medium was replaced twice weekly. All cell 
cultures were kept in humidified atmosphere at 37°C and 5% CO
2
. The micromasses 
were stimulated with E. coli lipopolysaccharide (LPS) (Invivogen, San Diego, CA, 
USA), recombinant human TNFα (Abcam, Cambridge, UK), recombinant human 
IL-1β (R&D systems, Oxford, UK) and recombinant human IL-10 (Life Technologies 
Europe, Bleiswijk, The Netherlands) at concentrations and timing as indicated in the 
text.
Micromass immunohistochemistry   
For immunohistochemical analysis, micromasses were fixated for 2h in 2% 
paraformaldehyde in phosphate-buffered saline (PBS)/1mM CaCl
2, 
dehydrated and 
embedded in paraffin. 7 µm sections were deparaffinized, rehydrated and incubated 
with antibodies 11-fibrau (1:100 for 60 minutes) (clone D7-fib, Imgen, distributed 
by ITK Diagnostics, Uithoorn, The Netherlands), mouse anti-human CD68 (1:100 for 
60 minutes) (M0814, DAKO, Heverlee, Belgium) or control mouse IgG2aκ (X0943, 
DAKO) and IgG1κ (X0931, DAKO) respectively. Endogenous Peroxidase activity was 
blocked with 3% H
2
O
2
 (Merck Millipore, Amsterdam, The Netherlands) in methanol. 
Subsequently, the sections were incubated with the secondary HRP-conjugated 
rabbit-anti-mouse IgA/G/M (1:200 for 60 minutes) (P0260, DAKO). Peroxidase was 
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developed with diaminobenzidine and counterstained with hematoxylin for 60 
seconds. 
Plasmid cloning and lentivirus production  
For the production of lentiviral vectors, we made use of the third generation self-
inactivating lentiviral (sin) vector system. The vector for pRRL-cPPT-CXCL10p-IL10-
PRE-SIN has been described previously.12 To obtain the pRRL-cPPT-PGK-IL10-PRE-
SIN vector, the PGK-luciferase vector from our previous studies18 was predigested 
and the CXCL10p-IL10 vector was digested with SalI and NheI (New England Biolabs, 
Ipswich, MA, USA) and the IL-10 gene was ligated in the predigested PGK promoter 
vector. For generation of the CXCL10p-fluc-RPL22p-rluc dual luciferase vector, a new 
multiple cloning site (mcs) was inserted in the SIN vector between the SalI and NheI 
sites, containing restriction sequences for XhoI-AgeI-SpeI-PmeI-AfeI-AscI-SalI-HpaI-
NheI. The XhoI overhang from the mcs was compatible with the SalI overhang from 
the SIN vector. The mcs was used to clone the RPL22 promoter (cloned from human 
gDNA (Promega), the renilla luciferase gene from the pMCS-green Renilla luciferase 
vector (ThermoScientific, Waltham, MA, USA) and the CXCL10 promoter in one 
construct. The promoter from the RPL22 gene was selected based on low variability 
in multiple microarrays.19 All primer sequences are listed in Table 1. The lentivirus 
production, purification and quantification were performed as described previously 
20. Transduction of micromasses was performed with 150 ng virus/micromass in 
complete RPMI medium supplemented with 8 µg/ml polybrene (Sigma).
Confocal microscopy  
For confocal microscopy, day 9 micromasses produced from an OA patient were 
transduced with lentiviral PGK-GFP and fixed in 1% paraformaldehyde, 48h after 
transduction. Micromasses were stained with DAPI (Molecular Probes, Oregon, 
USA) at a concentration of 0.2 ug/ml in PBS for 10 minutes, followed by three 
washing steps in PBS. Micromasses were mounted in Fluoromount-G (Southern 
Biotech, Alabama, USA). Confocal pictures were taken at 200x magnification using 
the Olympus Fluoview FV1000 laser scanning microscope (Olympus, Zoeterwoude, 
The Netherlands). DAPI and GFP were imaged using lasers at excitation wavelengths 
of 405 nm and 488 nm respectively. Image processing was performed using the 
Fluoview Viewer Sofware V4.1 (Olympus).
Flow cytometry 
For flow cytometry analysis, micromasses were melted on ice for 2h, 48h after 
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transduction with lentiviral PGK-GFP. The cell suspension was incubated with 
antibodies 11-Fibrau and subsequently with donkey-anti-mouse conjugated 
to Alexa Fluor 568 (1:100 for 30 minutes) (A-10037, Thermo Scientific), or cell 
suspensions were incubated with mouse-anti-human CD68, conjugated to PE (1:20 
for 60 minutes) (12-0689, eBioscience, San Diego, CA, USA). The flow cytometry 
was performed on the FACS Cyan (Beckman Coulter, Woerden, The Netherlands) 
using the 488 nm laser at the FL1, FL3 and FL7 channels for GFP, 11-Fibrau and CD68 
respectively.
Luciferase measurements  
The luciferase measurements were performed in 96-well white clear-bottom 
plates (Greiner Bio-one) using the Dual-Glo luciferase assay system (Promega). 
Micromasses were transferred to a well and lyzed in Dual-Glo reagent for 10 minutes. 
Firefly luciferase light production was measured on a Clariostar (BMG, Offenburg, 
Germany). Subsequently, the lysates were incubated for 10 minutes with Stop & Glo 
before measuring the Renilla luciferase light production. The values were corrected 
for the background signal and depicted as relative light units (RLU).
RNA isolation and qPCR 
RNA isolation and qPCR were performed as described previously.20 
The primer sequences are listed in Table 1.  
Table 1: List of oligonucleotide primer sequence  
Oligo description Sequence (5’→3’)
MCS_oligoA TCGAGACCGGTACTAGTGTTTAAACAGCGCTGGCGCGCCGTCG
ACGTTAACG
MCS_oligoB CTAGCGTTAACGTCGACGGCGCGCCAGCGCTGTTTAAACACTA
GTACCGGTC
RPL22_prom_FW TTTTACTAGTGGCGGCCTGGCTACAGCAAA
RPL22_prom_RV TTTTGGATCCGGCGGCAGCGGAGTTAGAAAG
GAPDH_qPCR_FW ATCTTCTTTTGCGTCGCCAG
GAPDH_qPCR_RV TTCCCCATGGTGTCTGAGC
SOCS3_qPCR_FW TCGGACCAGCGCCACTT
SOCS3_qPCR_RV CACTGGATGCGCAGGTTCT
TNFa_qPCR_FW TCTTCTCGAACCCCGAGTGA
TNFa_qPCR_RV CCTCTGATGGCACCACCAG
IL-1b_qPCR_FW TGGGTAATTTTTGGGATCTACACTCT
IL-1b_qPCR_RV AATCTGTACCTGTCCTGCGTGTT
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Multiplex ELISA assay  
Cytokine concentrations were determined by luminex multianalyte technology 
on the Bio-Plex 200 (Bio-Rad, Hercules, CA, USA) in combination with Bio-Plex pro 
human cytokine kits (Bio-Rad) according to the manufacturer’s protocol. For IL-10 
and IL-6 measurements, the micromass culture supernatants were first diluted 25x. 
Samples below the detection limit were set at the lowest measureable quantity to 
perform statistical analysis.
Statistical analysis  
Statistical analysis was performed using the Student’s t-test, 1-way ANOVA and 2-way 
ANOVA. Results are depicted as mean +/- SD and P-values < 0.05 were regarded 
as significant. For statistical comparisons between conditions including multiple 
patients, patients were first individually normalized for the control conditions.
 
Results
The synovial micromass membrane contains FLS and MLS.  
In previous studies that used the synovial micromass model, primary FLS were used 
that had been cultured for multiple passages. However, sustained culture of FLS can 
result in phenotype alterations21 and in FLS micromasses the contribution of MLS is 
omitted. Therefore, we first tested the ability of synovial cell suspensions derived 
from digested synovium to form a lining layer in micromass culture. After 7 days, 
cells had migrated to the micromass-medium interface and resembled a synovial 
membrane (Fig. 1). The sections were stained using the 11-fibrau antibody, which 
revealed that most cells in the lining are synovial fibroblast-like cells (Fig. 1B). In 
addition, we performed a staining for the macrophage marker CD68. Macrophages 
were also present in the micromasses and appeared in the lining at day 7 (Fig. 1D). 
This shows that the synovial micromass model can be used to study a membrane 
that resembles the architecture and composition of the synovial lining. When the 
micromasses were transduced with a lentiviral PGK-GFP vector, GFP expression was 
mainly observed in the lining layer (Fig. 1E) and to a lesser extent in the sublining. 
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Figure 1: Immunohistochemical detection of fibroblasts and macrophages in synovial micromasses. 
Synovial micromasses were generated from digested synovial tissue cell suspension and cultured 
for 7 days. (A) IgG control antibody for 11-Fibrau staining. (B) 11-fibrau (brown) staining for synovial 
fibroblasts. (C) IgG control antibody for CD68-staining. (D) CD68-staining (brown) for macrophages. 
(E) Confocal fluorescent image of the micromass after transduction with lentiviral PGK-GFP. Side view 
with DAPI (blue) and GFP (green) staining. The micromasses used in Figure 1A-D were derived from RA 
material and similar results were obtained staining OA micromass sections.
The transduction efficiency and virus tropism were assessed using flow cytometry. 
Around 6% of the cells expressed GFP after transduction and both FLS (6.7% of 
the 78.7% 11-Fibrau-positive cells) and MLS (5.3% of the 38.0% CD68-positive cells) 
were transduced (Fig. S2).
The CXCL10 promoter responsiveness in synovial micromasses  
The micromasses were transduced with a lentiviral vector to study the response of 
theCXCL10 promoter, the promoter of our choice to obtain autoregulated transgene 
expression. The vector contained a CXCL10p-firefly luciferase reporter and an 
RPL22p-renilla luciferase gene to correct for micromass cellularity and transduction 
efficiency. Micromasses were transduced after forming a lining to resemble the in 
vivo synovial membrane transduction and stimulated with LPS, TNFα or IL-1β for 
6 hours. Previous studies have found an upregulation of multiple plasma proteins 
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in the OA synovial fluid, which similar to DAMPs can activate macrophages in a 
TLR-4-dependent manner.13 We therefore included the TLR-4-specific stimulus LPS 
in our studies. Although not significant for every individual patient, stimulation 
with LPS, TNFα or IL-1β resulted in a significant upregulation of CXCL10 promoter 
activity (Fig. 2A-C). These results show that the cells in the micromass lining can 
be transduced by lentiviruses and disease-related triggers can activate the CXCL10 
promoter. Interestingly, one patient (OA4) showed no significant response to any of 
the stimuli.
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Figure 2: Activation of the CXCL10 promoter in synovial cell micromasses by LPS, TNFα and IL-1β. 
Synovial micromasses of 4 OA patients were transduced with the CXCL10p-fluc-RPL22p-rluc dual 
luciferase construct and stimulated for 6h with (A) 100 ng/ml LPS, (B) 10 ng/ml TNFα or (C) 10 ng/
ml IL-1β and compared to the unstimulated medium condition. The signal ratio was calculated as 
fireflyRLU/renillaRLU +/- SD. Micromasses are depicted as individual points and different colours 
represent different patients. Statistical analysis between medium and stimulated condition was 
performed by Student’s t-test and comparisons within individual patient samples were calculated by 
2-way ANOVA. * =P<0.05, ** =P<0.01.
 
The effects of IL-10 protein on synovial micromasses  
After having established that the CXCL10 promoter can mediate regulated expression 
in OA synovial micromasses, we set out to determine whether the transgene IL-10 
can be a potential candidate for local treatment of OA. We first determined if IL-
10 can lead to SOCS3 expression in the synovial micromasses. After 2h stimulation 
with recombinant IL-10, SOCS3 was significantly upregulated (Fig. 3A). In addition, 
SOCS3 expression could also be induced by LPS and TNFα as previously described.22 
Stimulation of the micromasses with LPS and TNFα for 4h resulted in significant 
upregulation of TNFα and IL-1β mRNA (Fig. 3B,C). In LPS-stimulated conditions, IL-
10 could reduce this induction. IL-6 was also upregulated after pro-inflammatory 
stimulation (Fig. 3C), but IL-10 could not reduce IL-6 expression. These results show 
that cells from the synovial micromass are responsive to IL-10 and downregulate 
the production of cytokines after stimulation, possibly via the induction of SOCS3.
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Figure 3: Gene expression in synovial micromasses after stimulation with LPS and 
TNFα in the absence or presence of IL-10.       
Micromasses from synovial cell suspensions (3 per group) were cultured until lining formation was 
evident. Subsequently, the micromasses were stimulated for 2h or 4h with medium containing 100 ng/
ml LPS, 10 ng/ml TNFα, 10 ng/ml IL-1β in the absence and presence of 10 ng/ml IL-10. Gene expression 
levels of SOCS3 at 2h (A), TNFα at 4h (B), IL-1β at 4h (C) and IL-6 at 4h were measured. Expression levels 
are depicted as threshold cycle (Ct) +/- SD, corrected for GAPDH expression. Statistical comparison 
within stimulation groups was performed by 2-way ANOVA and between groups by 1-way ANOVA. * 
=P<0.05, ** =P<0.01, *** =P<0.001.
 
We subsequently determined if the inducibility of the CXCL10 promoter can be 
used to provide relevant IL-10 levels in synovial micromasses. After formation of 
the lining, the micromasses were transduced with IL-10 lentiviruses under control 
of the constitutive active PGK promoter or the inducible CXCL10 promoter. The 
IL-10 levels in the supernatant of the micromasses were determined after 24h 
stimulation with LPS and TNFα. Micromasses transduced with PGK-luciferase 
control virus only produced low quantities of IL-10, indicating that the background 
production of endogenous IL-10 is low, even after stimulation with LPS or TNFα (Fig. 
4). Under control of the PGK promoter, high levels of IL-10 were secreted into the 
supernatant, which did not significantly differ after stimulation with LPS or TNFα. In 
contrast, micromasses transduced with CXCL10p-IL10 showed an increase in IL-10 
production after stimulation with either LPS or TNFα.
Next, we used the micromass culture supernatants to investigate if the IL-10 
production from the transduced micromasses can influence the inflammatory 
response in the synovial lining. Under control conditions without stimulation, the 
micromasses already produced the pro-inflammatory cytokines IL-1β and IL-6 
(Fig. 5A,B). The production increased after stimulation with LPS or TNFα, which 
has also been observed in vivo.23 The stimulatory effects of LPS and TNFα on the 
release of IL-1β could be abolished by both constitutive (84.8% after LPS and 83.9% 
after TNFα) and inducible (70.7% after LPS and 87.4% after TNFα) expression of 
IL-10. Similar effects were observed for LPS-induced IL-6 secretion (Fig. 5B). After 
stimulation with LPS, the IL-6 production was decreased by 67.1% by PGK-IL10 and 
71.0% by CXCL10p-IL10. TNFα was below detection limits in multiple unstimulated 
micromasses (Fig. 5C). After stimulation with LPS, TNFα was produced by the 
micromasses, but virus treatment showed no significant effects. These results show 
Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a 
three-dimensional micromass model of the human synovial membrane
160
that treatment of a synovial lining with the inducible CXCL10 promoter for the 
expression of IL-10 can reduce the production of pro-inflammatory cytokines and 
can inhibit stimulation of the lining.
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Figure 4: Production of IL-10 by transduced micromasses. Micromasses from synovial cell 
suspensions were transduced with lentiviral vectors coding for PGK-luciferase, PGK-IL10 or CXCL10p-
IL10 after formation of a synovial lining. Subsequently, the micromasses were stimulated with medium 
containing 100 ng/ml LPS (A) or 10 ng/ml TNFα (B). The IL-10 concentration in the supernatant after 
24h was measured using a multiplex Elisa assay. Concentrations below 1 pg/ml were included in the 
statistical analysis, but are shown as 1 pg/ml in the Figure. An nsufficient number of micromasses 
could be generated from patients 10 and 12 to determine the response to TNFα. The medium, LPS- 
and TNFα-stimulated groups were compared by 1-way ANOVA. * =P<0.05, ** =P<0.01.
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Figure 5: Cytokine production by stimulated micromasses treated with IL-10 viral vectors. 
Micromasses from synovial cell suspensions of 5 patients were transduced with lentiviral vectors 
coding for PGK-luciferase, PGK-IL10 or CXCL10p-IL10 after formation of a synovial lining. Subsequently, 
the micromasses were stimulated with medium containing 100 ng/ml LPS (all patients) or 10 ng/ml 
TNFα (3 patients). The concentrations of IL-1β (A), IL-6 (B) and TNFα (C) in the supernatant after 24h 
were measured using a multiplex ELISA assay. IL-1β and TNFα could only be quantified in 3 patients. 
Because of high variations in IL-6 production between patients, the values were first normalized for 
every individual patient for PGK-luc unstimulated. The basal values (pg/ml) were 2.7x105, 6.5x105, 
2.7x104, 5.1x104 and 3.3x105 respectively. The medium, LPS- and TNFα-stimulated groups were 
compared by t-test. Significancies without a capped line were compared to PGK-luc. * =P<0.05, ** 
=P<0.01, *** =P<0.001.
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Discussion
In this study we set out to study the therapeutic potential of disease-inducible 
gene therapy for OA using the CXCL10p-IL10 lentivirus in a synovial lining model 
resembling early stage OA that includes both synovial fibroblasts and synovial 
macrophages. After digestion of a synovial tissue sample the cells were mixed with 
Matrigel to obtain a synovial micromass, in which both FLS and MLS migrated to 
the micromass edge to form a lining. After transduction with a lentiviral CXCL10-
promoter reporter vector, the CXCL10 promoter could be significantly induced by 
pro-inflammatory stimulation. When the CXCL10 promoter drived the expression 
of the gene coding for anti-inflammatory IL-10, sufficient IL-10 could be produced 
to reduce the release of IL-1β and IL-6 after stimulation with TNFα or LPS.  
 In vitro studies with human synovial cells are often performed in monolayer 
culture, in which the cells might behave and interact differently from the complex 
structural organization in the joint.24 To improve in vitro synovium studies, Kiener at al. 
developed a 3D synovial lining model.25 Primary FLS are mixed with matrigel to form 
a micromass structure, in which the FLS migrate towards the outside to form a lining 
layer, a phenomenon not observed with dermal fibroblasts. The micromass lining shows 
many similarities to the synovial lining. It expresses the synovial fibroblast marker 
PRG4 and produces extracellular matrix.26 MLS were not included in these studies, 
but the FLS could support the survival of monocytes from peripheral blood.  
 Interestingly, macrophages in culture without the appropriate stimulation 
undergo apoptosis.27 Kiener et al. showed that primary monocytes from the blood 
are not viable in micromasses when cultured alone, but could survive for over 3 
weeks when cultured together with FLS.26 We showed that the micromasses can 
also support the survival of synovial macrophages and that the macrophages 
resided in the lining. Because the micromasses do not show the fibrotic changes 
and macromolecular cartilage and bone detritus-rich synoviopathy observed in 
late stage OA, the synovial micromass might more closely mimic early stage OA 
compared to synovial explants from joint replacement remnants. This enables the 
possibility to test therapeutic strategies in an early disease stage where inhibition 
of inflammation might prevent disease progression.
During inflammation, synovial macrophages become activated and produce 
pro-inflammatory cytokines, matrix-degrading enzymes and promote synovial 
hyperplasia.28 The synovial micromass model based on primary tissue digestions can 
be a suitable model to study these processes. The inclusion of MLS in the micromasses 
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is particularly important for testing IL-10-based therapies, since the primary receptor 
subunit for IL-10, IL-10R1, is most strongly expressed on cells of hematopoietic 
origin.29,30 After transduction of the micromasses with lentiviral PGK-GFP, transgene 
expression was predominantly observed in the membrane, which is similar to 
observations with intra-articular injections of lentivirus in vivo,31 providing further 
support that micromasses are an adquate model for the synovial membrane.  
 IL-10 is a powerful anti-inflammatory cytokine and IL-10-based gene therapy 
has proven to be effective in multiple animal models of OA and cartilage damage, 
alone and in combination with IL-1 receptor antagonist (IL-1Ra) or IL-4.32,33 Low 
innate production of IL-10 by blood cells upon lipopolysaccharide (LPS) stimulation 
ex vivo is associated with an increased risk of OA.34 In addition, it has been concluded 
from a systematic review that physical exercise has positive effects on pain and 
disability in knee OA.35 These effects might be mediated by IL-10, which was found 
to be upregulated in the synovial fluid after exercise.36 In addition to the inhibition 
of inflammation and matrix-degrading enzymes, IL-10 has chondroprotective and 
anabolic effects on cartilage by stimulating chondrocyte proliferation, stimulating 
the production of extracellular matrix components and reducing chondrocyte 
apoptosis.2,37 One of the mechanisms by which IL-10 can exert its anti-inflammatory 
effects, is by inducing the expression of SOCS3.38 SOCS3 can inhibit JAK-STAT signaling 
induced by cytokine receptor activation.39 A second anti-inflammatory mechanism 
proposed for IL-10 is the inhibition of proteins that stabilize TNFα mRNA.40 As a 
result, the TNFα mRNA becomes prone to degradation mediated by the 3’UTR AU-
rich elements (AREs). We have found both upregulation of SOCS3 and reduced levels 
of TNFα mRNA after treatment with recombinant IL-10, indicating that IL-10 might 
inhibit the inflammatory response in synovial micromasses at multiple levels.  
 The levels of TNFα, IL-1β and IL-6 are increased in OA patients and high 
levels are associated with increased radiographic progression.41 We have observed 
increased production of these cytokines by the micromasses under inflammatory 
conditions. TNFα and IL-1β mRNA could be down-regulated by IL-10 and the 
produced levels of IL-1β and IL-6 decreased after treatment with both PGK-IL10 
and CXCL10p-IL10. Interestingly, the variation in basal IL-10 production between 
patients after transduction with CXCL10p-IL10 was bigger compared to the IL-10 
production after stimulation with LPS or after transduction with PGK-IL10 (Fig. 
4). The variation in basal IL-10 production from the CXCL10p-IL10-transduced 
micromasses might result from a variation in tissue composition or differences in 
inflammatory imprinting of synovial cells between patients rather than transduction 
efficiency, because less variation in IL-10 production after transduction with PGK-
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IL10 was observed.
Conclusions  
We showed that 3D micromasses that are made from primary synovial cells of OA 
patients form a synovial lining consisting of fibroblast-like and macrophage-like 
synoviocytes and the micromassas might be a useful tool to study synovium in 
vitro. The micromass lining can be transduced by lentiviruses and provide disease-
inducible expression of sufficient amounts of IL-10 to reduce the production of pro-
inflammatory cytokines by the micromasses. Gene therapy with the CXCL10p-IL-10 
vector might be a promising strategy for local treatment of early OA. 
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Supplementary Figure S1: HE stainings of 7 μm cryosections obtained from patient biopsies used in 
this study.
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Supplementary Figure S2: Scatter plots of flow cytometry analysis of micromasses transduced with 
PGK-GFP. 7 days after formation, the micromasses were transduced with lentiviral PGK-GFP. 48h after 
transduction, the micromasses were melted and stained for FLS (11-Fibrau) and MLS (CD68) markers. 
Cells were first gated for the live gate. (A) GFP signal and forward scatter (B) GFP signal and 11-Fibrau 
signal (C) GFP signal and CD68 signal. The scatter plots are representative for multiple experiments.
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Gene therapy in murine models of arthritis
Rheumatoid Arthritis (RA) is a systemic autoimmune disease affecting joints of 
an estimated 1% of the world population. Despite much research effort in the 
identification of risk factors and the underlying immunology, many questions still 
remain about the disease etiology. Although RA still cannot be cured most patients 
can nowadays be successfully treated using the available medication, including the 
disease-modifying drugs (DMARDs) methotrexate and biological drugs. These drugs 
are injected on a regular basis and cause continuous systemic immunosuppression 
that can lead to side effects like opportunistic infections. The fact that the biologicals 
are protein-based drugs sparked the hypothesis that the medication might also be 
produced by cells in the synovium. By transducing the synovial cells with a viral 
vector encoding a therapeutic protein, the inflammation can be locally inhibited. An 
additional level of regulation that can be introduced using this approach is by using 
inflammation-sensitive promoters that induce the transcription of the drug only 
during active disease. The local and disease-responsive production of biologicals 
could be a long-term solution for affected patient joints, while minimizing systemic 
side effects. 
We set out to explore this approach in a murine model of RA in Chapter 2. 
In microarray data of streptococcal cell wall (SCW)-induced arthritis, several genes 
were found to be upregulated compared to healthy joints. The promoters of these 
genes were possible candidates for regulated gene expression and cloned in front 
of a luciferase reporter gene. These promoter-reporter constructs were injected in 
mouse joints and the light production by the luciferase reporter was assessed during 
SCW-induced arthritis. The Saa3 and Mmp13 promoters performed best with a high 
activity in diseased joints compared to healthy joints and activation peaks at day 1 and 
day 4/7 respectively. For therapeutic application, the luciferase reporter gene was 
replaced by the anti-inflammatory Interleukin-10 (IL-10). In SCW-induced arthritis, 
the Saa3p-IL10 and Mmp13p-IL10 significantly reduced synovitis and proteoglycan 
depletion in the murine knee joint and the systemic Keratinocyte Chemoattractant 
(KC) levels. These therapeutic effects were associated with increased expression of 
Suppressor of Cytokine Signaling 3 (SOCS3) and IL-1 Receptor Antagonist (IL-1RA) in 
the synovial tissue. Ideally, future development of RA drugs based on this approach 
can result in a therapy for the treatment of joints refractory for current medication 
strategies with low off-target exposure. 
A more challenging joint disease to obtain clinical remission is osteoarthritis 
(OA). Although OA is the most common joint disease, no drugs are available to 
modify the disease course. Despite the probable involvement of wear-and-tear, 
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OA has many pathological changes in common with RA on a local level, including 
the influx of inflammatory immune cells, the production and activation of matrix-
degrading enzymes and synovial fibrosis. Many proteins have therefore been 
suggested to have therapeutic potential, but systemically injected proteins hardly 
reach the joint and proteins injected in the joint are rapidly cleared. We therefore 
hypothesized that gene therapy could be a promising strategy to test the potential 
of protein-based drugs for the treatment of OA. In Chapter 3, Tumor Necrosis Factor 
Alpha (TNFα)-stimulated gene 6 (TSG-6) was selected to inhibit OA, because of the 
anti-inflammatory properties, protection against cartilage damage in experimental 
RA, inhibition of Metalloproteinase (MMP) activation and inhibition of bone 
remodeling.1-3 In vitro constitutive overexpression of TSG-6 in osteoclasts could 
reduce the bone resorption of dentin slices, showing the biological activity of our 
viral vector. In vivo, we tested the TSG-6 lentiviral vector in the Collagenase-induced 
arthritis model, which features inflammation at early time points and results in joint 
damage at day 42. However, in the TSG-6 lentivirus-treated group we observed no 
reduction in inflammation and no reduction of cartilage damage. Instead, ectopic 
bone formation occurred at the medial collateral ligament, which could be observed 
on histology and X-ray analysis. The ectopic bone formation might be the result 
of a disturbed repair mechanism and we believe that TSG-6 is not suitable for OA 
gene therapy. The search for disease-modifying OA drugs will therefore continue 
and ideally, a therapy should first prove successful in murine models of OA before 
proceeding to living humans.
Testing potential therapies in a human setting: tackling the challenges
The translation of the findings in mouse models to the human system commonly 
starts with in vitro assays before proceeding to clinical trials. Many in vitro 
experiments rely on primary biopsies with a disease phenotype obtained from 
patients. Several practical and scientific challenges are encountered when designing 
these experiments. For example, primary material should be used as soon as 
possible before the disease phenotype of the tissue is lost. Because the patient 
donors required for the studies are treated one-by-one at irregular times at different 
days, this poses a logistic challenge. To enable researchers to synchronize the use of 
biopsies from several donors, we have studied the effects of several cryopreservation 
media on synovial biopsies in Chapter 4. The goal of this study was to find a slow-
freezing cryopreservation protocol that did not influence the cell viability, histological 
integrity of the tissue, disease phenotype of the cells and inflammatory response of 
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the biopsy. From several commercially available cryopreservation media, we found 
that CS10 and CryoSFM could both provide storage of the biopsies in liquid nitrogen 
without loss of the investigated variables. The establishment of an easy-to-perform 
and robust cryopreservation protocol is essential for the development of a synovial 
tissue biobank with live patient biopsies. 
In vitro experiments with biopsies have an added value compared to 
monolayer culture, because the biopsies contain all cell types found in the diseased 
synovium and the cells maintain their important cell-cell and cell-matrix interactions. 
A disadvantage of the biopsies is that many disease processes, like hyperplasia and 
fibrosis have already occurred. In addition, a large variability between multiple 
biopsies from within a single patient can be observed. To improve the 3-dimensional 
culture options for human synovium, we further investigated the synovial membrane 
model initially developed Kiener et al.4 In these experiments synovial fibroblasts 
were mixed with cold liquid Matrigel. At 37°C the Matrigel became solid and the 
cells migrated toward the surface and formed a lining layer similar to the lining 
layer in synovium. In Chapter 5 we analyzed the composition and behavior of cells 
in micromasses constructed from complete synovial biopsy digestions. Synovial 
fibroblasts and synovial macrophages were the cell types that predominantly 
survived in the micromass and both cell types appeared in the lining after 7-14 
days culture. Additional cell types from the synovial biopsies, including T cells, B 
cells and epithelial cells disappeared over time under our culture conditions. Lining 
hyperplasia could be observed after 3 weeks stimulation with TNFα, a pathological 
phenomenon also observed in inflamed synovium. The synovial micromasses could 
also be cryopreserved without loss of sensitivity to inflammatory stimuli. Synovial 
biopsies can thus be digested and the complete cell suspension can be used to 
generate micromasses when the material becomes available and cryopreserved 
after lining formation. Subsequently, at the start of an experiment the appropriate 
number of micromasses from the required amount of donors can be thawed.
CXCL10p-IL10 lentiviral gene therapy
The Saa3 promoter, which showed the strongest inflammatory response in the 
murine arthritis, was not the most suitable for application in the human system. 
In humans, Saa3 is a pseudogene not coding for a protein, so the human Saa3 
promoter sequence is therefore no promising candidate for regulation of transgene 
production. The promoter response of the murine Saa3 promoter in human cells 
was inferior to other promoters (not shown). We therefore initiated a new search 
for disease-responsive promoters to provide disease-responsive IL-10 gene therapy 
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in human cells. In Chapter 6, we compared microarrays of synovial tissue of RA 
patients with healthy control synovium and selected all genes that were significantly 
upregulated at least 10-fold in RA compared to healthy controls with a minimum 
average probe signal intensity in RA of 500 (arbitrary units), which resulted in a 
list of 22 genes. In lipopolysaccharide (LPS)-stimulated synovial cell suspensions we 
determined which of these genes was most responsive to inflammatory stimulation 
in our target cell population. The CXCL10 gene showed the highest induction and the 
CXCL10 promoter was cloned in a luciferase reporter construct for further analysis. 
Using this reporter vector we found that the CXCL10 promoter was activated by 
the serum of RA patients and showed a strong reaction to TNFα with a peak after 
8-12 hours. The promoter activity decreased in time as the TNFα concentration 
dropped, but could be re-activated by TNFα after 96h. The regulated expression is 
pivotal for the offer-meets-demand behavior of the intended gene therapy. When 
the luciferase transgene was replaced by the human IL-10 gene and synovial cell 
suspensions were transduced using the CXCL10p-IL10 lentiviral vector, the cells 
could produce IL-10 which increased after stimulation with LPS. The produced IL-10 
levels could adequately reduce the production of pro-inflammatory cytokines by 
the synovial cells, most notably TNFα and IL-1β.
We subsequently tested the CXCL10p-IL10 lentiviral vector in synovial 
micromasses produced from biopsies from OA donors to assess the anti-inflammatory 
potential of the gene therapy in an inflammatory OA setting in Chapter 7. Similar to 
the experiments using cell suspensions, we observed increased production of IL-10 
by the micromasses after stimulation with LPS or TNFα. In CXCL10p-IL10-treated 
micromasses, we observed a decrease in production of pro-inflammatory IL-1β 
and IL-6 both at basal level and after stimulation. The anti-inflammatory potential 
of the CXCL10 promoter-based IL-10 expression was as efficient as constitutive 
expression by the PGK promoter. Similar to the IL-10 overexpression in the mouse 
model in chapter 2, we observed increased expression of SOCS3 in IL-10-stimulated 
micromasses, which might be an important mediator of the anti-inflammatory IL-10 
effects.
In conclusion, we have shown in this thesis the potential of disease-inducible IL-10 
gene therapy for the treatment of inflammatory joint disease in murine arthritis 
and in a well-characterized 3D model of the human synovial lining. 
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Future considerations
Gene therapy for RA and OA
The history of gene therapy and the cornerstone clinical trials that lead to the 3 
currently approved gene therapy drugs are described in the introduction. The initial 
focus of gene therapy research was on treating lethal genetic defects, but most 
current clinical trials are directed against different types of cancer. However, an 
increasing amount of trials is also addressing non-lethal diseases, such as retinal 
disorders, RA and OA. Although inducible gene therapy for RA has the potential to 
provide long-lasting treatment with minimal side effects, much revenue is currently 
generated with quite effective medication which reduces the appeal to invest in 
gene therapy by pharmaceutical companies.5 Despite this hurdle, a phase I gene 
therapy clinical trial was approved in 2016 for the Dutch company Arthrogen to test 
an AAV5 vector with Interferon-β under control of an artificial promoter containing 
repeats of NFκB transcription factor binding sites. Interestingly, IL-10 has been 
identified as one of the predominant downstream proteins responsible for the 
anti-inflammatory effects of Interferon-β.6,7 The results and safety analysis of this 
vector will be very important for future trials for RA gene therapy. In contrast to RA, 
there is no effective treatment that can slow down the progression of OA. With the 
increasing evidence that OA is not only wear-and-tear, it might be expected that 
more funds will be invested in the development of a treatment for OA, compared 
to RA. The added value of gene therapy in this field can be to provide long-term 
bioavailability of protein-based drugs in the joint. The primary emphasis will 
therefore be on finding proteins with therapeutic effects, rather than fine-tuning 
the expression of available transgenes with inducible promoters. In this thesis, we 
have found that in experimental OA, TSG-6 is not a suitable transgene, but in the 
micromass model IL-10 could inhibit the inflammatory response. The therapeutic 
effects of IL-10 can be further studied in models that not exclusively focus on 
inflammation.
In the initial phases of our research with lentiviral vectors, several reviews were 
published that advocated the use of AAV vectors for gene therapy instead of 
integrating viral vectors,8,9 because of the low AAV pathogenicity and the potential 
danger of integrating viruses we contemplated whether to switch to an AAV vector. 
However, in recent clinical trials with modern integrating viruses that lack viral 
enhancers and the technical advances that enable single cell analysis, it has been 
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observed that with the latest generation of lentiviruses the integration sites do not 
correlate with subsequent cell proliferation.10 The association between integration 
near pro-oncogenes and clonal expansion of blood cells had recently been observed 
in a clinical trial after retroviral transduction,11 although it was later stated that no 
leukemia developed during 33 months follow-up of the 9 patients. Based on these 
observations we believe that a lentiviral vector-based IL-10 gene therapy can be a 
useful vector to provide long-term IL-10 expression. The increasing body of safety 
data from clinical trials with different vector types and the ever increasing follow-up 
time of patients from the recent trials will reveal the actual safety and long-term 
clinical efficacy of these vectors and eventually shape the public opinion on gene 
therapy for non-lethal diseases.
The CXCL10 promoter
In our studies we put particular effort in the quest for the most optimal disease-
inducible promoter. Instead of combining multiple repeats of transcription factor 
binding sites in a synthetic promoter, we looked for genes of which the promoter 
sequence has evolved to induce expression during disease. We therefore analyzed 
microarrays of synovial tissue and for human application found several genes that 
were highly increased in microarrays for RA tissue compared to healthy controls. 
To determine if the upregulation was not the result of a shift in cell composition 
of the biopsy, but rather an induction of expression, we checked the expression 
in stimulated synovial cells. The CXCL10 promoter showed the highest induction 
and previous promoter mutation studies have shown that the CXCL10 promoter 
contains functional binding sites for several different transcription factors and a 
TATA-box.12,13 This indicates that the promoter can be activated by different triggers 
without the requirement of many cis-acting elements. However, an interesting 
improvement to the CXCL10 promoter could be obtained by including enhancer 
regions in the construct, similar to the previously applied IL1/IL6 promoter, which 
consisted of an IL-1 enhancer element coupled to the IL-6 promoter.14 The ENCODE 
consortium has recently performed large-scale functional analysis of the human 
genome.15 One of the key objectives was to map all distal enhancer elements to their 
associated promoters. One significantly correlated enhancer region was identified 
for the CXCL10 promoter, which was located ~466 kb upstream of the promoter 
region.16 Although the enhancer has not been investigated, the incorporation of the 
enhancer in the lentiviral CXCL10-promoter constructs might increase the sensitivity 
to inflammatory stimuli or decrease the background activity of the promoter.
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In addition to providing disease-responsive gene therapy, the inducible promoters 
might be used as reporter systems when coupled to the luciferase transgene. We 
have observed that the Saa3 promoter is activated early during experimental arthritis 
and the Mmp13 promoter activity peaked at a later time point, which indicates that 
the promoters correlate with acute inflammation and synovial repair mechanisms 
respectively. In addition, previous experiments have shown that the Saa3 promoter 
is responsive to factors in the serum of RA patients17 and we have observed a similar 
response with the CXCL10 promoter. Because the promoter activation is the net 
result of activating and inhibiting factors, a combination of promoter reporters 
might reflect the disease activity and therapy response or be of prognostic value. 
There is great demand for accurate assays and the promoter reporters can easily 
be studied using the serum or synovial fluid of appropriate patient cohorts. In such 
assays, reporter cells stably transduced with promoter reporter constructs can be 
stimulated with patient serum and the amount of light production can reflect the 
disease activity in the patient. This might for example be used to determine the 
therapy response to expensive biologicals at early time points, so a switch to a 
different biological therapy can be made early on. For these experiments, we have 
several promoter-reporters available that were derived from the genes identified 
in the RA microarrays (Chapter 6, Table 1). Although we could not obtain sufficient 
transgene expression for gene therapy with several of these vectors (eg. promoters 
from CXCL13, NMES1 and CXCL9), an application of these promoters in a reporter 
assay could still be interesting.
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Gentherapie in muismodellen van reumatische ziekten  
Reumatoïde artritis (RA) is een chronische auto-immuunziekte die de gewrichten 
aantast van ongeveer 1% van de wereldbevolking. Ondanks de vele onderzoeken 
die zijn gedaan om de risicofactoren voor het ontwikkelen van RA te vinden, is nog 
steeds niet volledig bekend hoe de ziekte precies ontstaat. Het lukt op dit moment 
dan ook nog niet om RA te genezen en een moderne behandeling richt zich daarom 
op het onderdrukken van de ontstekingsreactie. Dit gebeurt onder andere met 
reumaremmers (disease-modifying anti-rheumatic drugs, DMARDs). Voorbeelden 
hiervan zijn methotrexaat en biologische reumaremmers op eiwit-basis (biologicals). 
Deze medicijnen worden vaak wekelijks geïnjecteerd en onderdrukken het 
immuunsysteem in het hele lichaam, waardoor bijwerkingen zoals infecties kunnen 
ontstaan. Omdat eiwitten door cellen gemaakt worden, is enige tijd geleden het 
idee geopperd om gewrichtscellen zelf de biologicals te laten produceren. Door 
met een virus het bouwplan (gen) voor een biological aan te bieden aan cellen in 
de binnenbekleding van het gewricht (synovium) kan de ontsteking mogelijk lokaal 
worden onderdrukt. Bovendien is het mogelijk een ziektegevoelige schakelaar in te 
bouwen in het bouwplan, waardoor de biological uitsluitend geproduceerd wordt 
tijdens perioden van actieve ontsteking. Door de lokale en ziektegevoelige productie 
van de medicijnen kan een gewricht met een enkele injectie mogelijk voor langere 
tijd worden beschermd, terwijl de bijwerkingen worden beperkt.
 Dit concept zijn we eerst gaan verkennen in een muismodel voor RA in 
Hoofdstuk 2. We hebben gekeken in de ontstoken gewrichten van deze muizen 
welke genen hier vooral geactiveerd zijn in vergelijking met gezonde gewrichten. De 
schakelaars (promotors) van deze genen zijn mogelijke kandidaten voor de ziekte-
gereguleerde therapie. Om deze promotors te onderzoeken, zijn ze gekopieerd 
uit het genoom en voor het gen van een lichtgevend luciferase-eiwit gezet. De 
hoeveelheid licht die hiermee wordt geproduceerd is een maat voor de activiteit 
van de promotor. Deze zogeheten promotor-reporters zijn geïnjecteerd in de 
gewrichten van muizen met experimentele artritis en vervolgens is gekeken naar 
de hoeveelheid licht in de gewrichten. De promotors die het meest geactiveerd 
werden door de artritis waren van de genen Saa3 en Mmp13. Om de therapeutische 
mogelijkheden te bepalen met deze promotors, is het bouwplan voor de luciferase 
reporter vervangen door het ontstekingsremmende eiwit interleukine-10 (IL-
10). Hierdoor ontstonden de virale medicijnen Saa3p-IL10 en Mmp13p-IL10. In 
de muizenknieën met experimentele artritis zorgden behandelingen met Saa3p-
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IL10 en Mmp13p-IL10 voor een afname van ontsteking en voor verminderde 
effecten op het kraakbeen van het gewricht in vergelijking met muizen met een 
controlebehandeling. In het synovium zagen wij een verhoging van de productie 
van de ontstekingsremmende eiwitten Suppressor of cytokine signaling 3 (SOCS3) 
en IL-1 receptor antagonist (IL-1RA), wat mogelijk voor deze effecten heeft gezorgd. 
Daarnaast was er in het serum van de behandelde muizen een afname te zien van 
de ontstekingsmarker keratinocyte chemoattractant (KC). Deze benadering kan in 
de toekomst mogelijk leiden tot een behandeling voor gewrichten die nog niet op 
medicatie reageren met verminderde kans op bijwerkingen.
 Een grotere uitdaging voor behandeling vormt de gewrichtsziekte artrose 
(osteoartritis, OA). Ondanks dat artrose de meest voorkomende gewrichtsaandoening 
is, zijn er nog geen medicijnen beschikbaar die aangrijpen op het ziekteproces. In 
klassieke opvattingen werd OA vaak uitsluitend gezien als gewrichtsslijtage, maar 
tegenwoordig zijn er veel aanwijzingen dat ook ontsteking een actieve rol speelt bij 
het ziekteproces. Dit zorgt voor enkele overeenkomsten met RA op lokaal niveau, 
zoals het binnendringen van ontstekingscellen, de productie van schadelijke 
enzymen en fibrose van het synovium. Verschillende eiwitten zijn in het verleden 
voorgesteld om OA te behandelen, maar intraveneus toegediende eiwitten bereiken 
het gewricht slecht en herhaalde injecties in het gewricht zijn onwenselijk. Wij 
verwachten daarom dat gentherapie een effectieve manier kan zijn om voor langere 
tijd eiwitten in het OA-gewricht geproduceerd te krijgen. Dit hebben wij onderzocht 
in Hoofdstuk 3. Het eiwit Tumor necrosis factor alpha (TNFα)-stimulated gene 6 (TSG-
6) is geselecteerd voor de behandeling, omdat bekend is dat het in muismodellen 
van RA de ontsteking kan remmen, het kraakbeen kan beschermen en de productie 
van schadelijke enzymen kan verminderen. Helaas zagen wij van deze behandeling 
geen verbetering in de ontsteking of de kraakbeenschade. In plaats daarvan trad 
botvorming op in de gewrichtsbanden. Deze ongewenste bijwerking is mogelijk het 
gevolg van een verstoord reparatieproces. Op grond van dit resultaat bevelen wij 
TSG-6 niet aan als therapie voor OA. De uitdaging voor de behandeling van OA blijft 
voorlopig dus het vinden van een geschikt eiwit voor een gentherapie.
Het testen van mogelijke therapieën in mensen: de uitdagingen oplossen
Het vertalen van de bevindingen in muizen naar de menselijke situatie start vaak 
met reageerbuisproeven met menselijk materiaal voordat nieuwe medicijnen in 
de kliniek worden getest. Veel van deze experimenten zijn gebaseerd op biopten 
die uit patiënten worden gehaald en snel moeten worden gebruikt voordat dat 
het materiaal ziekte-eigenschappen verliest. Dit is uitdagend, omdat verschillende 
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patiënten die voor een studie nodig zijn op verschillen momenten behandeld 
worden. Om deze experimenten logistiek beter te kunnen stroomlijnen, hebben wij 
in Hoofdstuk 4 gekeken naar een methode om de biopten levend in te vriezen. Het 
doel was om een invriesmethode te vinden die geen invloed had op de overleving, 
de vorm en de ontstekingsgevoeligheid van de biopten. Dit bleek te lukken als de 
biopten werden ingevroren in invriesvloeistof CS10 of CryoSFM. Het invriezen van 
biopten biedt de mogelijkheid om het materiaal van verschillende donoren tegelijk 
te gebruiken, maar biedt ook de mogelijkheid om een biobanken met biopten op te 
zetten en materiaal uit te wisselen.
 Het gebruik van biopten heeft een meerwaarde voor onderzoek in 
vergelijking met de kweek van losse cellen, omdat in biopten de interacties tussen 
cellen onderling en met het omliggende weefsel behouden blijven. Echter, veel 
ziekteprocessen zoals een verdikking van het synovium kunnen in deze biopten niet 
meer worden onderzocht, omdat deze al plaatsgevonden hebben. Daarnaast is er 
grote variatie tussen de weefselstukjes die uit de biopten kunnen worden gehaald. 
Om de mogelijkheden voor onderzoek naar het synovium in een 3-dimensionale 
setting te verbeteren, hebben wij geprobeerd om een modelsysteem van een 
andere onderzoeksgroep verder te verbeteren in Hoofdstuk 5. Hiervoor hebben 
we gewrichtscellen losgemaakt en gemengd met Matrigel, dat vloeibaar is als het 
koud is, maar stolt bij 37°C. Gedurende de eerste 7-14 dagen in kweek bewogen 
de belangrijkste cellen uit het synovium, de fibroblast-achtige en macrofaag-
achtige cellen, naar de oppervlakte en vormden een membraan dat veel lijkt op het 
synoviale membraan voordat de ziekteprocessen beginnen. Deze 3-dimensionale 
kweekmethode wordt micromass genoemd. Als we deze micromasses gedurende 3 
weken stimuleerden met ontstekingsprikkel TNFα, dan ontstond een verdikking van 
het synovium, wat een bekend ziekteproces is. Daarnaast bleek dat de micromasses 
met het in hoofdstuk 4 beschreven protocol konden worden ingevroren, zonder 
verlies van de gevoeligheid voor ontstekingsprikkels. De micromasses kunnen 
dus een waardevol model zijn voor het bestuderen van nieuwe medicijnen op 
ziekteprocessen van het synovium.
Gentherapie met de lentivirale vector CXCL10p-IL10
De Saa3 promotor die het best functioneerde in de muisstudie van hoofdstuk 2 
bleek een stuk minder bruikbaar in menselijke cellen. De humane analoog van de 
Saa3 promotor zorgt bijvoorbeeld niet voor de productie van een eiwit. Voor de 
vertaling van de IL-10 gentherapie naar de mens zijn we daarom op zoek gegaan 
naar een andere promotor in Hoofdstuk 6. Hiervoor is gekeken van welke eiwitten 
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de productie in een reumatisch gewricht verhoogd is in vergelijking met een gezond 
gewricht. Dit was het geval voor 22 eiwitten, waarvan de promotors dus kandidaten 
zijn voor ziektegestuurde gentherapie in menselijke cellen. Vervolgens is gekeken 
in gekweekte gewrichtscellen met een ontstekingsprikkel welk gen het meest 
geactiveerd werd en dit bleek CXCL10 te zijn. De promotor van CXCL10 is daarom 
gekopieerd naar een luciferase reporter. Deze bleek vervolgens sterk geactiveerd te 
raken door verschillende ontstekingsprikkels en door bloed van reumapatiënten. 
Bovendien nam de activiteit van de promotor na een ontstekingsprikkel in de 
loop van de tijd weer af, om vervolgens weer gevoelig te worden voor een nieuwe 
prikkel; een belangrijke eigenschap voor een ziektegestuurde therapie. Daarom 
is de luciferase reporter achter de CXCL10 promotor vervangen door IL-10 tot de 
CXCL10p-IL10 lentivirale vector, de beoogde gentherapie voor de menselijke cellen. 
Deze therapie is in menselijke gewrichtscellen geplaatst en na een ontstekingsprikkel 
werd inderdaad een verhoogde productie van IL-10 gemeten in het kweekmedium. 
De geproduceerde hoeveelheid IL-10 bleek voldoende om tegelijkertijd de productie 
van ontstekingseiwitten zoals TNFα en IL-1β te remmen.
 Na deze resultaten hebben we de CXCL10p-IL10 gentherapie getest 
in micromasses gemaakt van OA synovium in Hoofdstuk 7. Ook hier bleken 
ontstekingsprikkels TNFα en lipopolysaccharide (LPS) te zorgen voor een verhoogde 
productie van IL-10 door de micromasses. En ook in de micromasses vonden wij 
hierdoor een afname van de ontstekingsfactoren IL-1β en IL-6. De therapeutische 
kracht van de IL-10 geproduceerd met de CXCL10 promotor was vergelijkbaar met 
die van de continu actieve PGK promotor. Daarnaast vonden we net zoals in de 
muisstudie van hoofdstuk 2 een verhoogde productie van het ontstekingsremmende 
eiwit SOCS3 na behandeling met IL-10. Hiermee hebben wij aangetoond dat onze 
CXCL10p-IL10 behandeling ook succesvol is in een geavanceerd model van menselijk 
synovium.
Eindconclusie
Concluderend hebben wij in dit proefschrift aangetoond dat ziektegevoelige 
gentherapie met het ontstekingsremmende eiwit IL-10 in staat is om de 
ontstekingsreactie te onderdrukken in zowel een muismodel van artritis, alsook in 
humane gewrichtscellen en in een 3-dimensionaal model van het humane synovium. 
Dit is een belangrijke stap in de zoektocht naar een medicijn voor reumatische 
ziekten dat voor langere tijd een gewricht kan beschermen, terwijl de blootstelling 
van andere organen wordt beperkt. 
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Het schrijven van een proefschrift is niet mogelijk zonder de hulp van een hoop 
mensen. Niet alleen vanwege de wetenschappelijke ondersteuning, maar ook voor 
de prettige sfeer, waardoor ik mijn promotietraject in het warme nest van Lab 
Reuma als heel fijn heb ervaren. Ik wil dan ook iedereen bedanken die hieraan heeft 
bijgedragen, maar in het bijzonder de volgende mensen:
Beste Fons, allereerst wil ik jou enorm bedanken voor al je hulp en inzicht bij het 
onderzoek. Meerdere keren ben ik met twijfels over het te volgen pad jouw kantoor 
binnengestapt, maar altijd ben ik er met nieuwe ideeën, inspiratie en nieuwe 
energie weer naar buiten gestapt. Met de goede kritische vragen en het bieden van 
veel vrijheid (of in ieder geval het wekken van de indruk van vrijheid, zoals je zelf 
zegt) heb je veel bijgedragen aan mijn ontwikkeling tot volwassen onderzoeker. Dat 
gecombineerd met een oprechte betrokkenheid bij je personeel zorgt voor een heel 
fijne en productieve werksfeer.
Ook Wim wil ik bedanken voor het vertrouwen dat ik heb gekregen om bij 
Reumatische Ziekten mijn promotie te mogen doen. Vooral tijdens de eerste fase 
van de promotie hebben we elkaar gezien, maar de inzichten in het functioneren 
van de wetenschappelijke wereld, waardoor bijvoorbeeld al was af te leiden dat de 
gentherapie met PRG-4 waarschijnlijk niet zou werken, zullen mij nog lang bijblijven.
Rogier, mijn tweede copromotor, als arts ben jij van ons degene die uiteindelijk het 
beste weet wat zich in de patiënt zelf afspeelt en die kennis is onmisbaar bij het 
onderzoek naar een ziekte. Daarnaast heb je mij de kans gegeven om na het aflopen 
van mijn aio-contract mijn kennis te verbreden naar de B cellen en het isoleren 
van die cellen uit het bloed van patiënten met een auto-immuunziekte. Tijdens 
onze (lange) ritjes naar het AMC voor (korte) meetings is er veel gelegenheid om te 
speculeren over moeilijke experimenten.
Beste Miranda, aan jou heb ik veel te danken. Van jou heb ik geleerd dat er systemen 
bestaan waardoor je al je samples altijd terug kan vinden en je 2 jaar later nog weet 
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zoals een van onze studenten dat eens zo mooi zei. Ondanks  de substantiële hekel 
die je hebt ontwikkeld aan de micromasses heb je een enorme bijdrage geleverd 
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aan de data in dit proefschrift. Ook naast het pipetteren en injecteren hebben we 
veel gezellige momenten gehad, zoals de ‘cappucino-momenten’ als er iets te vieren 
of te verwerken was, of gewoon als er tijd voor was. Ik ben dan ook heel blij dat je 
mijn paranimf wil zijn!
Werkgroep 2 is een mooie werkgroep om deel van uit te maken. Senior AIO Onno, 
in U1 ben ik begonnen en van jou heb ik veel geleerd over het reilen en zeilen 
binnen lab reuma en de vele technieken die er in ons lab beschikbaar zijn. Als een 
soort persoonlijke secretaresse mocht ik vervolgens enkele keren per dag over het 
lab lopen om je te zoeken als er weer telefoon voor je was in U1. We hebben prettig 
samengewerkt en mooie gesprekken gehad. Daarom ben ik blij dat ook jij mijn 
paranimf wil zijn. Claire, mede cappucino-drinker, Vasteloavesbiës, je kan lekker 
koken zoals we weten van de Claire Culinair. De laatste periode zijn we nog buren 
geweest en heb ik veel bewondering gekregen voor je planning-skills en uitvoerige 
experiment-beschrijvingen. Ik wens je nog veel succes met de TAM-receptoren. 
Ook de andere wetenschappers van groepje 2, Bartijn, Renske, Silke, Marina, 
Juan, Ben en Shahla wil ik bedanken voor de wetenschappelijke input tijdens de 
maandagochtenden en daarbuiten. Eline, tijdens je zwangerschapsverlof mocht ik de 
paper afmaken die uiteindelijk in de proefschriften van ons beiden het vlaggenschip 
is geworden. Bedankt! De invriespaper is voor het grootste deel de verdienste van 
Marieke. Naast de vele uren die we gestoken hebben in het selecteren van papers 
voor de systematic review (die er misschien ooit nog wel gaat komen…) en achter 
de confocal voor mooie micromass-plaatjes, had ik lang niet direct gedacht dat juist 
de cryopreservatie een belangrijke plaats in mijn proefschrift zou krijgen.
PetervdK, PetervL en Marije, als werkgroepsleiders van de andere werkgroepen wil 
ik ook jullie bedanken. Jullie waren altijd bereid te helpen bij de experimenten die 
raakvlak hadden met jullie onderwerpen.
Lab Reuma functioneert als een geoliede machine en dat is voor een groot deel 
te danken aan de analisten. Elly, Birgitte, Annet, Monique en Liduine, voor het 
snijden van de echt belangrijke histologie, hulp bij de echt moeilijke kleuringen en 
een echt betrouwbare Luminex-meting zijn jullie altijd te vinden. Marianne, jij bent 
ook een belangrijke schakel in de machine, waardoor alles ook administratief goed 
is geregeld.
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Ook de andere onderzoekers van het lab hebben een belangrijke bijdrage geleverd 
aan dit proefschrift. Esmeralda, Irene, Ellen, Arjen, Wouter, Rik, Rebecca, Laurie, 
Stephanie, Edwin, Guiliana, Niels, Henk, Dennis, Wojchiech, Daphne, Marijn en 
Menno, ondanks dat iedereen zijn eigen onderwerp heeft, is iedereen altijd bereid 
om te helpen met technieken, materialen te delen, zinvolle feedback te geven en 
te zorgen voor gezelligheid tijdens pauzes, op borrels en dagjes uit. Martijn, omdat 
wij even buurmannen zijn geweest heb ik in het dankwoord van jouw proefschrift 
een eigen regel gekregen. Bij dezen heb je die dan ook in mijn dankwoord. Ook 
mijn nieuwe collega’s bij de afdeling BioMoleculaire Chemie wil ik graag bedanken. 
In onze hechte groep waar ik mij al direct thuis voelde, heb ik mijn spectrum aan 
technieken en kennis over eiwitten al enorm uit kunnen breiden. 
Arjan en Guus, heren van de legendarische schaakavonden bij onze eigen 3-koppige 
club ‘Het Kreupele Paard’. Beginnen met een kapsalon en vervolgens onder het 
genot van speciaalbier de edele schaaksport een eer bewijzen. Ik hoop dat we 
deze traditie nog lang vol kunnen houden en dat ik jullie uiteindelijk de vervelende 
openingen zoals het Frans en Scandinavisch af kan leren.
Thomas, Emma, Luuk, Tessa, Jon San en Lynn, als studenten hebben ook jullie een 
waardevolle bijdrage geleverd aan mijn onderzoekslijnen. Hopelijk heb ik jullie ook 
iets kunnen leren over het leven als onderzoeker en de wondere wereld van de 
wetenschap. Succes met jullie verdere carrières!
Voor het behoud van een positieve energie en ontspanning zijn op sommige 
momenten de clubjes en verenigingen een heel goede uitkomst gebleken. Op 
zondagavond zijn er natuurlijk altijd trouw de heren van C.O.W.art: Michiel, Bram, 
Jasper en Maik. ”Wat doen jullie dan? Wat voor muziek maken jullie?” Tja, we 
drinken koffie en daarna bedenken we een nummer in een genre dat we nog niet 
eerder gespeeld hebben. Wie het wil horen moet onze SoundCloud maar opzoeken. 
En Michiel, nog extra bedankt voor het maken van de kaft. Als ik had geweten dat 
je ook met de computer een mooie micromass kunt maken, dan had mij dat veel 
confocale microscopie kunnen besparen. Gedurende mijn promotie heb ik ook de 
eer gehad om hopman te mogen zijn van de verkenners van Jong Arcen. Ik vind het 
bijzonder dat we het elk jaar voor elkaar krijgen om voor alle groepen samen –van 6 
tot 18 jaar– een onvergetelijk zomerkamp te organiseren en dat we onder het genot 
van wat ploppertjes uren kunnen kletsen bij het kampvuur. Ook mijn teamgenoten 
bij schaakvereniging UVS, met recht Uit Vrienden Samengesteld, zorgden voor een 
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mooie afwisseling van pipetteren op het lab.
Lieve pap en mam, een goed begin is het halve werk. En voor het goede begin 
hebben jullie gezorgd. Ik hoop dat ik dezelfde goede start mee kan geven aan jullie 
kleinkind. Ook mijn broertjes Rick en Niek en zusje Tessa hebben altijd bijgedragen 
aan de mooie sfeer in Huize Broeren. Potjes MAD op de gammele uitklapbare 
pinicktafels in onze enorme vouwwagen, schuilen achter het glazen scherm voor 
de golf van de Splash in Duinrell en de uitgebreide Broeren-picknicks op de trappen 
van historische monumenten zijn allemaal mooie herinneringen, waarvan ik hoop 
er nog veel meer te mogen maken.
Als laatste wil ik natuurlijk mijn gezinnetje bedanken, wat stiekem voor mij toch het 
belangrijkste is in het leven. Lieve Nikkie, jij was me al voorgegaan met het schrijven 
van een proefschrift, dus ik heb een goed voorbeeld gehad. InDesign stond al op 
de computer en een vers getrainde editor was al in huis. Door jou was het altijd 
weer fijn om thuis te komen en kon ik mislukte experimenten of besmettingen 
van zeldzame cellijnen snel relativeren en ondanks dat ik mijn dagen vaak erg vol 
plan heb jij altijd veel begrip voor de dingen die ik doe. In de laatste fase van mijn 
promotietraject zijn we dan ook getrouwd, een van de mooiste keuzes van mijn 
leven. Op onze huwelijksreis kwamen we erachter dat je zwanger was en uiteindelijk 
is onze mooie dochter Lise geboren. Lise, kleine muis, papa is enorm trots op de 
schattige geluidjes die je kan maken en de lieve lach die je hebt. Mijn geluk zit in 
een klein rompertje!
